
Journal Menu
► ▼ Journal Menu-
- Current Oncology Home
- Aims & Scope
- Editorial Board
- Reviewer Board
- Topical Advisory Panel
- Instructions for Authors
- Special Issues
- Topics
- Sections & Collections
- Article Processing Charge
- Indexing & Archiving
- Editor’s Choice Articles
- Most Cited & Viewed
- Journal Statistics
- Journal History
- Journal Awards
- Society Collaborations
- Conferences
- Editorial Office
Journal Browser
► ▼ Journal Browser-
arrow_forward_ios
Forthcoming issue
arrow_forward_ios Current issue - Volumes not published by MDPI
Need Help?
Announcements
30 November 2023
MDPI Insights: The CEO's Letter #6 - MDPI Spain Summit and ResearchGate

Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
MDPI Spain Summit
Stefan Tochev (CEO, MDPI) gives the opening speech at the MDPI Spain Summit.
On Friday 10 November 2023 I was in Barcelona, Spain, to deliver the opening presentation and participate in a panel at MDPI’s Spain Summit, a two-day event, inspired by our salon events in China.
With 16 Editors-in-Chief (EiCs) and 20 Editorial Board Members (EBMs) in attendance, the event, organized by our conference team and Barcelona office, featured presentations on open access (OA), MDPI, and publishing market trends in Spain.
The event provided a great opportunity to engage with stakeholders from various MDPI journals, including Nutrients, Vaccines, Buildings, IJMS, and others. We were able to gather feedback and have open conversations around manuscript quality, the peer-review process, and journal development, as well as accreditation agencies.
The main objective of this Summit was to bring together Editors representing MDPI journals across various disciplines within Spanish universities and research centers, primarily from the Barcelona area. The aim was to facilitate an open and fruitful discussion regarding the development of their journals, the future of OA in Spain, and to provide meaningful interactions and networking opportunities.
Connecting with Editorial Board Members
Stefan Tochev in conversation with Summit participants: "Our EBMs are passionate about the journals they serve."
Interacting with our EBMs in person provides a valuable opportunity to show how important it is to us to connect with them, hear their perspectives on their journals and learn more about their own experience collaborating with MDPI.
From my conversations, it was clear that our EBMs are passionate about the journals they serve. I know the advice they provide may sometimes involve just small tweaks, but these can lead to important improvements. As the saying goes, small hinges swing open big doors.
As at November 2023, MDPI has over 6,300 EBMs affiliated with Spanish institutions, with more than 30 of them serving as EiCs or section EiCs. Furthermore, over 68,000 Spanish scholars have contributed as reviewers in MDPI journals.
Open Access in Spain
In 2023, Spain implemented legislation mandating immediate OA for all publicly funded research, aligning with the EU’s Plan S initiative to expedite the transition to OA. The Spanish government also approved a four-year, €23.8 million annual budget for the first national OA strategy, aiming to make publicly funded research freely accessible upon publication. This strategy aims to strengthen the quality and transparency of research in Spain, and to help promote movement towards a digital, low-carbon economy.
For further details of Spain's OA policy and the history of government mandates, click here.
Spain has already seen a notable decline in subscription-only articles, decreasing by 62% over a 10-year period, while gold OA increased by 42%. Green OA slightly decreased, suggesting a shift towards publishing in gold OA journals rather than traditional subscription-based ones. Here are some statistics from Scopus.
A big thank-you to the various MDPI teams, including our conference team and the Barcelona office, for organizing this very successful event!
MDPI colleagues from various offices gathered to host and support the first MDPI Spain Summit, in Barcelona, Spain.
I think this type of gathering has the potential to become an annual event in various locations. For example, Manchester could be an option, as we have over 30 EiCs and over 3,000 EBMs in the UK, a top market for MDPI that publishes high-quality research.
Impactful Research
769 Editorial Board Members of MDPI Journals Recognized as Highly Cited Researchers in 2023
Congratulations to our 769 Editorial Board Members from 40 countries/territories who have been awarded Highly Cited Researcher status for 2023 by Clarivate. This recognition is based on their outstanding scientific research contributions and significant influence in various fields, as evidenced by Web of Science data.
Click here to view the full list of 769 Editorial Board Members.
Clarivate's Highly Cited ResearchersTM list identifies individuals with exceptional impact in scientific and social science domains over the past decade. Their papers rank in the top 1% of citations in 21 fields analysed in ‘Essential Science Indicators,’ showcasing their substantial influence.
This year, 7,125 Highly Cited Researcher 2023 designations were issued to 6,849 individuals from 67 countries, representing just 1 in 1,000 researchers worldwide.
These researchers demonstrate exceptional influence, representing a small fraction of contributors pushing the boundaries of knowledge, contributing to global well-being, sustainability, and security.
Congratulations to these scholars for their remarkable achievement: we are honoured to have them on board with our journals!
Inside MDPI
Corporate Marketing and Communications Strategy Session
Members of MDPI’s Corporate Marketing & Communications team.
For the past few years, I have led the Corporate Marketing & Communications department in our annual strategy session.
This typically involves 2–3 days of focused sessions covering key topics including budgeting, hiring targets, campaign reviews, and planning for the upcoming year, department strategy, and structure.
We are constantly exploring ways to optimize the Corporate Marketing & Communications department to support MDPI’s primary objectives and better convey the MDPI story while serving the scholarly community.
The strategy session also serves as a team-building activity, during which the team voted on bowling!
Strategy Session
In this strategy session, we looked at how to align our teams in order to better streamline our content with our campaigns, build a dedicated marketing team to strategically support our core MDPI products, expand our communications teams and functionalities to focus on company-critical campaigns and press releases, align our new brand design system with our marketing initiatives, set up a community and engagement team to support various teams with their outreach and communication efforts, and increase our use of data in the evaluation of campaign performance.
To grow in these areas, we will be hiring for various positions, including those of Public Relations Manager, Communications Manager, Internal Communications Manager, Campaign Manager, Marketing Associate, and Editorial Engagement Manager.
I am grateful for the way our Corporate Marketing & Communications department has grown and gelled over the years, and I look forward to supporting the department teams and their ideas for the future.
Coming Together for Science
ResearchGate and MDPI Partner to Boost the Visibility of Open Access Content through Journal Home
Stefan Tochev (CEO, MDPI) and Sören Hofmayer (Co-Founder and Chief Strategy Officer, ResearchGate) meet in Berlin, Germany to take their ongoing discussion further.
When I assumed the role of CEO at MDPI, my primary focus was to initiate the building of essential partnerships and collaborations within our industry. After all, I am a firm believer in achieving our goals by helping others achieve theirs and focusing on co-opetition wherever there is an opportunity. I first touched on the notion of co-opetition in MDPI Insights: The CEO's Letter #3, particularly when discussing collaborations with Elsevier.
In light of this, Sören Hofmayer (Co-Founder and Chief Strategy Officer at ResearchGate) and I connected recently to continue a discussion that had been ongoing for months. I was quickly brought up to speed and felt there was an opportunity for MDPI journals to pilot the Journal Home service that ResearchGate had launched. This would provide a new way for MDPI to engage with authors and readers and amplify the visibility of our journals.
While I receive many offers and opportunities for discussions with vendors, I am a firm believer that timing is everything, and in this case, the time for us is now. Sören and I met in person during my recent visit to Berlin and decided to proceed with piloting ten MDPI journals with the Journal Home service.
The press release below provides further details.
Press Release: Berlin (Germany) and Basel (Switzerland), 15 November 2023
ResearchGate, the professional network for researchers, and MDPI, the largest open access publisher in the world and a pioneer in open access publishing, today announced a partnership that will see ten of MDPI’s open access journals benefit from an enhanced presence on ResearchGate through its innovative Journal Home offering.
This new partnership will expand the reach and visibility of MDPI’s participating flagship journals with ResearchGate’s highly relevant community of more than 25 million researchers globally.
Around 210,000 version-of-record articles from these 10 titles will be readily available on ResearchGate, including the full archive material and all new articles as they are published. These journals also benefit from enhanced brand visibility, with dedicated journal profiles, prominent representation on all associated article pages and all relevant touchpoints across the ResearchGate network – keeping the journals top-of-mind with their reader and author audiences. All articles covered by the new partnership will automatically be added to the authors’ publication records in ResearchGate. This not only reduces MDPI authors’ needs for direct management but also offers them valuable insights into the impact of their work, including data about readership and citations.
Closing Thoughts
November is Men’s Health Awareness Month
Stefan Tochev (CEO, MDPI) listening to music as he writes at a coffee shop in Basel, Switzerland.
November is dedicated to raising awareness of various men’s health issues. I have been fortunate to have positive male role models in my life, and I strive to share my experiences with others.
I used to take part in Movember, growing my moustache throughout November to raise awareness and funds and to help “change the face of men’s health.” With male family and friends impacted by physical and mental health issues, I have recently become more interested in men’s overall well-being.
Men often face stigma involving the perceived need always to be strong and have things figured out. Recently, I’ve had meaningful conversations with male friends and colleagues about issues we rarely discuss, and it was a positive experience.
Various factors impact men’s health and well-being, all too easily leading to risky health behaviours including a lack of health awareness, poor health education, and negative, culturally induced, behaviour patterns in our work and personal lives. I hope we can break down these barriers in our work environment.
Healthy men help build healthy families and a healthy society
Men are less likely than women to seek help with their physical and mental health struggles. This is a reminder to prioritize your overall well-being. I hope that as men, we will continue to open up to one another, becoming vulnerable in order to share what we are going through. By sharing and by supporting each other, we can learn and grow together. You are not alone, and when you fall, you can still get up and stand tall.
From one broski to another, you are loved and appreciated. I hope this mindset carries into December and beyond.
Mindfulness
Our content team recently released a handful of articles on mindfulness, a practice that I believe provides a good opportunity for stress release and self-reflection:
Chief Executive Officer
MDPI AG
21 November 2023
769 Editorial Board Members of MDPI Journals Achieve Highly Cited Researcher Recognition in 2023

We extend our sincere congratulations to the 769 Editorial Board Members of our journals – from 40 different countries/territories – who have been recognized as Highly Cited Researchers for the year 2023 by Clarivate. They are being recognized for their high-quality scientific research achievements and outstanding contributions to their professional fields, as indicated by Web of Science data.
Clarivate's annual list of Highly Cited ResearchersTM identifies the most highly cited scientists for the past decade who stand out for their significant and broad influence in various scientific and social science domains. Their impactful papers are among the top 1 per cent in the citation distribution of one or more of 21 fields analyzed in the "Essential Science Indicators", distinguishing them as hugely influential among their peers.
This year, 7,125 Highly Cited Researcher 2023 designations were issued to 6,849 individuals from 67 countries, representing just 1 in 1,000 researchers worldwide.
This means that these researchers have demonstrated an incredible level of significant and broad influence in their chosen field or fields over the last decade. They represent a small fraction of the researcher population whose contributions disproportionately push the boundaries of knowledge, enhancing global well-being, sustainability, and security.
Congratulations to the scholars for their noteworthy achievement – we are honored to have them on board with our journals!
Abate, Antonio |
Jaiswal, Amit K. |
Shen, Zexiang |
10 November 2023
Current Oncology | World Neuroendocrine Tumor Awareness Day (NET Cancer Day) 2023

World Neuroendocrine Tumor Awareness Day (NET Cancer Day) takes place annually on the 10 November and it is coordinated by the International Neuroendocrine Cancer Alliance (INCA). The main objectives of this event are to increase awareness about various types of neuroendocrine tumors (NETs), advocate for scientific progress by addressing unmet needs, and foster global collaboration to tackle the challenges faced by NET patients and the medical community in terms of timely diagnosis, optimal treatment, and support.
In celebration of NET Cancer Day 2023, Current Oncology (ISSN: 1718-7729) has curated a collection of open access scholarly research studies focused on neuroendocrine tumors. Our intention is to disseminate new scientific knowledge to the world on this significant occasion.
1. “Efficacy of 177Lu-Dotatate Induction and Maintenance Therapy of Various Types of Neuroendocrine Tumors: A Phase II Registry Study”
by Golmehr Sistani, Duncan E. K. Sutherland, Amol Mujoomdar, Daniele P. Wiseman, Alireza Khatami, Elena Tsvetkova, Robert H. Reid and David T. Laidley
Curr. Oncol. 2021, 28(1), 115–127; https://doi.org/10.3390/curroncol28010015
Available online: https://www.mdpi.com/1718-7729/28/1/15
2. “Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors”
by Taymeyah Al-Toubah, Brian Morse and Jonathan Strosberg
Curr. Oncol. 2022, 29(2), 510–515; https://doi.org/10.3390/curroncol29020046
Available online: https://www.mdpi.com/1718-7729/29/2/46
3. “Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden”
by Nai-Wen Kang, Kien-Thiam Tan, Chien-Feng Li and Yu-Hsuan Kuo
Curr. Oncol. 2021, 28(6), 4587–4596; https://doi.org/10.3390/curroncol28060388
Available online: https://www.mdpi.com/1718-7729/28/6/388
4. “A Case of ALK-Rearranged Combined Lung Adenocarcinoma and Neuroendocrine Carcinoma with Diffuse Bone Metastasis and Partial Response to Alectinib”
by Chloe A. Lim, Norbert Banyi, Tracy Tucker, Diana N. Ionescu and Barbara Melosky
Curr. Oncol. 2022, 29(2), 848–852; https://doi.org/10.3390/curroncol29020072
Available online: https://www.mdpi.com/1718-7729/29/2/72
5. “Resection of Non-Functional Pancreatic Neuroendocrine Neoplasms—A Single-Center Retrospective Outcome Analysis”
by Kirsten Lindner, Daniel Binte, Jens Hoeppner, Ulrich F. Wellner, Dominik M. Schulte, Sebastian M. Schmid, Kim Luley, Inga Buchmann, Lars Tharun, Tobias Keck et al.
Curr. Oncol. 2021, 28(4), 3071–3080; https://doi.org/10.3390/curroncol28040268
Available online: https://www.mdpi.com/1718-7729/28/4/268
6. “Neuroendocrine Carcinomas of the Uterine Cervix, Endometrium, and Ovary Show Higher Tendencies for Bone, Brain, and Liver Organotrophic Metastases”
by Hyung Kyu Park
Curr. Oncol. 2022, 29(10), 7461–7469; https://doi.org/10.3390/curroncol29100587
Available online: https://www.mdpi.com/1718-7729/29/10/587
7. “Better Prognosis of Gastric Neuroendocrine Carcinoma Than Gastric Adenocarcinoma among Whites in the United States: A Propensity Score Matching Analysis Based on SEER”
by Zefeng Li, Hu Ren, Lulu Zhao, Xiaojie Zhang, Tongbo Wang, Chongyuan Sun, Penghui Niu, Wanqing Wang, He Fei, Chunguang Guo et al.
Curr. Oncol. 2022, 29(7), 4879–4892; https://doi.org/10.3390/curroncol29070387
Available online: https://www.mdpi.com/1718-7729/29/7/387
8. “The Management and Outcomes of Patients with Extra-Pulmonary Neuroendocrine Neoplasms and Brain Metastases”
by Zainul-Abedin Kapacee, Jennifer Allison, Mohammed Dawod, Xin Wang, Melissa Frizziero, Bipasha Chakrabarty, Prakash Manoharan, Catherine McBain, Was Mansoor, Angela Lamarca et al.
Curr. Oncol. 2022, 29(7), 5110–5125; https://doi.org/10.3390/curroncol29070405
Available online: https://www.mdpi.com/1718-7729/29/7/405
9. “Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors”
by Nicole Brighi, Giuseppe Lamberti, Elisa Andrini, Cristina Mosconi, Lisa Manuzzi, Giada Donati, Andrea Lisotti and Davide Campana
Curr. Oncol. 2023, 30(2), 1381–1394; https://doi.org/10.3390/curroncol30020106
Available online: https://www.mdpi.com/1718-7729/30/2/106
10. “Comparison of Transarterial Bland and Chemoembolization for Neuroendocrine Tumours: A Systematic Review and Meta-Analysis”
by E. Tai, S. Kennedy, A. Farrell, A. Jaberi, J. Kachura and R. Beecroft
Curr. Oncol. 2020, 27(6), 537–546; https://doi.org/10.3747/co.27.6205
Available online: https://www.mdpi.com/1718-7729/27/6/6205
1 November 2023
MDPI Insights: The CEO's Letter #5 - OA Week, UK, and Strategy

Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
Open Access Week 2023 – the Global Drive to Open Continues
As the world's largest open-access (OA) publisher, we believe that unrestricted access to research findings is the cornerstone of transparency, efficiency, and quality control across scientific disciplines. At MDPI, we provide free, immediate access to scientific papers, empowering scientists to examine, validate, replicate, and build upon existing results. This minimizes redundancy, optimizes resources, and fosters innovative approaches.
International OA Week, held from 23 to 29 October 2023, provided a unique opportunity to link the global movement toward open sharing and open science with the progress of policy changes at the local level. Our mission, during OA Week and all the year round, is to offer educational resources highlighting the benefits of open-access publishing. The MDPI Blog is a valuable resource for information on open access and open science.
Core principles of OA publishing
Accessibility, transparency, and collaboration are core principles of OA publishing. OA aims to break down barriers that have traditionally restricted research access, ensuring that knowledge is available to all, regardless of financial situation or institutional affiliations. Our commitment to diverse pathways for OA publishing worldwide includes discounts for researchers. You can learn more about how MDPI supports scientific communities here.
One of the key strengths of OA publishing is its ability to facilitate interdisciplinary research. By removing paywalls and promoting knowledge-sharing across disciplines, OA encourages collaboration and innovation. Researchers from various fields can access and build upon each others’ work, fostering a holistic approach to addressing complex global challenges.
OA holds the potential to democratize knowledge, advance science, and drive positive societal change.
Policy driving change
Governments, institutions, and funding agencies have recognized the transformative potential of OA and have implemented policies to promote it. These policies often require publicly funded research to be made openly accessible, accelerating the growth of OA repositories and journals. Check out our spotlights on OA policies in the US, EU and China.
OA publishing is continuously evolving, with community-driven models and technologies shaping its future. Initiatives such as “Plan S” and “cOAlition S” promote OA publishing from the perspective of national funders, requiring grantees to publish their research openly. A new policy announced by the US administration last year mandates that, with effect from January 2026, all US federally funded research should be freely and immediately available after publication.
Additionally, preprint servers such as MDPI's Preprints.org, which allow researchers to share their findings before formal peer review, have gained popularity, enhancing the speed at which new knowledge is disseminated. The rise of blockchain technology is also being explored to ensure transparency and authenticity in scholarly publishing.
For more than two decades, OA publishing has been revolutionizing academic publishing by promoting accessibility, transparency, and collaboration. Its support for interdisciplinary research, evolving policies, and innovative practices all contribute to its growing influence in the global research community. As OA continues to expand, it holds the potential to democratize knowledge, advance science, and drive positive societal change.
MDPI is proud to lead the transition to open access.
Read more:
Impactful Research
Spotlight on Smart Cities
Smart cities will serve as a cornerstone for future human development. Their implementation will help us tackle many of the significant challenges we are facing – climate change, ageing populations, waste management, public safety, travel, and so on. Recognising the importance of this multifaceted field, MDPI launched the inaugural issue of Smart Cities in 2018 to provide an advanced forum for research into smart technology and society. Here we take a look at how this journal has developed, and its impact in this exciting field.
As at 30 October, 2023, Smart Cities has published 421 papers and has an Impact Factor of 6.4. It also has a CiteScore of 8.5, and more than one quarter of its published papers – 124 – have been cited 10 times or more.
Highly cited papers in Smart Cities
Below are several highly cited papers recently published in Smart Cities. Citation metrics are current as at 31 October 2023.
1. “Introducing the “15-Minute City”: Sustainability, Resilience and Place Identity in Future Post-Pandemic Cities”
Authors: Carlos Moreno, Zaheer Allam, Didier Chabaud, Catherine Gall and Florent Pratlong
Smart Cities 2021, 4(1), 93-111; https://doi.org/10.3390/smartcities4010006
Citations: Crossref (338), Scopus (366), Web of Science (270), Google Scholar (710)
The paper discusses the socio-economic impacts of the COVID-19 on cities, including increasing inequalities and rising unemployment. It introduces the concept of the "15-Minute City," a form of "chrono-urbanism," as a response to the challenges posed by the pandemic.
2. “A Review on Electric Vehicles: Technologies and Challenges”
Authors: Julio A. Sanguesa, Vicente Torres-Sanz, Piedad Garrido, Francisco J. Martinez and Johann M. Marquez-Barja
Smart Cities 2021, 4(1), 372-404; https://doi.org/10.3390/smartcities4010022
Citations: Crossref (359), Scopus (363), Web of Science (268), Google Scholar (558)
This paper provides an overview of the progress in Electric Vehicles (EVs), focusing on battery technology, charging methods, and emerging research challenges. It also analyzes the global EV market and its future outlook.
3. “IoT in Smart Cities: A Survey of Technologies, Practices and Challenges”
Authors: Abbas Shah Syed, Daniel Sierra-Sosa, Anup Kumar and Adel Elmaghraby
Smart Cities 2021, 4(2), 429-475; https://doi.org/10.3390/smartcities4020024
Citations: Crossref (121), Scopus (151), Web of Science (91), Google Scholar (215)
This paper gives an overview of the Internet of Things (IoT) in the context of Smart Cities, discussing the fundamental components, technologies, architectures, networking technologies, and artificial algorithms that underpin IoT-based Smart City systems.
4. “Artificial Intelligence Techniques in Smart Grid: A Survey”
Authors: Olufemi A. Omitaomu and Haoran Niu
Smart Cities 2021, 4(2), 548-568; https://doi.org/10.3390/smartcities4020029
Citations: Crossref (76), Scopus (94), Web of Science (57), Google Scholar (120)
This survey paper reviews the utilization of artificial intelligence (AI) techniques in the context of the smart grid. It covers various applications of AI in load forecasting, power grid stability assessment, fault detection, and security issues in the smart grid and power systems.
5. “The Metaverse as a Virtual Form of Smart Cities: Opportunities and Challenges for Environmental, Economic, and Social Sustainability in Urban Futures”
Authors: Zaheer Allam, Ayyoob Sharifi, Simon Elias Bibri, David Sydney Jones and John Krogstie
Smart Cities 2022, 5(3), 771-801; https://doi.org/10.3390/smartcities5030040
Citations: Crossref (72), Scopus (75), Web of Science (43), Google Scholar (176)
This paper discusses the concept of the Metaverse, a virtual world introduced by Meta (formerly Facebook), and its potential impact on urban life. It explores how emerging technologies such as AI, Big Data, IoT, and Digital Twins could reshape urban design and services in the context of the Metaverse.
Testimonial
“It was indeed a great and pleasant experience with MDPI regarding our recent publication. The submission process was very straightforward and less time-consuming than the norm. The review process was very fast compared to many other open access journals, which is praiseworthy. The support from the Editorial Office during the revision process was highly useful as well. We look forward to publishing with MDPI in the future, and I will most definitely recommend MDPI to my colleagues and collaborators.” – Dr. Luís Rosa, University of Minho
Article in Smart Cities: Mobile Networks and Internet of Things Infrastructures to Characterize Smart Human Mobility
Inside MDPI
MDPI Manchester office, UK Visit
Allie Shi (Editorial Director, MDPI), Stefan Tochev (CEO, MDPI), Jamie Anderson (Manchester Office Manager, MDPI), Michael O’Sullivan (Senior Scientific Officer, MDPI), Hushneara Akhtar, and Becky Castellon (IOAP Team Lead, MDPI), dining out in Manchester, UK.
In October, I visited MDPI’s new office in Manchester. During the visit, I connected with our English Editing (EE) managers, Scientific Officer, members of the Editorial team, the Marketing team, and IOAP Team Lead.
Our Manchester office focuses primarily on EE services and provides local support for the UK market. Additionally, we regularly visit Editorial Board members and participate in local conferences.
I would like to thank Jamie Anderson, Manchester Office Manager, and her team, for their deep commitment to our Manchester staff and to MDPI’s impact on the UK market.
The UK by numbers
The UK is a hub for the world’s top universities, making it a key market for MDPI and the publishing world in general. It is home to two of the top-five-ranked universities globally, 11 in the top 100, and 15 in the top 200.
As a result, the UK plays a key role in MDPI’s global market. As at October 2023, it ranks as the seventh-largest contributor to the total number of papers published by MDPI. We have 3,500 Editorial Board members affiliated with UK institutions, including 34 serving as Editors-in-Chief (EiCs). Our commitment to collaboration with institutions is evident in the UK, where we have successfully established some 60 Institutional Open Access Program (IOAP) agreements with esteemed institutions, such as the University of Oxford, the University of Cambridge, Imperial College London, the University of Edinburgh, and more.
According to InCites Dataset + ESCI for the period 2018–2022, as at October 2023, nearly 65% of UK papers are now published as OA. Just over 10% of total OA publications are by UK authors. UK papers are known for their high quality, with an average of 11 citations per paper. Furthermore, 2.16% of UK papers are in the top 1% of cited papers, and 14.61% are in the top 10% of cited papers, showcasing their impact.
We are currently hiring EEs in various locations worldwide.
English Editing at MDPI
Our English Editing (EE) department consists of two main branches, Quality Control and Learning and Development, reflecting our priorities. We are continuously enhancing the quality of our English Editing services and have raised the relevant standards, which now extend to company-wide communications. English editors participate in international interviews, conduct English assessments, and provide colleagues with presentations on ways to improve their use of written and spoken English.
While expanding, the EE department has proactively refocused its efforts on the quality of our work and how the English Editing department can benefit the company more broadly. We currently have approximately 140 full-time English Editors based across five offices worldwide, supplemented by over 700 freelance English editors.
Our Manchester office serves as the hub for the EE Department, with EE Managers situated there, except for Kurtis Jackson, who serves as the Head of EE and is located in our Basel office. Manchester EEs play a critical role in establishing and developing EE teams in our other offices, overseeing management and recruitment. The EE department plays a vital role in MDPI’s operations, as it is the department that touches every published paper. If this work interests you, I encourage you to explore our available EE positions, whether you are seeking full-time or freelance opportunities.
Testimonials
“MDPI provides an excellent service compared to any other previously used services. It delivers fast and high-quality results but at an affordable price.” – Ardha Apriyanto, University of Potsdam
“In my role as a professor, I consider that MDPI Author Services offer an excellent quality in the editing of Western academic writing while maintaining the required standards of clarity, precision and rigor. Additionally, delivery times are fast compared to other available services.” – Jesus Insuasti, University of Nariño
Read more:
Coming Together for Science
STM and Frankfurt Book Fair
Attending STM
MDPI has been a proud sponsor of the STM Conference for several years. The STM Conference is a dynamic event featuring interactive sessions, expert panellists, idea-sharing, and ample networking opportunities. On 16 October, the event kicked off with arrival drinks, sponsored by MDPI, followed by a welcoming dinner, providing a great chance to connect and network with industry professionals. The following day was filled with speakers, sessions, and further opportunities to connect. STM exemplifies the collaborative spirit of the scientific community, with session topics including achieving open, visible, and impactful research at scale; maintaining research integrity in a rapidly changing world; and exploring the impact of ever-evolving technology in the scholarly community.
Meeting with Web of Science
On a personal note, one of the highlights of STM was a candid and productive conversation with Nandita Quaderi, Editor-in-Chief and SVP at Web of Science. During our discussion, we talked about MDPI, Web of Science, the IJERPH delisting, and ways of moving forward. This open conversation aimed at fostering better collaboration for the future.
“We discussed ways to improve our communication and collaboration.”
I appreciated our frank discussion and felt that Nandita wholeheartedly supports open access. She also expressed her appreciation for the monthly CEO Letter, which she sees as a way to add personality to the MDPI brand and provide insight into the great work we do at MDPI. While we highlighted the positives, we also discussed ways to improve our communication and collaboration moving forward. This meeting alone made the trip worthwhile, and I hope Nandita doesn’t mind my sharing that she found our chat to be “the most honest and constructive discussion” she’s had with someone from MDPI in recent years.
75th Frankfurt Book Fair
Jelena Milojevic (Book Editor, MDPI), Jovana Dubajic (Book Editor, MDPI), Evan Escamilla (Project Manager, MDPI), Laura Wagner (Head of Books, MDPI), and Jenny Knowles (Commissioning Editor, MDPI), at the Frankfurt Book Fair in Frankfurt am Main, Germany.
For the 75th time, the Frankfurter Buchmesse opened its doors in October to celebrate exciting stories and their authors. If you haven’t yet had the chance to visit the Frankfurt Book Fair, I highly recommend it. It’s the largest book fair in the world, attracting thousands of visitors from around the globe. This is the place to gain valuable industry insights from top-class publishing professionals, connect with publishers directly, and learn about the latest trends in publishing.
MDPI Books
Our Books team was also present at the Frankfurt Book Fair, networking and learning from various panels. Did you know that our MDPI Books department publishes OA Books?
The book publishing program includes monographs, book series, edited books and reprints of special issues and topical collections, among other book types.
If you have a book proposal you would like to discuss, please feel free to contact our Books team to understand the benefits and methods of publishing your next book with the OA model.
Closing Thoughts
MDPI Strategy Meeting
As the newly appointed CEO, this is my first year leading the MDPI Senior Management Strategy session. I saw it as an opportunity to explore what MDPI has the potential to become in the next five years. Guided by the vision of its founder and President, Dr. Shu-kun Lin, the company has accomplished remarkable feats over the past 27 years and currently holds the position as the world’s third-largest academic publisher, following Springer Nature and Elsevier.
Our primary objective is to build upon the milestones of the past decades and consolidate MDPI’s position as well-established publishing brand. The two-day meeting emphasized the importance of communicating MDPI’s values more actively via its brand and adopting a straightforward yet impactful approach to managing MDPI as a mature academic publisher.
“Our primary objective is to consolidate MDPI’s position as well-established publishing brand”
As the world’s number one open-access publisher, MDPI has long been a game-changer in the scholarly community, serving millions of authors. The challenge in being a trailblazer is the need to continuously improve and at the same time explore the next blue-ocean strategy, while also maintaining the smooth operation of the business. Our collection model, featuring guest-curated thematic topics in the form of Special Issues, has disrupted the industry. Other publishers closely study us and attempt to replicate our models. The future of this collection model is something we are actively addressing – while, of course, looking ahead to what comes next!
Chief Executive Officer
MDPI AG
25 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Bone and Soft Tissue Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Bone and Soft Tissue Oncology” listed below:
1. “Synovial Sarcoma: A Clinical Review”
by Aaron M. Gazendam, Snezana Popovic, Sohaib Munir, Naveen Parasu, David Wilson and Michelle Ghert
Curr. Oncol. 2021, 28(3), 1909–1920; https://doi.org/10.3390/curroncol28030177
Available online: https://www.mdpi.com/1718-7729/28/3/177
2. “Current Overview of Treatment for Metastatic Bone Disease”
by Shinji Tsukamoto, Akira Kido, Yasuhito Tanaka, Giancarlo Facchini, Giuliano Peta, Giuseppe Rossi and Andreas F. Mavrogenis
Curr. Oncol. 2021, 28(5), 3347–3372; https://doi.org/10.3390/curroncol28050290
Available online: https://www.mdpi.com/1718-7729/28/5/290
3. “Emerging Concepts in the Surgical Management of Peri-Acetabular Metastatic Bone Disease”
by Aaron Gazendam, Daniel Axelrod, David Wilson and Michelle Ghert
Curr. Oncol. 2021, 28(4), 2731–2740; https://doi.org/10.3390/curroncol28040238
Available online: https://www.mdpi.com/1718-7729/28/4/238
4. “The Role of a Navigational Radiofrequency Ablation Device and Concurrent Vertebral Augmentation for Treatment of Difficult-to-Reach Spinal Metastases”
by Claudio Pusceddu, Davide De Francesco, Luca Melis, Nicola Ballicu and Alessandro Fancellu
Curr. Oncol. 2021, 28(5), 4004–4015; https://doi.org/10.3390/curroncol28050340
Available online: https://www.mdpi.com/1718-7729/28/5/340
5. “The Surgical Management of Proximal Femoral Metastases: A Narrative Review”
by Daniel Axelrod, Aaron M. Gazendam and Michelle Ghert
Curr. Oncol. 2021, 28(5), 3748–3757; https://doi.org/10.3390/curroncol28050320
Available online: https://www.mdpi.com/1718-7729/28/5/320
6. “We’re on a Merry-Go-Round”: Reflections of Patients and Carers after Completing Treatment for Sarcoma”
by Rhys Weaver, Moira O’Connor, Richard Carey Smith, Dianne Sheppard and Georgia K. B. Halkett
Curr. Oncol. 2021, 28(4), 3003–3014; https://doi.org/10.3390/curroncol28040263
Available online: https://www.mdpi.com/1718-7729/28/4/263
7. “Assessment of Risk of Bias in Osteosarcoma and Ewing’s Sarcoma Randomized Controlled Trials: A Systematic Review”
by Robert Koucheki, Aaron M. Gazendam, Jonathan R. Perera, Anthony Griffin, Peter Ferguson, Jay Wunder and Kim Tsoi
Curr. Oncol. 2021, 28(5), 3771–3794; https://doi.org/10.3390/curroncol28050322
Available online: https://www.mdpi.com/1718-7729/28/5/322
8. “Impact of an Augmented Reality Navigation System (SIRIO) on Bone Percutaneous Procedures: A Comparative Analysis with Standard CT-Guided Technique”
by Eliodoro Faiella, Gennaro Castiello, Caterina Bernetti, Giuseppina Pacella, Carlo Altomare, Flavio Andresciani, Bruno Beomonte Zobel and Rosario Francesco Grasso
Curr. Oncol. 2021, 28(3), 1751–1760; https://doi.org/10.3390/curroncol28030163
Available online: https://www.mdpi.com/1718-7729/28/3/163
9. “Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report”
by Thierry Alcindor, Sungmi Jung and Lucy Gilbert
Curr. Oncol. 2021, 28(3), 2146–2149; https://doi.org/10.3390/curroncol28030199
Available online: https://www.mdpi.com/1718-7729/28/3/199
10. “The Role of Denosumab for Surgical Outcomes in Patients with Giant Cell Tumour of Bone: A Systematic Review”
by Abha Gupta, Lisa Durocher-Allen, Snezana Popovic, Richard Tozer, Xiaomei Yao and Michelle Ghert
Curr. Oncol. 2021, 28(2), 1302–1313; https://doi.org/10.3390/curroncol28020124
Available online: https://www.mdpi.com/1718-7729/28/2/124
24 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Breast Cancer”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Breast Cancer” listed below:
1. “Exercise to Reduce Anthracycline-Mediated Cardiovascular Complications in Breast Cancer Survivors”
by Sonu S. Varghese, Will J. Johnston, Cameron R. Eekhoudt, Melanie R. Keats, Davinder S. Jassal and Scott A. Grandy
Curr. Oncol. 2021, 28(5), 4139–4156; https://doi.org/10.3390/curroncol28050351
Available online: https://www.mdpi.com/1718-7729/28/5/351
2. “Comparison of the Quality of Life of Patients with Breast or Colon Cancer with an Arm Vein Port (TIVAD) Versus a Peripherally Inserted Central Catheter (PICC)”
by Brent Burbridge, Hyun Lim, Lynn Dwernychuk, Ha Le, Tehmina Asif, Amer Sami and Shahid Ahmed
Curr. Oncol. 2021, 28(2), 1495–1506; https://doi.org/10.3390/curroncol28020141
Available online: https://www.mdpi.com/1718-7729/28/2/141
3. “The Challenge of Return to Work after Breast Cancer: The Role of Family Situation, CANTO Cohort”
by Elsa Caumette, Inès Vaz-Luis, Sandrine Pinto, Julie Havas, Thomas Bovagnet, Garazi Ruiz de Azua, Antonio Di Meglio, Anne-Laure Martin, Sibille Everhard, Paul Cottu et al.
Curr. Oncol. 2021, 28(5), 3866–3875; https://doi.org/10.3390/curroncol28050330
Available online: https://www.mdpi.com/1718-7729/28/5/330
4. “A Multidisciplinary Approach to Implement Personalized Breast Cancer Treatment and Care Plans”
by Rashida Haq, Amy Kong and Pauline Gulasingam
Curr. Oncol. 2021, 28(1), 767–782; https://doi.org/10.3390/curroncol28010075
Available online: https://www.mdpi.com/1718-7729/28/1/75
5. “Longitudinal Symptom Burden Trajectories in a Population-Based Cohort of Women with Metastatic Breast Cancer: A Group-Based Trajectory Modeling Analysis”
by Suman Budhwani, Rahim Moineddin, Walter P. Wodchis, Camilla Zimmermann and Doris Howell
Curr. Oncol. 2021, 28(1), 879–897; https://doi.org/10.3390/curroncol28010087
Available online: https://www.mdpi.com/1718-7729/28/1/87
6. “Cancer-Specific Outcomes in the Elderly with Triple-Negative Breast Cancer: A Systematic Review”
by Jenny Yoon, Gregory Knapp, May Lynn Quan and Antoine Bouchard-Fortier
Curr. Oncol. 2021, 28(4), 2337–2345; https://doi.org/10.3390/curroncol28040215
Available online: https://www.mdpi.com/1718-7729/28/4/215
7. “Narratives of Survivorship: A Study of Breast Cancer Pathographies and Their Place in Cancer Rehabilitation”
by Åsa Mohlin and Katarina Bernhardsson
Curr. Oncol. 2021, 28(4), 2840–2851; https://doi.org/10.3390/curroncol28040249
Available online: https://www.mdpi.com/1718-7729/28/4/249
8. “Factors Associated with “Survivor Identity” in Men with Breast Cancer”
by Kathryn L. Dalton, Sheila N. Garland, Peggy Miller, Bret Miller, Cheri Ambrose and Richard J. Wassersug
Curr. Oncol. 2021, 28(3), 1696–1705; https://doi.org/10.3390/curroncol28030158
Available online: https://www.mdpi.com/1718-7729/28/3/158
9. “Results from a Theory-Guided Survey to Support Breast Cancer Trial Participation: Barriers, Enablers, and What to Do about them”
by Jamie C. Brehaut, Kelly Carroll, Jenn Gordon, Justin Presseau, Dawn P. Richards, Dean A. Fergusson, Ian D. Graham and Susan Marlin
Curr. Oncol. 2021, 28(3), 2014–2028; https://doi.org/10.3390/curroncol28030187
Available online: https://www.mdpi.com/1718-7729/28/3/187
10. “Acute Care Use by Breast Cancer Patients on Adjuvant Chemotherapy in Alberta: Demonstrating the Importance of Measurement to Improving Quality”
by Che Hsuan David Wu, May Lynn Quan, Shiying Kong, Yuan Xu, Jeffrey Q. Cao, Sasha Lupichuk and Lisa Barbera
Curr. Oncol. 2021, 28(6), 4420–4431; https://doi.org/10.3390/curroncol28060375
Available online: https://www.mdpi.com/1718-7729/28/6/375
24 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Gastrointestinal Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Gastrointestinal Oncology” listed below:
1. “Artificial Intelligence in Colorectal Cancer Screening, Diagnosis and Treatment. A New Era”
by Athanasia Mitsala, Christos Tsalikidis, Michail Pitiakoudis, Constantinos Simopoulos and Alexandra K. Tsaroucha
Curr. Oncol. 2021, 28(3), 1581–1607; https://doi.org/10.3390/curroncol28030149
Available online: https://www.mdpi.com/1718-7729/28/3/149
2. “Pathological Features and Prognostication in Colorectal Cancer”
by Kabytto Chen, Geoffrey Collins, Henry Wang and James Wei Tatt Toh
Curr. Oncol. 2021, 28(6), 5356–5383; https://doi.org/10.3390/curroncol28060447
Available online: https://www.mdpi.com/1718-7729/28/6/447
3. “Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma”
by Yuji Eso, Haruhiko Takeda, Kojiro Taura, Atsushi Takai, Ken Takahashi and Hiroshi Seno
Curr. Oncol. 2021, 28(5), 4157–4166; https://doi.org/10.3390/curroncol28050352
Available online: https://www.mdpi.com/1718-7729/28/5/352
4. “Higher Efficiency of Percutaneous Microwave (MWA) Than Radiofrequency Ablation (RFA) in Achieving Complete Response in Cirrhotic Patients with Early Hepatocellular Carcinoma”
by Silvia Gaia, Michela Ciruolo, Davide Giuseppe Ribaldone, Emanuela Rolle, Enrica Migliore, Elena Mosso, Simone Vola, Alessandra Risso, Sharmila Fagoonee, Giorgio Maria Saracco et al.
Curr. Oncol. 2021, 28(2), 1034–1044; https://doi.org/10.3390/curroncol28020101
Available online: https://www.mdpi.com/1718-7729/28/2/101
5. “Screening for Colorectal Cancer Leading into a New Decade: The “Roaring ‘20s” for Epigenetic Biomarkers?”
by Hélder Almeida-Lousada, André Mestre, Sara Ramalhete, Aryeh J. Price, Ramon Andrade de Mello, Ana D. Marreiros, Ricardo Pires das Neves and Pedro Castelo-Branco
Curr. Oncol. 2021, 28(6), 4874–4893; https://doi.org/10.3390/curroncol28060411
Available online: https://www.mdpi.com/1718-7729/28/6/411
6. “Geographic and Socioeconomic Disparity of Gastric Cancer Patients in Canada”
by Leila Cattelan, Feras M. Ghazawi, Michelle Le, François Lagacé, Elham Rahme, Andrei Zubarev, Denis Sasseville, Ivan V. Litvinov, Kevin A. Waschke and Elena Netchiporouk
Curr. Oncol. 2021, 28(3), 2052–2064; https://doi.org/10.3390/curroncol28030190
Available online: https://www.mdpi.com/1718-7729/28/3/190
7. “Quality of Colon Cancer Care in Patients Undergoing Emergency Surgery”
by Keegan Guidolin, Rebecca Withers, Farhana Shariff, Shady Ashamalla and Ashlie Nadler
Curr. Oncol. 2021, 28(3), 2079–2086; https://doi.org/10.3390/curroncol28030192
Available online: https://www.mdpi.com/1718-7729/28/3/192
8. “Resection of Non-Functional Pancreatic Neuroendocrine Neoplasms—A Single-Center Retrospective Outcome Analysis”
by Kirsten Lindner, Daniel Binte, Jens Hoeppner, Ulrich F. Wellner, Dominik M. Schulte, Sebastian M. Schmid, Kim Luley, Inga Buchmann, Lars Tharun, Tobias Keck et al.
Curr. Oncol. 2021, 28(4), 3071–3080; https://doi.org/10.3390/curroncol28040268
Available online: https://www.mdpi.com/1718-7729/28/4/268
9. “The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis”
by Suganija Lakkunarajah, Daniel A. Breadner, Hanbo Zhang, Ellen Yamanaka, Andrew Warner and Stephen Welch
Curr. Oncol. 2021, 28(5), 4031–4041; https://doi.org/10.3390/curroncol28050342
Available online: https://www.mdpi.com/1718-7729/28/5/342
10. “Recent Advances in Photodynamic Imaging and Therapy in Hepatobiliary Malignancies: Clinical and Experimental Aspects”
by Atsushi Nanashima, Masahide Hiyoshi, Naoya Imamura, Koichi Yano, Takeomi Hamada and Kengo Kai
Curr. Oncol. 2021, 28(5), 4067–4079; https://doi.org/10.3390/curroncol28050345
Available online: https://www.mdpi.com/1718-7729/28/5/345
23 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Genitourinary Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Genitourinary Oncology” listed below:
1. “Immunohistochemistry for Prostate Biopsy—Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making”
by Philipp Mandel, Mike Wenzel, Benedikt Hoeh, Maria N. Welte, Felix Preisser, Tahir Inam, Clarissa Wittler, Clara Humke, Jens Köllermann, Peter Wild et al.
Curr. Oncol. 2021, 28(3), 2123–2133; https://doi.org/10.3390/curroncol28030197
Available online: https://www.mdpi.com/1718-7729/28/3/197
2. “Correlation of Urine Loss after Catheter Removal and Early Continence in Men Undergoing Radical Prostatectomy”
by Benedikt Hoeh, Felix Preisser, Mike Wenzel, Clara Humke, Clarissa Wittler, Jan L. Hohenhorst, Maja Volckmann-Wilde, Jens Köllermann, Thomas Steuber, Markus Graefen et al.
Curr. Oncol. 2021, 28(6), 4738–4747; https://doi.org/10.3390/curroncol28060399
Available online: https://doi.org/10.3390/curroncol28060399
3. “The Utility of Combined Target and Systematic Prostate Biopsies in the Diagnosis of Clinically Significant Prostate Cancer Using Prostate Imaging Reporting and Data System Version 2 Based on Biparametric Magnetic Resonance Imaging”
by Daiki Kato, Kaori Ozawa, Shinichi Takeuchi, Makoto Kawase, Kota Kawase, Chie Nakai, Manabu Takai, Koji Iinuma, Keita Nakane, Hiroki Kato et al.
Curr. Oncol. 2021, 28(2), 1294–1301; https://doi.org/10.3390/curroncol28020123
Available online: https://www.mdpi.com/1718-7729/28/2/123
4. “Extreme Hypofractionation with SBRT in Localized Prostate Cancer”
by Maria Antonia Gómez-Aparicio, Jeannette Valero, Begoña Caballero, Rafael García, Ovidio Hernando-Requejo, Ángel Montero, Alfonso Gómez-Iturriaga, Thomas Zilli, Piet Ost, Fernando López-Campos, et al.
Curr. Oncol. 2021, 28(4), 2933–2949; https://doi.org/10.3390/curroncol28040257
Available online: https://www.mdpi.com/1718-7729/28/4/257
5. “Spontaneous Regression of Metastatic Renal Cell Carcinoma after SARS-CoV-2 Infection: A Report of Two Cases”
by Tomas Buchler, Lukas Fiser, Jaroslava Benesova, Hana Jirickova and Jana Votrubova
Curr. Oncol. 2021, 28(5), 3403–3407; https://doi.org/10.3390/curroncol28050294
Available online: https://www.mdpi.com/1718-7729/28/5/294
6. “Prognostic Impact of APOBEC3B Expression in Metastatic Urothelial Carcinoma and Its Association with Tumor-Infiltrating Cytotoxic T Cells”
by Hyunho Kim, Okran Kim, Myung Ah Lee, Ji Youl Lee, Sung-Hoo Hong, U-Syn Ha, Kwangil Yim and In-Ho Kim
Curr. Oncol. 2021, 28(3), 1652–1662; https://doi.org/10.3390/curroncol28030154
Available online: https://www.mdpi.com/1718-7729/28/3/154
7. “Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC)”
by Ibon Gurruchaga Sotés, Ana Nuño Alves, Sandra Vicente Arregui and Carmen Santander Lobera
Curr. Oncol. 2021, 28(4), 2346–2350; https://doi.org/10.3390/curroncol28040216
Available online: https://www.mdpi.com/1718-7729/28/4/216
8. “Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer”
by Tim Wollenweber, Lucia Zisser, Elisabeth Kretschmer-Chott, Michael Weber, Bernhard Grubmüller, Gero Kramer, Shahrokh F. Shariat, Markus Mitterhauser, Stefan Schmitl, Chrysoula Vraka et al.
Curr. Oncol. 2021, 28(5), 3692–3704; https://doi.org/10.3390/curroncol28050315
Available online: https://www.mdpi.com/1718-7729/28/5/315
9. “Prostate Cancer Metastasis to the Pituitary Gland Manifesting as Corticosteroid Withdrawal, and the Impact of the Switch from Prednisone to Dexamethasone on Survival Time”
by Okeroghene Ataikiru, Mahmoud Abdelsalam, Mrudula Avileli and Trina Hynes
Curr. Oncol. 2021, 28(6), 4291–4297; https://doi.org/10.3390/curroncol28060365
Available online: https://www.mdpi.com/1718-7729/28/6/365
10. “Cost–Utility Analysis of Radiation Treatment Modalities for Intermediate-Risk Prostate Cancer”
by Najlaa Alyamani, Jiheon Song, Sasha van Katwyk, Kednapa Thavorn, Julie Renaud, Alain Haddad, Miller MacPherson and Marc Gaudet
Curr. Oncol. 2021, 28(4), 2385–2398; https://doi.org/10.3390/curroncol28040219
Available online: https://www.mdpi.com/1718-7729/28/4/219
20 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Childhood, Adolescent and Young Adult Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Childhood, Adolescent and Young Adult Oncology” listed below:
1. “A Cross-Sectional Survey Exploring the Impact of the COVID-19 Pandemic on the Cancer Care of Adolescents and Young Adults”
by Kaitlyn Howden, Camille Glidden, Razvan G. Romanescu, Andrew Hatala, Ian Scott, Julie Deleemans, Karine Chalifour, Geoff Eaton, Abha A. Gupta, James M. Bolton et al.
Curr. Oncol. 2021, 28(4), 3201–3213; https://doi.org/10.3390/curroncol28040278
Available online: https://www.mdpi.com/1718-7729/28/4/278
2. “The Role of PET in Supratentorial and Infratentorial Pediatric Brain Tumors”
by Angelina Cistaro, Domenico Albano, Pierpaolo Alongi, Riccardo Laudicella, Daniele Antonio Pizzuto, Giuseppe Formica, Cinzia Romagnolo, Federica Stracuzzi, Viviana Frantellizzi, Arnoldo Piccardo et al.
Curr. Oncol. 2021, 28(4), 2481–2495; https://doi.org/10.3390/curroncol28040226
Available online: https://www.mdpi.com/1718-7729/28/4/226
3. “The Neurokinin-1 Receptor Is a Target in Pediatric Rhabdoid Tumors”
by Julian Kolorz, Salih Demir, Adrian Gottschlich, Iris Beirith, Matthias Ilmer, Daniel Lüthy, Christoph Walz, Mario M. Dorostkar, Thomas Magg, Fabian Hauck et al.
Curr. Oncol. 2022, 29(1), 94–110; https://doi.org/10.3390/curroncol29010008
Available online: https://www.mdpi.com/1718-7729/29/1/8
4. “A Retrospective Comparative Analysis of Outcomes and Prognostic Factors in Adult and Pediatric Patients with Osteosarcoma”
by Stefano Testa, Benjamin D. Hu, Natalie L. Saadeh, Allison Pribnow, Sheri L. Spunt, Gregory W. Charville, Nam Q. Bui and Kristen N. Ganjoo
Curr. Oncol. 2021, 28(6), 5304–5317; https://doi.org/10.3390/curroncol28060443
Available online: https://www.mdpi.com/1718-7729/28/6/443
5. “Parents’ Experiences with Home-Based Oral Chemotherapy Prescribed to a Child Diagnosed with Acute Lymphoblastic Leukemia: A Qualitative Study”
by Étienne Camiré-Bernier, Erwan Nidelet, Amel Baghdadli, Gabriel Demers, Marie-Christine Boulanger, Marie-Claude Brisson, Bruno Michon, Sophie Lauzier and Isabelle Laverdière
Curr. Oncol. 2021, 28(6), 4377–4391; https://doi.org/10.3390/curroncol28060372
Available online: https://www.mdpi.com/1718-7729/28/6/372
20 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Health Economics”
As Current Oncology (ISSN: 1718-7729) is of an open-access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Health Economics” listed below:
1. “Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients”
by Yuti P. Patel, Donald Husereau, Natasha B. Leighl, Barbara Melosky and Julian Nam
Curr. Oncol. 2021, 28(6), 5278–5294; https://doi.org/10.3390/curroncol28060441
Available online: https://www.mdpi.com/1718-7729/28/6/441
2. “Cost Analysis of Laparoscopic Low Anterior Resection vs. Transanal Endoscopic Microsurgery for Rectal Neoplasms”
by Katerina Neumann, Nirmal Randhawa, Jason Park and David J. Hochman
Curr. Oncol. 2021, 28(3), 1795–1802; https://doi.org/10.3390/curroncol28030167
Available online: https://www.mdpi.com/1718-7729/28/3/167
3. “The Out-of-Pocket Cost Burden of Cancer Care—A Systematic Literature Review”
by Nicolas Iragorri, Claire de Oliveira, Natalie Fitzgerald and Beverley Essue
Curr. Oncol. 2021, 28(2), 1216–1248; https://doi.org/10.3390/curroncol28020117
Available online: https://www.mdpi.com/1718-7729/28/2/117
4. “Cost Minimization Analysis of Hypofractionated Radiotherapy”
by Hannah L.Yaremko, Gordon E. Locke, Ronald Chow, Michael Lock, Robert Dinniwell and Brian P. Yaremko
Curr. Oncol. 2021, 28(1), 716–725; https://doi.org/10.3390/curroncol28010070
Available online: https://www.mdpi.com/1718-7729/28/1/70
5. “Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Tumors versus Standard of Care”
by Adam J. N. Raymakers, David Cameron, Scott Tyldesley and Dean A. Regier
Curr. Oncol. 2021, 28(3), 1857–1866; https://doi.org/10.3390/curroncol28030172
Available online: https://www.mdpi.com/1718-7729/28/3/172
6. “Comparing Manufacturer Submitted and Pan-Canadian Oncology Drug Review Reanalysed Incremental Cost-Effectiveness Ratios for Novel Oncology Drugs”
by Ronak Saluja, Tina Jiao, Liza Koshy, Matthew Cheung and Kelvin K. W. Chan
Curr. Oncol. 2021, 28(1), 606–618; https://doi.org/10.3390/curroncol28010060
Available online: https://www.mdpi.com/1718-7729/28/1/60
7. “Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer”
by Megan M. Tu, Mark Clemons, Carol Stober, Ahwon Jeong, Lisa Vandermeer, Mihaela Mates, Phillip Blanchette, Anil Abraham Joy, Olexiy Aseyev, Gregory Pond et al.
Curr. Oncol. 2021, 28(3), 1847–1856; https://doi.org/10.3390/curroncol28030171
Available online: https://www.mdpi.com/1718-7729/28/3/171
by Anca Prica, Annette E. Hay, Michael Crump, Nicole Mittmann, Lois E. Shepherd, Ralph M. Meyer, Kevin I. Imrie, Nancy Risebrough, Marina Djurfeldt, Bingshu E. Chen et al.
Curr. Oncol. 2021, 28(2), 1256–1261; https://doi.org/10.3390/curroncol28020119
Available online: https://www.mdpi.com/1718-7729/28/2/119
19 October 2023
Open Access Week 2023 – the Global Drive to Open Continues

MDPI has been a strong proponent of the open access publishing model right from the beginning. As one of the pioneering fully open access publishers, we firmly believe that unrestricted access to research findings forms the foundation for better transparency, efficiency, and quality control across all scientific disciplines.
In December 2022, we reached a significant milestone by surpassing one million articles published. That is one million articles freely available to all, to circulate and build upon!
Offering free and immediate access to scientific papers empowers scientists to examine, validate, replicate, and expand upon existing results. This not only helps prevent redundancy and optimizes how resources are used but also paves the way for innovative new approaches.
The International Open Access Week takes place from 23 to 29 October 2023, providing a unique opportunity to connect the global movement towards open sharing and open science with the progress of policy transformations at the local level.
Our goal, during Open Access Week as well as throughout the year, is to offer resources for educating people about the benefits of open access publishing. The MDPI Blog offers a wealth of information around open access and open science.
Promoting the values of accessibility, transparency, and collaboration
Open access publishing embodies the fundamental values of democratizing knowledge and fostering global accessibility. It aims to break down barriers that have traditionally limited access to scholarly work, ensuring that knowledge is available to all, regardless of their financial or institutional affiliations.
Discounts are part of our commitment to ensuring there are diverse pathways to Open Access publishing for researchers worldwide. MDPI supports scientific communities in several different ways.
One of the key strengths of open access publishing lies in its ability to facilitate interdisciplinary research. By removing paywalls and promoting the sharing of knowledge across disciplines, OA encourages collaboration and innovation. Researchers from diverse fields can access and build upon each other's work, fostering a holistic approach to addressing complex global challenges.
Funders' policies are getting aligned with open science
Governments, institutions, and funding agencies have recognized the transformative potential of open access and have implemented policies to promote it. These policies often mandate that publicly funded research should be made openly accessible. Such initiatives have accelerated the growth of open access repositories and journals, reinforcing the commitment to open access principles. Check our spotlights on OA policies in the US, EU and China.
Open access publishing is continually evolving, with innovative and community-driven models and technologies shaping its future. Initiatives like "Plan S" and "cOAlition S" promote the adoption of OA publishing from the national funders’ perspective by requiring grantees to publish their research openly. A new policy announced by the US administration last year requires that, as of January 2026, all US federally funded research be made freely and immediately available after publication.
Additionally, preprint servers such as MDPI's Preprints.org, which allow researchers to share their findings before formal peer review, have gained popularity, enhancing the speed at which new knowledge is disseminated. The rise of blockchain technology is also being explored to ensure transparency and authenticity in scholarly publishing.
For more than twenty years, open access scholarly publishing has been revolutionizing academia by promoting the values of accessibility, transparency, and collaboration. Its support for interdisciplinary research, evolving policies, and innovative practices all contribute to its growing influence in the global research community. As open access continues to expand, it holds the potential to democratize knowledge, advance science, and drive positive societal change.
MDPI is proud to be a leader in the transition to open access.
19 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Thoracic Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Thoracic Oncology” listed below:
1. “The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer at a Canadian Academic Center: A Retrospective Chart Review”
by Goulnar Kasymjanova, Aksa Anwar, Victor Cohen, Khalil Sultanem, Carmela Pepe, Lama Sakr, Jennifer Friedmann and Jason S. Agulnik
Curr. Oncol. 2021, 28(6), 4247–4255; https://doi.org/10.3390/curroncol28060360
Available online: https://www.mdpi.com/1718-7729/28/6/360
2. “Real-World Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Extensive-Stage Small Cell Lung Cancer in Canada”
by Dylan E. O’Sullivan, Winson Y. Cheung, Iqra A. Syed, Daniel Moldaver, Mary Kate Shanahan, D. Gwyn Bebb, Christina Sit, Darren R. Brenner and Devon J. Boyne
Curr. Oncol. 2021, 28(4), 3091–3103; https://doi.org/10.3390/curroncol28040270
Available online: https://www.mdpi.com/1718-7729/28/4/270
3. “Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancer—A Cost-Efficient Strategy in a Public Healthcare System”
by Maisam Makarem, Doreen A. Ezeife, Adam C. Smith, Janice J. N. Li, Jennifer H. Law, Ming-Sound Tsao and Natasha B. Leighl
Curr. Oncol. 2021, 28(5), 3268–3279; https://doi.org/10.3390/curroncol28050284
Available online: https://www.mdpi.com/1718-7729/28/5/284
4. “Immunotherapy in Extensive-Stage Small Cell Lung Cancer”
by Rola El Sayed, and Normand Blais
Curr. Oncol. 2021, 28(5), 4093–4108; https://doi.org/10.3390/curroncol28050347
Available online: https://www.mdpi.com/1718-7729/28/5/347
5. “Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database”
by Heidi A. I. Grosjean, Samantha Dolter, Daniel E. Meyers, Philip Q. Ding, Igor Stukalin, Siddhartha Goutam, Shiying Kong, Quincy Chu, Daniel Y. C. Heng, D. Gwyn Bebb et al.
Curr. Oncol. 2021, 28(5), 4213–4222; https://doi.org/10.3390/curroncol28050357
Available online: https://www.mdpi.com/1718-7729/28/5/357
6. “Meta-Analysis of Neoadjuvant Immunotherapy for Patients with Resectable Non-Small Cell Lung Cancer”
by Christopher Cao, Anthony Le, Matthew Bott, Chi-Fu Jeffrey Yang, Dominique Gossot, Franca Melfi, David H. Tian and Allen Guo
Curr. Oncol. 2021, 28(6), 4686–4701; https://doi.org/10.3390/curroncol28060395
Available online: https://www.mdpi.com/1718-7729/28/6/395
7. “Real World Analysis of Small Cell Lung Cancer Patients: Prognostic Factors and Treatment Outcomes”
by Sarah Sharman Moser, Jair Bar, Inna Kan, Keren Ofek, Raanan Cohen, Nikhil Khandelwal, Varda Shalev, Gabriel Chodick and Nava Siegelmann-Danieli
Curr. Oncol. 2021, 28(1), 317–331; https://doi.org/10.3390/curroncol28010036
Available online: https://www.mdpi.com/1718-7729/28/1/36
8. “Contribution of the IdyllaTM System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of EGFR Mutations”
by Constance Petiteau, Gwladys Robinet-Zimmermann, Adèle Riot, Marine Dorbeau, Nicolas Richard, Cécile Blanc-Fournier, Frédéric Bibeau, Simon Deshayes, Emmanuel Bergot, Radj Gervais et al.
Curr. Oncol. 2021, 28(6), 4432–4445; https://doi.org/10.3390/curroncol28060376
Available online: https://www.mdpi.com/1718-7729/28/6/376
9. “Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis”
by Koichi Ando, Ryo Manabe, Yasunari Kishino, Sojiro Kusumoto, Toshimitsu Yamaoka, Akihiko Tanaka, Tohru Ohmori, Tsukasa Ohnishi and Hironori Sagara
Curr. Oncol. 2021, 28(2), 1094–1113; https://doi.org/10.3390/curroncol28020106
Available online: https://www.mdpi.com/1718-7729/28/2/106
10. “Health Resource and Cost Savings Achieved in a Multidisciplinary Lung Cancer Clinic”
by Christopher J. L. Stone, Ana P. Johnson, Danielle Robinson, Andriy Katyukha, Rylan Egan, Sophia Linton, Christopher Parker, Andrew Robinson and Geneviève C. Digby
Curr. Oncol. 2021, 28(3), 1681–1695; https://doi.org/10.3390/curroncol28030157
Available online: https://www.mdpi.com/1718-7729/28/3/157
18 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Surgical Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Surgical Oncology” listed below:
1. “Synovial Sarcoma: A Clinical Review”
by Aaron M. Gazendam, Snezana Popovic, Sohaib Munir, Naveen Parasu, David Wilson and Michelle Ghert
Curr. Oncol. 2021, 28(3), 1909–1920; https://doi.org/10.3390/curroncol28030177
Available online: https://www.mdpi.com/1718-7729/28/3/177
2. “Combined Exoscopic and Endoscopic Technique for Craniofacial Resection”
by Kenichiro Iwami, Tadashi Watanabe, Koji Osuka, Tetsuya Ogawa, Shigeru Miyachi and Yasushi Fujimoto
Curr. Oncol. 2021, 28(5), 3945–3958; https://doi.org/10.3390/curroncol28050336
Available online: https://www.mdpi.com/1718-7729/28/5/336
3. “Emerging Concepts in the Surgical Management of Peri-Acetabular Metastatic Bone Disease”
by Aaron Gazendam, Daniel Axelrod, David Wilson and Michelle Ghert
Curr. Oncol. 2021, 28(4), 2731–2740; https://doi.org/10.3390/curroncol28040238
Available online: https://www.mdpi.com/1718-7729/28/4/238
4. “The Surgical Management of Proximal Femoral Metastases: A Narrative Review”
by Daniel Axelrod, Aaron M. Gazendam and Michelle Ghert
Curr. Oncol. 2021, 28(5), 3748–3757; https://doi.org/10.3390/curroncol28050320
Available online: https://www.mdpi.com/1718-7729/28/5/320
5. “Incidence, Etiology, Prevention and Management of Ureteroenteric Strictures after Robot-Assisted Radical Cystectomy: A Review of Published Evidence and Personal Experience”
by Shintaro Narita, Mitsuru Saito, Kazuyuki Numakura and Tomonori Habuchi
Curr. Oncol. 2021, 28(5), 4109–4117; https://doi.org/10.3390/curroncol28050348
Available online: https://www.mdpi.com/1718-7729/28/5/348
6. “The Role of Denosumab for Surgical Outcomes in Patients with Giant Cell Tumour of Bone: A Systematic Review”
by Abha Gupta, Lisa Durocher-Allen, Snezana Popovic, Richard Tozer, Xiaomei Yao and Michelle Ghert
Curr. Oncol. 2021, 28(2), 1302–1313; https://doi.org/10.3390/curroncol28020124
Available online: https://www.mdpi.com/1718-7729/28/2/124
7. “Do Preoperative Transfusions Impact Prognosis in Moderate to Severe Anaemic Surgical Patients with Colon Cancer?”
by Nicolò Tamini, Luca Gianotti, Shadya Darwish, Salvatore Petitto, Davide Bernasconi, Massimo Oldani, Fabio Uggeri, Marco Braga and Luca Nespoli
Curr. Oncol. 2021, 28(6), 4634–4644; https://doi.org/10.3390/curroncol28060391
Available online: https://www.mdpi.com/1718-7729/28/6/391
8. “Salvage Surgical Resection after Linac-Based Stereotactic Radiosurgery for Newly Diagnosed Brain Metastasis”
by Ryosuke Matsuda, Takayuki Morimoto, Tetsuro Tamamoto, Nobuyoshi Inooka, Tomoko Ochi, Toshiteru Miyasaka, Shigeto Hontsu, Kaori Yamaki, Sachiko Miura, Yasuhiro Takeshima et al.
Curr. Oncol. 2021, 28(6), 5255–5265; https://doi.org/10.3390/curroncol28060439
Available online: https://www.mdpi.com/1718-7729/28/6/439
9. “National Variations in the Work-Up, Investigation, and Surgical Management of Ductal Carcinoma In Situ of the Breast across Canadian Surgeons”
by Ryerson Seguin and Lashan Peiris
Curr. Oncol. 2021, 28(2), 1366–1375; https://doi.org/10.3390/curroncol28020130
Available online: https://www.mdpi.com/1718-7729/28/2/130
10. “Extent of Groin Dissection in Melanoma: A Mixed-Methods, Population-Based Study of Practice Patterns and Outcomes”
by Suzana Küpper, Janice L. Austin, Brittany Dingley, Yuan Xu, Kristine Kong, Mantaj Brar, Frances C. Wright, Carolyn Nessim, Antoine Bouchard-Fortier and May Lynn Quan
Curr. Oncol. 2021, 28(6), 5422–5433; https://doi.org/10.3390/curroncol28060452
Available online: https://www.mdpi.com/1718-7729/28/6/452
18 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Palliative and Supportive Care”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Palliative and Supportive Care” listed below:
1. “Virtual Care in Patients with Cancer: A Systematic Review”
by Simron Singh, Glenn G. Fletcher, Xiaomei Yao and Jonathan Sussman
Curr. Oncol. 2021, 28(5), 3488–3506; https://doi.org/10.3390/curroncol28050301
Available online: https://www.mdpi.com/1718-7729/28/5/301
2. “Safety of Immune Checkpoint Inhibitors in Elderly Patients: An Observational Study”
by Agnese Paderi, Sara Fancelli, Enrico Caliman, Serena Pillozzi, Elisabetta Gambale, Marinella Micol Mela, Laura Doni, Francesca Mazzoni and Lorenzo Antonuzzo
Curr. Oncol. 2021, 28(5), 3259–3267; https://doi.org/10.3390/curroncol28050283
Available online: https://www.mdpi.com/1718-7729/28/5/283
3. “Risk-Stratified Pathways for Cancer Survivorship Care: Insights from a Deliberative Multi-Stakeholder Consultation”
by Dominique Tremblay, Nassera Touati, Karine Bilodeau, Catherine Prady, Susan Usher and Yves Leblanc
Curr. Oncol. 2021, 28(5), 3408–3419; https://doi.org/10.3390/curroncol28050295
Available online: https://www.mdpi.com/1718-7729/28/5/295
4. “RELIEF: A Digital Health Tool for the Remote Self-Reporting of Symptoms in Patients with Cancer to Address Palliative Care Needs and Minimize Emergency Department Visits”
by Ravi Bhargava, Bonnie Keating, Sarina R. Isenberg, Saranjah Subramaniam, Pete Wegier and Martin Chasen
Curr. Oncol. 2021, 28(6), 4273–4280; https://doi.org/10.3390/curroncol28060363
Available online: https://www.mdpi.com/1718-7729/28/6/363
5. “Describing Sources of Uncertainty in Cancer Drug Formulary Priority Setting across Canada”
by Kristina Jenei, Stuart Peacock, Michael Burgess and Craig Mitton
Curr. Oncol. 2021, 28(4), 2708–2719; https://doi.org/10.3390/curroncol28040236
Available online: https://www.mdpi.com/1718-7729/28/4/236
6. “Post-Treatment Adverse Health Correlates among Prostate Cancer Survivors in a Sample of Men Residing in Atlantic Canada”
by Gabriela Ilie, Robert Rutledge and Ellen Sweeney
Curr. Oncol. 2021, 28(4), 2812–2822; https://doi.org/10.3390/curroncol28040246
Available online: https://www.mdpi.com/1718-7729/28/4/246
7. “A Multidisciplinary Approach to Implement Personalized Breast Cancer Treatment and Care Plans”
by Rashida Haq, Amy Kong and Pauline Gulasingam
Curr. Oncol. 2021, 28(1), 767–782; https://doi.org/10.3390/curroncol28010075
Available online: https://www.mdpi.com/1718-7729/28/1/75
8. “Quality of Colon Cancer Care in Patients Undergoing Emergency Surgery”
by Keegan Guidolin, Rebecca Withers, Farhana Shariff, Shady Ashamalla and Ashlie Nadler
Curr. Oncol. 2021, 28(3), 2079–2086; https://doi.org/10.3390/curroncol28030192
Available online: https://www.mdpi.com/1718-7729/28/3/192
9. “Canadian Resources, Programs, and Models of Care to Support Cancer Survivors’ Transition beyond Treatment: A Scoping Review”
by Claudia Romkey-Sinasac, Stephanie Saunders and Jacqueline Galica
Curr. Oncol. 2021, 28(3), 2134–2145; https://doi.org/10.3390/curroncol28030198
Available online: https://www.mdpi.com/1718-7729/28/3/198
10. “Narratives of Survivorship: A Study of Breast Cancer Pathographies and Their Place in Cancer Rehabilitation”
by Åsa Mohlin and Katarina Bernhardsson
Curr. Oncol. 2021, 28(4), 2840–2851; https://doi.org/10.3390/curroncol28040249
Available online: https://www.mdpi.com/1718-7729/28/4/249
17 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Gynecologic Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Gynecologic Oncology” listed below:
1. “Cytochrome 4Z1 Expression Is Correlated with Poor Prognosis in Patients with Cervical Cancer”
by Yousef M. Al-saraireh, Fatemah O. F. O. Alshammari, Ahmed M. M. Youssef, Yahya M. Al-sarayra, Renata A. Al-saraireh, Ghadeer H. Al-muhaisen, Yanal S. Al-mahdy, Ahlam M. Al-Kharabsheh, Seham M. Abufraijeh and Hamzeh Mohammad Alrawashdeh
Curr. Oncol. 2021, 28(5), 3573–3584; https://doi.org/10.3390/curroncol28050306
Available online: https://www.mdpi.com/1718-7729/28/5/306
2. “The Challenge of Return to Work after Breast Cancer: The Role of Family Situation, CANTO Cohort”
by Elsa Caumette, Inès Vaz-Luis, Sandrine Pinto, Julie Havas, Thomas Bovagnet, Garazi Ruiz de Azua, Antonio Di Meglio, Anne-Laure Martin, Sibille Everhard, Paul Cottu et al.
Curr. Oncol. 2021, 28(5), 3866–3875; https://doi.org/10.3390/curroncol28050330
Available online: https://www.mdpi.com/1718-7729/28/5/330
3. “Feasibility of a Pilot Randomized Controlled Trial Examining a Multidimensional Intervention in Women with Gynecological Cancer at Risk of Lymphedema”
by Shirin M. Shallwani, Anna Towers, Anne Newman, Shannon Salvador, Angela Yung, Lucy Gilbert, Walter H. Gotlieb, Xing Zeng and Doneal Thomas
Curr. Oncol. 2021, 28(1), 455–470; https://doi.org/10.3390/curroncol28010048
Available online: https://www.mdpi.com/1718-7729/28/1/48
4. “Long-Term Results of Postoperative Hypofractionated Accelerated Breast and Lymph Node Radiotherapy (HypoAR) with Hypofractionated Boost”
by Ioannis M. Koukourakis, Marianthi Panteliadou, Axiotis G. Giakzidis, Christos Nanos, Ioannis Abatzoglou, Alexandra Giatromanolaki and Michael I. Koukourakis
Curr. Oncol. 2021, 28(5), 3474–3487; https://doi.org/10.3390/curroncol28050300
Available online: https://www.mdpi.com/1718-7729/28/5/300
5. “Omental Macrophagic “Crown-like Structures” Are Associated with Poor Prognosis in Advanced-Stage Serous Ovarian Cancer”
by Yu-Ling Liang, Chang-Ni Lin, Hsing-Fen Tsai, Pei-Ying Wu, Sheng-Hsiang Lin, Tse-Ming Hong and Keng-Fu Hsu
Curr. Oncol. 2021, 28(5), 4234–4246; https://doi.org/10.3390/curroncol28050359
Available online: https://www.mdpi.com/1718-7729/28/5/359
6. “A Case of Stevens–Johnson Syndrome in Recurrent Late-Stage Ovarian Cancer Patient after Management of Chronic Pain with Elastomeric Pump”
by Andrej Cokan, Vida Gavrić Lovrec and Iztok Takač
Curr. Oncol. 2021, 28(4), 2928–2932; https://doi.org/10.3390/curroncol28040256
Available online: https://www.mdpi.com/1718-7729/28/4/256
7. “Radiation-Induced Emesis (RIE) in Extended-Field Radiotherapy for Gynecological Malignancies: Dosimetric and Non-Dosimetric Factors”
by Yu-Ming Wang, Yi-Fan Chen, Pei-Yi Lee, Meng-Wei Ho and Eng-Yen Huang
Curr. Oncol. 2021, 28(5), 3602–3609; https://doi.org/10.3390/curroncol28050308
Available online: https://www.mdpi.com/1718-7729/28/5/308
8. “Could the Long-Term Oncological Safety of Laparoscopic Surgery in Low-Risk Endometrial Cancer also Be Valid for the High–Intermediate- and High-Risk Patients? A Multi-Center Turkish Gynecologic Oncology Group Study Conducted with 2745 Endometrial Cancer Cases. (TRSGO-End-001)”
by Mehmet Ali Vardar, Ahmet Baris Guzel, Salih Taskin, Mete Gungor, Nejat Ozgul, Coskun Salman, Umran Kucukgoz-Gulec, Ghanim Khatib, Cagatay Taskiran, Ilkkan Dünder et al.
Curr. Oncol. 2021, 28(6), 4328–4340; https://doi.org/10.3390/curroncol28060368
Available online: https://www.mdpi.com/1718-7729/28/6/368
9. “ERCC1 19007 Polymorphism in Greek Patients with Advanced Urothelial Cancer Treated with Platinum-Based Chemotherapy: Effect of the Changing Treatment Paradigm: A Cohort Study by the Hellenic GU Cancer Group”
by Aristotelis Bamias, Konstantinos Koutsoukos, Nikos Gavalas, Roubini Zakopoulou, Kimon Tzannis, Nikos Dedes, Anna Boulouta, Charalampos Fragkoulis, Eythymios Kostouros, Athanasios Dellis et al.
Curr. Oncol. 2021, 28(6), 4474–4484; https://doi.org/10.3390/curroncol28060380
Available online: https://www.mdpi.com/1718-7729/28/6/380
10. “Clinical Study of Sentinel Lymph Node Detection Using Photodynamic Eye for Abdominal Radical Trachelectomy”
by Naomi Harano, Masaru Sakamoto, Souta Fukushima, Shinnosuke Iwai, Yuki Koike, Shingo Horikawa, Kayo Suzuki, Chikage Narui, Kazuko Matsuoka, Rinko Ozeki et al.
Curr. Oncol. 2021, 28(6), 4709–4720; https://doi.org/10.3390/curroncol28060397
Available online: https://www.mdpi.com/1718-7729/28/6/397
14 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Head and Neck Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Head and Neck Oncology” listed below:
1. “Discrimination of Cancer Stem Cell Markers ALDH1A1, BCL11B, BMI-1, and CD44 in Different Tissues of HNSCC Patients”
by Kariem Sharaf, Axel Lechner, Stefan P. Haider, Robert Wiebringhaus, Christoph Walz, Gisela Kranz, Martin Canis, Frank Haubner, Olivier Gires and Philipp Baumeister
Curr. Oncol. 2021, 28(4), 2763–2774; https://doi.org/10.3390/curroncol28040241
Available online: https://www.mdpi.com/1718-7729/28/4/241
2. “Combination of Lenvatinib and Pembrolizumab as Salvage Treatment for Paucicellular Variant of Anaplastic Thyroid Cancer: A Case Report”
by Cristina Luongo, Tommaso Porcelli, Francesca Sessa, Maria Angela De Stefano, Francesco Scavuzzo, Vincenzo Damiano, Michele Klain, Claudio Bellevicine, Elide Matano, Giancarlo Troncone et al.
Curr. Oncol. 2021, 28(6), 5401–5407; https://doi.org/10.3390/curroncol28060450
Available online: https://www.mdpi.com/1718-7729/28/6/450
3. “Differential Expression of Non-Coding RNA Signatures in Thyroid Cancer between Two Ethnic Groups”
by Kristiana Rood, Khodeza Begum, Hanmin Wang, Yan C. Wangworawat, Ryan Davis, Celina R. Yamauchi, Mia C. Perez, Alfred A. Simental, Ria T. Laxa, Charles Wang et al.
Curr. Oncol. 2021, 28(5), 3610–3628; https://doi.org/10.3390/curroncol28050309
Available online: https://www.mdpi.com/1718-7729/28/5/309
4. “Clinicopathological Risk Factors for Contralateral Lymph Node Metastases in Intraoral Squamous Cell Carcinoma: A Study of 331 Cases”
by Christian Flörke, Aydin Gülses, Christina-Randi Altmann, Jörg Wiltfang, Henning Wieker and Hendrik Naujokat
Curr. Oncol. 2021, 28(3), 1886–1898; https://doi.org/10.3390/curroncol28030175
Available online: https://www.mdpi.com/1718-7729/28/3/175
5. “Use of Propensity Score Matching to Compare Short Outcomes from Transoral and External Surgical Approaches in Patients with Deep-Lobe Parotid Pleomorphic Adenomas”
by Yue Fan, Shuguang Li, Shuting Yu, Xiaoli Zhu, Xiaohua Shi, Wuyi Li, Zhiqiang Gao and Xingming Chen
Curr. Oncol. 2021, 28(4), 3115–3123; https://doi.org/10.3390/curroncol28040272
Available online: https://www.mdpi.com/1718-7729/28/4/272
6. “Outcomes of Post-Operative Treatment with Concurrent Chemoradiotherapy (CRT) in High-Risk Resected Oral Cavity Squamous Cell Carcinoma (OCSCC): A Multi-Institutional Collaboration”
by Arslan Babar, Neil M. Woody, Ahmed I. Ghanem, Jillian Tsai, Neal E. Dunlap, Matthew Schymick, Howard Y. Liu, Brian B. Burkey, Eric D. Lamarre, Jamie A. Ku et al.
Curr. Oncol. 2021, 28(4), 2409–2419; https://doi.org/10.3390/curroncol28040221
Available online: https://www.mdpi.com/1718-7729/28/4/221
7. “A Rare Coexistence of Paraneoplastic Cerebellar Degeneration: Papillary Thyroid Carcinoma”
by Zeynep Özözen Ayas and Gülgün Uncu
Curr. Oncol. 2021, 28(1), 560–564; https://doi.org/10.3390/curroncol28010055
Available online: https://www.mdpi.com/1718-7729/28/1/55
8. “Occurrence of Arrhythmias in Women with Thyroid Cancer Receiving Suppressive Doses of Levothyroxine”
by Karol Kaziród-Wolski, Aldona Kowalska, Janusz Sielski, Magdalena Biskup-Frużyńska and Grzegorz Piotrowski
Curr. Oncol. 2021, 28(6), 5009–5018; https://doi.org/10.3390/curroncol28060420
Available online: https://www.mdpi.com/1718-7729/28/6/420
9. “WNT8B as an Independent Prognostic Marker for Nasopharyngeal Carcinoma”
by Chawalit Ngernsombat, Pongphol Prattapong, Noppadol Larbcharoensub, Krittika Khotthong and Tavan Janvilisri
Curr. Oncol. 2021, 28(4), 2529–2539; https://doi.org/10.3390/curroncol28040230
Available online: https://www.mdpi.com/1718-7729/28/4/230
10. “Distinct Outcomes of Oropharyngeal Squamous Cell Carcinoma Patients after Distant Failure According to p16 Status: Implication in Therapeutic Options”
by Anouchka Modesto, Aurore Siegfried, Amelie Lusque, Sébastien Vergez, Jerome Sarini, Laurent Brouchet, Emmanuelle Uro-Coste, Pierre Graff-Cailleaud and Jean Pierre Delord
Curr. Oncol. 2021, 28(3), 1673–1680; https://doi.org/10.3390/curroncol28030156
Available online: https://www.mdpi.com/1718-7729/28/3/156
14 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Psychosocial Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Psychosocial Oncology” listed below:
1. “COVID-19 Pandemic Stressors and Psychological Symptoms in Breast Cancer Patients”
by Véronique Massicotte, Hans Ivers and Josée Savard
Curr. Oncol. 2021, 28(1), 294–300; https://doi.org/10.3390/curroncol28010034
Available online: https://www.mdpi.com/1718-7729/28/1/34
2. “Personality Traits and Urinary Symptoms Are Associated with Mental Health Distress in Patients with a Diagnosis of Prostate Cancer”
by Charles Gillis, Gabriela Ilie, Ross Mason, Gregory Bailly, Joseph Lawen, David Bowes, Nikhilesh Patil, Derek Wilke, Robert David Harold Rutledge, David Bell et al.
Curr. Oncol. 2021, 28(4), 2993–3002; https://doi.org/10.3390/curroncol28040262
Available online: https://www.mdpi.com/1718-7729/28/4/262
3. “Examining the Pathoplastic Moderating Role of Education on the Association between Depressive Mood and Self-Rated Health among Cancer Survivors: A Population-Based Study”
by Anao Zhang, Kaipeng Wang and Adam S. DuVall
Curr. Oncol. 2021, 28(5), 4042–4052; https://doi.org/10.3390/curroncol28050343
Available online: https://www.mdpi.com/1718-7729/28/5/343
4. “Psychosocial Distress in Adult Patients Awaiting Cancer Surgery during the COVID-19 Pandemic”
by David Forner, Sarah Murnaghan, Geoffrey Porter, Ross J. Mason, Paul Hong, S. Mark Taylor, James Bentley, Gregory Hirsch, Christopher W. Noel, Matthew H. Rigby et al.
Curr. Oncol. 2021, 28(3), 1867–1878; https://doi.org/10.3390/curroncol28030173
Available online: https://www.mdpi.com/1718-7729/28/3/173
5. “Treatment Regret, Mental and Physical Health Indicators of Psychosocial Well-Being among Prostate Cancer Survivors”
by Cassidy Bradley, Gabriela Ilie, Cody MacDonald, Lia Massoeurs, Jasmine Dang Cam-Tu Vo and Robert David Harold Rutledge
Curr. Oncol. 2021, 28(5), 3900–3917; https://doi.org/10.3390/curroncol28050333
Available online: https://www.mdpi.com/1718-7729/28/5/333
6. “A Cross-Sectional Survey Exploring the Impact of the COVID-19 Pandemic on the Cancer Care of Adolescents and Young Adults”
by Kaitlyn Howden, Camille Glidden, Razvan G. Romanescu, Andrew Hatala, Ian Scott, Julie Deleemans, Karine Chalifour, Geoff Eaton, Abha A. Gupta, James M. Bolton et al.
Curr. Oncol. 2021, 28(4), 3201–3213; https://doi.org/10.3390/curroncol28040278
Available online: https://www.mdpi.com/1718-7729/28/4/278
13 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Medical Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Medical Oncology” listed below:
1. “Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome”
by Sim Vermeulen, Gil Awada, Marleen Keyaerts, Bart Neyns and Hendrik Everaert
Curr. Oncol. 2021, 28(3), 1630–1640; https://doi.org/10.3390/curroncol28030152
Available online: https://www.mdpi.com/1718-7729/28/3/152
2. “The Rethinking Clinical Trials (REaCT) Program. A Canadian-Led Pragmatic Trials Program: Strategies for Integrating Knowledge Users into Trial Design”
by Deanna Saunders, Michelle Liu, Lisa Vandermeer, Mashari Jemaan Alzahrani, Brian Hutton and Mark Clemons
Curr. Oncol. 2021, 28(5), 3959–3977; https://doi.org/10.3390/curroncol28050337
Available online: https://www.mdpi.com/1718-7729/28/5/337
3. “Staging Investigations in Asymptomatic Early Breast Cancer Patients at the Cancer Centre of Southeastern Ontario”
by Dalia Kamel, Veronica Youssef, Wilma M. Hopman and Mihaela Mates
Curr. Oncol. 2021, 28(3), 2190–2198; https://doi.org/10.3390/curroncol28030203
Available online: https://www.mdpi.com/1718-7729/28/3/203
4. “Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice”
by Joyce O’Shaughnessy, Leisha A. Emens, Stephen Y. Chui, Wei Wang, Kenneth Russell, Shih-Wen Lin, Carlos Flores Avile, Patricia Luhn and Andreas Schneeweiss
Curr. Oncol. 2021, 28(4), 2741–2752; https://doi.org/10.3390/curroncol28040239
Available online: https://www.mdpi.com/1718-7729/28/4/239
5. “18F-DCFPyL (PSMA) PET in the Management of Men with Biochemical Failure after Primary Therapy: Initial Clinical Experience of an Academic Cancer Center”
by Ur Metser, Claudia Ortega, Douglas Hussey, Rosanna Chan, Alejandro Berlin, Antonio Finelli and Patrick Veit-Haibach
Curr. Oncol. 2021, 28(5), 3251–3258; https://doi.org/10.3390/curroncol28050282
Available online: https://www.mdpi.com/1718-7729/28/5/282
6. “The Past, Present, and Future of Economic Evaluations of Precision Medicine at the Committee for Economic Analyses of the Canadian Cancer Trials Group”
by Kelvin K. W. Chan, Matthew C. Cheung, Dean A. Regier, Annette Hay, Alexander V. Louie, Winson Y. Cheung, Jean-Eric Tarride, Suji Udayakumar and Nicole Mittmann
Curr. Oncol. 2021, 28(5), 3649–3658; https://doi.org/10.3390/curroncol28050311
Available online: https://www.mdpi.com/1718-7729/28/5/311
7. “Real World Analysis of Small Cell Lung Cancer Patients: Prognostic Factors and Treatment Outcomes”
by Sarah Sharman Moser, Jair Bar, Inna Kan, Keren Ofek, Raanan Cohen, Nikhil Khandelwal, Varda Shalev, Gabriel Chodick and Nava Siegelmann-Danieli
Curr. Oncol. 2021, 28(1), 317–331; https://doi.org/10.3390/curroncol28010036
Available online: https://www.mdpi.com/1718-7729/28/1/36
8. “Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group”
by Wei Fang Dai, Vanessa Arciero, Erica Craig, Brent Fraser, Jessica Arias, Darryl Boehm, Nevzeta Bosnic, Patricia Caetano, Carole Chambers, Barry Jones et al.
Curr. Oncol. 2021, 28(5), 4174–4183; https://doi.org/10.3390/curroncol28050354
Available online: https://www.mdpi.com/1718-7729/28/5/354
9. “Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise”
by Wei Fang Dai, Erica Craig, Brent Fraser, Alex Chambers, Helen Mai, M. Bryson Brown, Craig C. Earle, William K. Evans, Marc Geirnaert, Marianne Taylor et al.
Curr. Oncol. 2021, 28(6), 4645–4654; https://doi.org/10.3390/curroncol28060392
Available online: https://www.mdpi.com/1718-7729/28/6/392
10. “Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec”
by Jason S. Agulnik, Goulnar Kasymjanova, Carmela Pepe, Manjusha Hurry, Ryan N. Walton, Lama Sakr, Victor Cohen and David Small
Curr. Oncol. 2021, 28(6), 5179–5191; https://doi.org/10.3390/curroncol28060434
Available online: https://www.mdpi.com/1718-7729/28/6/434
12 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Neuro-Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Neuro-Oncology” listed below:
1. “Changes in Brain Energy and Membrane Metabolism in Glioblastoma following Chemoradiation”
by Astrid Ellen Grams, Stephanie Mangesius, Ruth Steiger, Ivan Radovic, Andreas Rietzler, Lisa Maria Walchhofer, Malik Galijašević, Julian Mangesius, Martha Nowosielski, Christian Franz Freyschlag et al.
Curr. Oncol. 2021, 28(6), 5041–5053; https://doi.org/10.3390/curroncol28060424
Available online: https://www.mdpi.com/1718-7729/28/6/424
2. “The Role of PET in Supratentorial and Infratentorial Pediatric Brain Tumors”
by Angelina Cistaro, Domenico Albano, Pierpaolo Alongi, Riccardo Laudicella, Daniele Antonio Pizzuto, Giuseppe Formica, Cinzia Romagnolo, Federica Stracuzzi, Viviana Frantellizzi, Arnoldo Piccardo et al.
Curr. Oncol. 2021, 28(4), 2481–2495; https://doi.org/10.3390/curroncol28040226
Available online: https://www.mdpi.com/1718-7729/28/4/226
3. “Clinicopathologic and Treatment Features of Long-Term Surviving Brain Metastasis Patients”
by Archya Dasgupta, Jayson Co, Jeff Winter, Barbara-Ann Millar, Normand Laperriere, Derek S. Tsang, Monique van Prooijen, Andrei Damyanovich, Robert Heaton, Catherine Coolens et al.
Curr. Oncol. 2021, 28(1), 549–559; https://doi.org/10.3390/curroncol28010054
Available online: https://www.mdpi.com/1718-7729/28/1/54
4. “The Influence of Gene Aberrations on Survival in Resected IDH Wildtype Glioblastoma Patients: A Single-Institution Study”
by Ondrej Kalita, Zuzana Sporikova, Marian Hajduch, Magdalena Megova Houdova, Rastislav Slavkovsky, Lumir Hrabalek, Matej Halaj, Yvona Klementova, Martin Dolezel, Jiri Drabek et al.
Curr. Oncol. 2021, 28(2), 1280–1293; https://doi.org/10.3390/curroncol28020122
Available online: https://www.mdpi.com/1718-7729/28/2/122
5. “A Contemporary Report of Clinical Outcomes in Patients with Melanoma Brain Metastases”
by William J. Phillips, Tabassom Baghai, Michael Ong, Bryan Lo, Andrea M. Ibrahim, Tyler K.T. Smith and Xinni Song
Curr. Oncol. 2021, 28(1), 428–439; https://doi.org/10.3390/curroncol28010045
Available online: https://www.mdpi.com/1718-7729/28/1/45
6. “Feasibility on the Use of Radiomics Features of 11[C]-MET PET/CT in Central Nervous System Tumours: Preliminary Results on Potential Grading Discrimination Using a Machine Learning Model”
by Giorgio Russo, Alessandro Stefano, Pierpaolo Alongi, Albert Comelli, Barbara Catalfamo, Cristina Mantarro, Costanza Longo, Roberto Altieri, Francesco Certo, Sebastiano Cosentino et al.
Curr. Oncol. 2021, 28(6), 5318–5331; https://doi.org/10.3390/curroncol28060444
Available online: https://www.mdpi.com/1718-7729/28/6/444
7. “Rationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma”
by Masazumi Fujii, Masao Kobayakawa, Kiyoshi Saito, Akihiro Inano, Akio Morita, Mitsuhiro Hasegawa, Akitake Mukasa, Takafumi Mitsuhara, Takeo Goto, Shigeru Yamaguchi et al.
Curr. Oncol. 2021, 28(1), 726–739; https://doi.org/10.3390/curroncol28010071
Available online: https://www.mdpi.com/1718-7729/28/1/71
8. “Hypofractionated Stereotactic Radiotherapy for the Treatment of Benign Intracranial Meningiomas: Long-Term Safety and Efficacy”
by Eric K. Nguyen, Gregory R. Pond, Jeffrey N. Greenspoon, Anthony C. Whitton and Crystal Hann
Curr. Oncol. 2021, 28(5), 3683–3691; https://doi.org/10.3390/curroncol28050314
Available online: https://www.mdpi.com/1718-7729/28/5/314
9. “Salvage Surgical Resection after Linac-Based Stereotactic Radiosurgery for Newly Diagnosed Brain Metastasis”
by Ryosuke Matsuda, Takayuki Morimoto, Tetsuro Tamamoto, Nobuyoshi Inooka, Tomoko Ochi, Toshiteru Miyasaka, Shigeto Hontsu, Kaori Yamaki, Sachiko Miura, Yasuhiro Takeshima et al.
Curr. Oncol. 2021, 28(5), 3683–3691; https://doi.org/10.3390/curroncol28050314
Available online: https://www.mdpi.com/1718-7729/28/5/314
10. “Adult Medulloblastoma Demographic, Tumor and Treatment Impact since 2006: A Canadian University Experience”
by Maria Camila Quinones, Karl Bélanger, Émilie Lemieux Blanchard, Bernard Lemieux, Jean-Paul Bahary, Laura G. Masucci, David Roberge, Cynthia Menard, Carole Lambert, France Berthelet et al.
Curr. Oncol. 2021, 28(4), 3104–3114; https://doi.org/10.3390/curroncol28040271
Available online: https://www.mdpi.com/1718-7729/28/4/271
12 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Hematology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Hematology” listed below:
1. “A Review on Splenic Diffuse Red Pulp Small B-Cell Lymphoma”
by Elif Yilmaz, Arashpreet Chhina, Victor E. Nava and Anita Aggarwal
Curr. Oncol. 2021, 28(6), 5148–5154; https://doi.org/10.3390/curroncol28060431
Available online: https://www.mdpi.com/1718-7729/28/6/431
2. “Total Body Irradiation for Hematopoietic Stem Cell Transplantation: What Can We Agree on?”
by Mitchell Sabloff, Steven Tisseverasinghe, Mustafa Ege Babadagli and Rajiv Samant
Curr. Oncol. 2021, 28(1), 903–917; https://doi.org/10.3390/curroncol28010089
Available online: https://www.mdpi.com/1718-7729/28/1/89
3. “How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen”
by José Cabeçadas, Victor E. Nava, Joao L. Ascensao and Maria Gomes da Silva
Curr. Oncol. 2021, 28(6), 4611–4633; https://doi.org/10.3390/curroncol28060390
Available online: https://www.mdpi.com/1718-7729/28/6/390
4. “Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor”
by Omar Alkharabsheh, Alhareth Alsayed, Diana M. Morlote and Amitkumar Mehta
Curr. Oncol. 2021, 28(1), 837–841; https://doi.org/10.3390/curroncol28010081
Available online: https://www.mdpi.com/1718-7729/28/1/81
5. “Impact of Oral Targeted Therapy on the Economic Burden of Chronic Lymphocytic Leukemia in Canada”
by Jean Lachaine, Catherine Beauchemin, Kimberly Guinan, Philippe Thebault, Andrew Aw, Versha Banerji, Isabelle Fleury and Carolyn Owen
Curr. Oncol. 2021, 28(1), 332–345; https://doi.org/10.3390/curroncol28010037
Available online: https://www.mdpi.com/1718-7729/28/1/37
6. “Spinal Manifestation of Malignant Primary (PLB) and Secondary Bone Lymphoma (SLB)”
by Melanie Barz, Kaywan Aftahy, Insa Janssen, Yu-Mi Ryang, Georg Prokop, Stephanie E. Combs, Philipp J. Jost, Bernhard Meyer and Jens Gempt
Curr. Oncol. 2021, 28(5), 3891–3899; https://doi.org/10.3390/curroncol28050332
Available online: https://www.mdpi.com/1718-7729/28/5/332
7. “The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry”
by Chris Varghese, Tracey Immanuel, Anna Ruskova, Edward Theakston and Maggie L. Kalev-Zylinska
Curr. Oncol. 2021, 28(2), 1544–1557; https://doi.org/10.3390/curroncol28020146
Available online: https://www.mdpi.com/1718-7729/28/2/146
8. “Low-Grade Primary Splenic CD10-Positive Small B-Cell Lymphoma/Follicular Lymphoma”
by Rami Abdulbaki, Parastou Tizro, Victor E. Nava, Maria Gomes da Silva and João L. Ascensão
Curr. Oncol. 2021, 28(6), 4821–4831; https://doi.org/10.3390/curroncol28060407
Available online: https://www.mdpi.com/1718-7729/28/6/407
9 October 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Bone and Soft Tissue Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Bone and Soft Tissue Oncology” shown below:
1. “A Case Series of Metastatic Malignant Gastrointestinal Neuroectodermal Tumors and Comprehensive Genomic Profiling Analysis of 20 Cases”
by Taylor Kandler, Eliane Cortez, Lani Clinton, Amanda Hemmerich, Osama Ahmed, Ralph Wong, Taylor Forns, Andrea J. MacNeill, Trevor D. Hamilton, Mohammadali Khorasani et al.
Curr. Oncol. 2022, 29(2), 1279–1297; https://doi.org/10.3390/curroncol29020109
Available online: https://www.mdpi.com/1718-7729/29/2/109
2. “Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw”
by Veronica Mollica, Giacomo Nuvola, Elisa Tassinari, Maria Concetta Nigro, Andrea Marchetti, Matteo Rosellini, Alessandro Rizzo, Costantino Errani and Francesco Massari
Curr. Oncol. 2022, 29(3), 1709–1722; https://doi.org/10.3390/curroncol29030142
Available online: https://www.mdpi.com/1718-7729/29/3/142
3. “Minimally Invasive Interventional Procedures for Metastatic Bone Disease: A Comprehensive Review”
by Nicolas Papalexis, Anna Parmeggiani, Giuliano Peta, Paolo Spinnato, Marco Miceli and Giancarlo Facchini
Curr. Oncol. 2022, 29(6), 4155–4177; https://doi.org/10.3390/curroncol29060332
Available online: https://www.mdpi.com/1718-7729/29/6/332
4. “Characteristic of Uterine Rhabdomyosarcoma by Algorithm of Potential Biomarkers for Uterine Mesenchymal Tumor”
by Saya Tamura, Takuma Hayashi, Tomoyuki Ichimura, Nobuo Yaegashi, Kaoru Abiko and Ikuo Konishi
Curr. Oncol. 2022, 29(4), 2350–2363; https://doi.org/10.3390/curroncol29040190
Available online: https://www.mdpi.com/1718-7729/29/4/190
5. “Outcomes of Hip Reconstruction for Metastatic Acetabular Lesions: A Scoping Review of the Literature”
by Sandeep Krishan Nayar, Thomas A. Kostakos, Olga Savvidou, Konstantinos Vlasis and Panayiotis J. Papagelopoulos
Curr. Oncol. 2022, 29(6), 3849–3859; https://doi.org/10.3390/curroncol29060307
Available online: https://www.mdpi.com/1718-7729/29/6/307
6. “Megaprosthesis for Metastatic Bone Disease—A Comparative Analysis”
by Joachim Thorkildsen, Thale Asp Strøm, Nils Jørgen Strøm, Simen Sellevold and Ole-Jacob Norum
Curr. Oncol. 2022, 29(5), 3460–3471; https://doi.org/10.3390/curroncol29050279
Available online: https://www.mdpi.com/1718-7729/29/5/279
7. “Osseous Union after Mandible Reconstruction with Fibula Free Flap Using Manually Bent Plates vs. Patient-Specific Implants: A Retrospective Analysis of 89 Patients”
by Michael Knitschke, Sophia Sonnabend, Fritz Christian Roller, Jörn Pons-Kühnemann, Daniel Schmermund, Sameh Attia, Philipp Streckbein, Hans-Peter Howaldt and Sebastian Böttger
Curr. Oncol. 2022, 29(5), 3375–3392; https://doi.org/10.3390/curroncol29050274
Available online: https://www.mdpi.com/1718-7729/29/5/274
8 October 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Health Economics”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Health Economics” shown below:
1. “The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer—A Systematic Literature Review with Application to the Canadian Context”
by Ivan Yanev, Jessy Gatete, Jr., Armen G. Aprikian, Jason Robert Guertin and Alice Dragomir
Curr. Oncol. 2022, 29(5), 3393–3424; https://doi.org/10.3390/curroncol29050275
Available online: https://www.mdpi.com/1718-7729/29/5/275
2. “The Pathway for New Cancer Drug Access in Canada”
by Joanna Gotfrit, William Dempster, Johanne Chambers and Paul Wheatley-Price
Curr. Oncol. 2022, 29(2), 455–464; https://doi.org/10.3390/curroncol29020041
Available online: https://www.mdpi.com/1718-7729/29/2/41
3. “Determinants of the Cancer Drug Funding Process in Canada”
by Joanna Gotfrit, Ashley Jackson, John J. W. Shin, David J. Stewart, Ranjeeta Mallick and Paul Wheatley-Price
Curr. Oncol. 2022, 29(3), 1997–2007; https://doi.org/10.3390/curroncol29030162
Available online: https://www.mdpi.com/1718-7729/29/3/162
4. “Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations”
by Louise Binder, Majd Ghadban, Christina Sit and Kathleen Barnard
Curr. Oncol. 2022, 29(3), 1514–1526; https://doi.org/10.3390/curroncol29030127
Available online: https://www.mdpi.com/1718-7729/29/3/127
5. “Challenges and Adaptations for Providing Smoking Cessation for Patients with Cancer across Canada during the COVID-19 Pandemic”
by Graham W. Warren, Caroline Silverman and Michelle Halligan
Curr. Oncol. 2022, 29(4), 2263–2271; https://doi.org/10.3390/curroncol29040184
Available online: https://www.mdpi.com/1718-7729/29/4/184
6. “Equity-Oriented Healthcare: What It Is and Why We Need It in Oncology”
by Tara C. Horrill, Annette J. Browne and Kelli I. Stajduhar
Curr. Oncol. 2022, 29(1), 186–192; https://doi.org/10.3390/curroncol29010018
Available online: https://www.mdpi.com/1718-7729/29/1/18
7. “Survival in Women with De Novo Metastatic Breast Cancer: A Comparison of Real-World Evidence from a Publicly-Funded Canadian Province and the United States by Insurance Status”
by Marie-France Savard, Elizabeth N. Kornaga, Adriana Matutino Kahn and Sasha Lupichuk
Curr. Oncol. 2022, 29(1), 383–391; https://doi.org/10.3390/curroncol29010034
Available online: https://www.mdpi.com/1718-7729/29/1/34
8. “Rapid Review of Real-World Cost-Effectiveness Analyses of Cancer Interventions in Canada”
by Andrea M. Guggenbickler, Heather K. Barr, Jeffrey S. Hoch and Carolyn S. Dewa
Curr. Oncol. 2022, 29(10), 7285–7304; https://doi.org/10.3390/curroncol29100574
Available online: https://www.mdpi.com/1718-7729/29/10/574
9. “Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021”
by Catherine Lau and George Dranitsaris
Curr. Oncol. 2022, 29(11), 8031–8042; https://doi.org/10.3390/curroncol29110635
Available online: https://www.mdpi.com/1718-7729/29/11/635
10. “Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s RWE Data Working Group”
by Wei Fang Dai, Claire de Oliveira, Scott Blommaert, Reka E. Pataky, David Tran, Zeb Aurangzeb, Cynthia Kendell, Chris Folkins, Chandy Somayaji, Jeff Dowden et al.
Curr. Oncol. 2022, 29(3), 2046–2063; https://doi.org/10.3390/curroncol29030165
Available online: https://www.mdpi.com/1718-7729/29/3/165
8 October 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Childhood, Adolescent and Young Adult Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Childhood, Adolescent and Young Adult Oncology” shown below:
1. “Subsequent Malignant Neoplasm of Bone in Children and Adolescent—Possibility of Multimodal Treatment”
by Anna Raciborska, Katarzyna Bilska, Tomasz Koziński and Carlos Rodriguez-Galindo
Curr. Oncol. 2022, 29(2), 1001–1007; https://doi.org/10.3390/curroncol29020085
Available online: https://www.mdpi.com/1718-7729/29/2/85
2. “The Impact of Exercise on Cardiotoxicity in Pediatric and Adolescent Cancer Survivors: A Scoping Review”
by Stephanie J. Kendall, Jodi E. Langley, Mohsen Aghdam, Bruce N. Crooks, Nicholas Giacomantonio, Stefan Heinze-Milne, Will J. Johnston, Melanie R. Keats, Sharon L. Mulvagh and Scott A. Grandy
Curr. Oncol. 2022, 29(9), 6350–6363; https://doi.org/10.3390/curroncol29090500
Available online: https://www.mdpi.com/1718-7729/29/9/500
3. “Recruiting Adolescent and Young Adult Cancer Survivors for Patient-Reported Outcome Research: Experiences and Sample Characteristics of the SURVAYA Study”
by Carla Vlooswijk, Lonneke V. van de Poll-Franse, Silvie H. M. Janssen, Esther Derksen, Milou J. P. Reuvers, Rhodé Bijlsma, Suzanne E. J. Kaal, Jan Martijn Kerst, Jacqueline M. Tromp, Monique E. M. M. Bos et al.
Curr. Oncol. 2022, 29(8), 5407–5425; https://doi.org/10.3390/curroncol29080428
Available online: https://www.mdpi.com/1718-7729/29/8/428
4. “The Transformation of Adolescent and Young Adult Oncological and Supportive Care in Canada: A Mixed Methods Study”
by Jonathan Avery, Emily Wong, Christine Harris, Stacy Chapman, Serena Uppal, Shaayini Shanawaz, Annemarie Edwards, Laura Burnett, Tushar Vora and Abha A. Gupta
Curr. Oncol. 2022, 29(7), 5126–5138; https://doi.org/10.3390/curroncol29070406
Available online: https://www.mdpi.com/1718-7729/29/7/406
5. “Reflections of Moral Suffering, Resilience, and Wisdom of Pediatric Oncology Social Workers during the COVID-19 Pandemic”
by Barbara Jones, Nancy Cincotta, Wendy Pelletier, Abigail Fry and Lori Wiener
Curr. Oncol. 2022, 29(9), 6177–6185; https://doi.org/10.3390/curroncol29090485
Available online: https://www.mdpi.com/1718-7729/29/9/485
7 October 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Dermato-Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Dermato-Oncology” shown below:
1. “Cutaneous Melanoma in Alpine Population: Incidence Trends and Clinicopathological Profile”
by Alessandra Buja, Massimo Rugge, Giuseppe De Luca, Emanuela Bovo, Manuel Zorzi, Chiara De Toni, Claudia Cozzolino, Antonella Vecchiato, Paolo Del Fiore, Romina Spina et al.
Curr. Oncol. 2022, 29(3), 2165–2173; https://doi.org/10.3390/curroncol29030175
Available online: https://www.mdpi.com/1718-7729/29/3/175
2. “Assessing Choroidal Nevi, Melanomas and Indeterminate Melanocytic Lesions Using Multimodal Imaging—A Retrospective Chart Review”
by Fredy Geiger, Sadiq Said, Anahita Bajka, Mario Damiano Toro, Maximilian Robert Justus Wiest, Marc Stahel, Daniel Barthelmes and Sandrine Anne Zweifel
Curr. Oncol. 2022, 29(2), 1018–1028; https://doi.org/10.3390/curroncol29020087
Available online: https://www.mdpi.com/1718-7729/29/2/87
3. “Treatment of Basal Cell Carcinoma with Electrochemotherapy: Insights from the InspECT Registry (2008–2019)”
by Giulia Bertino, Tobian Muir, Joy Odili, Ales Groselj, Roberto Marconato, Pietro Curatolo, Erika Kis, Camilla Kjaer Lonkvist, James Clover, Pietro Quaglino et al.
Curr. Oncol. 2022, 29(8), 5324–5337; https://doi.org/10.3390/curroncol29080423
Available online: https://www.mdpi.com/1718-7729/29/8/423
4. “Antibody-Negative Paraneoplastic Autoimmune Multiorgan Syndrome (PAMS) in a Patient with Follicular Lymphoma Accompanied by an Excess of Peripheral Blood CD8+ Lymphocytes”
by Thilo Gambichler, Yi-Pei Lee, Ilske Oschlies, Christina H. Scheel, Wolfram Klapper, Nico Nowack, Martin Doerler, Markus Stücker, Nasreddin Abolmaali and Laura Susok
Curr. Oncol. 2022, 29(4), 2395–2405; https://doi.org/10.3390/curroncol29040194
Available online: https://www.mdpi.com/1718-7729/29/4/194
5. “Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab—Real-World Experience in the Global SARS-CoV-2 Pandemic”
by Marta Pabianek, Aleksandra Lesiak, Dariusz Nejc, Łukasz Kuncman, Joanna Narbutt, Małgorzata Skibińska and Magdalena Ciążyńska
Curr. Oncol. 2022, 29(10), 7794–7801; https://doi.org/10.3390/curroncol29100616
Available online: https://www.mdpi.com/1718-7729/29/10/616
6. “An Epidemiological Update on Indoor Tanning and the Risk of Skin Cancers”
by Clio Dessinioti and Alexander J. Stratigos
Curr. Oncol. 2022, 29(11), 8886–8903; https://doi.org/10.3390/curroncol29110699
Available online: https://www.mdpi.com/1718-7729/29/11/699
7. “Basosquamous Basal Cell Carcinoma with Bone Marrow Metastasis”
by Lise Mayrin Økland Thunestvedt, Lars Helgeland, Ingeborg Margrethe Bachmann, Åsa Karlsdottir, Torjan Magne Haslerud and Håkon Reikvam
Curr. Oncol. 2022, 29(4), 2193–2198; https://doi.org/10.3390/curroncol29040178
Available online: https://www.mdpi.com/1718-7729/29/4/178
8. “Intravascular Large B-Cell Lymphoma: A Review with a Focus on the Prognostic Value of Skin Involvement”
by Thomas Breakell, Heidi Waibel, Stefan Schliep, Barbara Ferstl, Michael Erdmann, Carola Berking and Markus V. Heppt
Curr. Oncol. 2022, 29(5), 2909–2919; https://doi.org/10.3390/curroncol29050237
Available online: https://www.mdpi.com/1718-7729/29/5/237
2 October 2023
MDPI Insights: The CEO's Letter #4 - MDPI Presence in China

Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
Open Access in China
It is Saturday, 23 September, and I have just returned from an unforgettable 12-day trip to China, visiting our main offices in Beijing and Wuhan. In the wake of a packed and very enjoyable agenda of internal and external meetings, I would like to use this edition of the CEO Letter to showcase how MDPI supports the scholarly community in China.
Coincidentally, Jack McKenna, Communications Associate from MDPI’s corporate content team, has just released a blog article discussing China’s open access (OA) policy. It is a timely read, providing a concise overview of the development of the OA movement in China and reflecting on its future. I shall draw some content from Jack’s piece and use this edition of the CEO Letter to highlight the various ways in which MDPI is involved in this market. And it would be remiss of me not to include some pictures and highlights from my travels!
Open Access Policy in China
As per Jack’s post, in 2020, China became the world’s leading producer of research articles. Today, China is experiencing a “substantial growth rate in OA [Open Access] publication”. This growth is supported by the State’s commitment to research & development and its policy “requiring the promotion of open science”.
Over the past two decades, there have been gradual developments in China’s OA framework, with repositories and platforms being developed in a consistent manner. Currently, key institutions across China – including the National Science Library, the National Science and Technology Library, and the Natural Science Foundation of China – support OA. The State aims to establish consistent policies across government agencies – a framework for a more encompassing embrace of OA across institutions.
In China, the number of subscription-only articles decreased by nearly 30% over the 10-year period of 2011–2021, while gold OA increased by 22%. Between 2017 and 2020 alone, China published 800,921 academic papers in an OA format.
In 2023, as the leading publisher of academic research, China is pursuing “self-reliance”. Therefore, the State will be establishing consistent policies across government agencies, including those related to OA. Additionally, it will want to ensure that Chinese people can access the research that is supported by Chinese funding and produced by Chinese academics. For this reason, “Open Access is a matter of priority in China”.
MDPI Offices in China
While the history of MDPI begins in Basel, Switzerland, the story of MDPI’s founder is very much rooted in China. Dr. Shu-kun Lin, Founder and President of MDPI, graduated with a BSc from Wuhan University in 1982. He also studied physical chemistry at the Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences (1982–1986; MSc in 1985), and at the University of Louisville, USA (1987–1989). Dr. Lin completed his doctorate in organic chemistry at the Swiss Federal Institute of Technology (ETH-Zürich) in 1992.
Stefan Tochev (CEO, MDPI) at MDPI’s Wuhan office.
In 2002, MDPI’s Basel headquarters moved to Matthäusstrasse 11, 4052 Basel, and Dr. Lin opened an editorial office in Qingdao, China, which launched the journal Marine Drugs in the following year. Below is a list of MDPI’s current offices in China and their respective dates of inauguration:
- 2008: Beijing (Tongzhou, Haidian)
- 2013: Wuhan (Hankou, Guanggu)
- 2019: Tianjin
- 2021: Dalian
- 2021: Nanjing
Our Strength is in Our People
With over 6,000 MDPI staff, across 20 offices in 11 countries, MDPI is able to offer authors responsive and efficient round-the-clock support, enabling a rapid publication process.
In my experience, stakeholders are genuinely surprised when they realize the extent of our global operations. My response is to reiterate that our people are our strength. This is why we have fast and efficient processes and top-notch responsiveness. Our global presence ensures that your manuscript is constantly attended to, rather than sitting on someone’s desk. We prioritize our authors’ needs and act quickly to move things through the various stages of publication. MDPI is built on speed, convenience, and competence, which I believe are core pillars for success in any industry. We continually strive to improve our systems and processes on the basis of these core strengths. We literally have over 6,000 staff worldwide dedicated to serving your needs. It’s not magic: it’s people; it’s real.
Impactful Research
MDPI Awards
To support the academic community, and especially young researchers, and also to enhance communication among scientists, MDPI journals offer various awards in specific fields. We serve the scientific community by funding research to facilitate the development of sustainable global solutions through our annual World Sustainability Award and Emerging Sustainability Leader Award.
In 2022, MDPI made awards totalling over US$1 million in recognition and support of researchers worldwide.
Across our journal catalogue, we have granted over 2,000 awards to recognize and support researchers from all disciplines. Since 2016, these awards have served as a source of recognition, acknowledging the impact of research by heightening the influence of talented individuals. The award types mainly include the Young Investigator Award, the Best PhD Thesis Award, the Best Paper Award, and the Outstanding Reviewer Award.
To learn more about MDPI Awards and to find out which are currently available, please click here.
MDPI Awards to Scholars from China
Since 2021, there have been 23 Best Paper Awards granted to authors affiliated with Chinese institutions, identifying their papers as having high-quality scientific impact. A total of 45 Chinese scholars have received awards such as the Young Investigator Award, the Best PhD Thesis Award, the Outstanding Reviewer Award, and the Tu Youyou Award, among others. Prizes for these awards include MDPI grants for paid publications, totalling over CHF 70,000 for scholars affiliated with Chinese institutions.
MDPI’s Tu Youyou Award
Prof. Tu Youyou (left), Dr. Shu-Kun Lin (President, MDPI).
In 2015, Professor Tu Youyou was awarded the Nobel Prize in Physiology or Medicine “for her discoveries concerning a novel therapy against Malaria.” In order to commemorate Professor Tu’s contributions to human health and to promote the passion and spirit conveyed by her experiences, MDPI in 2016 established the ‘Tu Youyou Award’, which runs biennially to recognize outstanding scholars dedicated to the research of natural products and medicinal chemistry.
The 2022 Tu Youyou Award was granted to Prof. Dr. Xiaoguang Lei of Peking University. Click here to access the interview with the winner.
2015 Nobel Prize for Medicine Awarded to Professor Youyou Tu
Professor Tu’s work was celebrated in a Special Issue from Molecules on the occasion of her 80th birthday. The Special Issue: 'Artemisinin (Qinghaosu): Commemorative Issue in Honor of Professor Youyou Tu on the Occasion of her 80th Anniversary” was created five years before she won the Nobel Prize, highlighting the visibility MDPI provides researchers and their work.
Highly Cited Articles by Chinese Scholars Published in MDPI
Click here to access the most cited MDPI papers published by scholars affiliated with Chinese institutions. This list presents the most influential research from the more than 287,000 MDPI papers published by Chinese scholars. With over 9 million total citations, I encourage you to maximize your visibility and impact by publishing with MDPI, the number one most cited open access publisher.
Read more:
- Tu Youyou Award
- World Sustainability Awards
- Available Awards
Inside MDPI
Stefan Tochev (CEO, MDPI) with the Beijing Marketing team.
Marketing Department in China
During my visit to our offices in Beijing and Wuhan, I had the opportunity to meet with, and to present to, our local marketing teams. These teams are responsible for various journal-related and corporate promotional activities, including newsletters, conferences, seminars, author training, journal awards, content creation, digital marketing, and social media.
I was pleased by the ambition and curiosity of our marketing colleagues. They showed a strong desire to collaborate and acquire knowledge and tactics to effectively market and promote MDPI-journal-related activities. I presented some of the principles and objectives that we apply in the Corporate Marketing and Communications department, and used the opportunity to strengthen our collaborative communications across offices.
Stefan Tochev (CEO, MDPI) with the Wuhan Marketing team.
Coming Together for Science
Collaborations, Scholarships and Meetings
MDPI maintains partnerships with nearly 190 learned societies and over 800 institutions and consortia, helping to facilitate the transition to OA publishing. Our commitment to working with institutions is evident in China, where we have successfully established over 35 Institutional Open Access Programs (IOAP) with esteemed institutions such as the Tsinghua University, Huazhong University of Science and Technology, and Shanghai Jiao Tong University.
Our institutional partnerships, waiver programs, and article processing cost discounts create diverse pathways to OA publishing for researchers worldwide.
Scholarships in China
Since 2021, several MDPI journals (Sensors, Photonics, Coatings, Materials, Energies, and Journal of Fungi) have funded full scholarships for four Master’s and five Ph.D. projects in China. These scholarships align with Tianjin University, Wuhan University of Technology, Central South University, the Chinese Academy of Sciences, and the China University of Petroleum (Beijing).
Meeting with the Society of Chinese University Journals (CUJS)
Prof. Tieming Zhang (President of CUJS, centre) and MDPI colleagues at CUJS office.
I am pleased to have participated in some highly productive meetings during my visit to China, including one with the Society of Chinese University Journals (CUJS). The meeting involved Prof. Tieming Zhang (President of CUJS), Assoc. Prof. Xin Zhang (Vice President and Secretary General), and Dr. Fei Gao (Executive Member of CUJS). Alongside my colleagues Dr. Guoshi Liu, Dr. Giulia Stefenelli, and Anita Sun, I represented MDPI and held an open discussion to address any questions regarding OA and MDPI.
We discussed several methods for collaboration, including a workshop on the future of peer review, MDPI sponsoring a funding grant for early-career researchers, and transitioning journals from diamond to gold OA. I am thankful for the opportunity to have met our colleagues at CUJS in person and feel very confident about our future collaborations in support of OA publishing in China.
MDPI hosts free academic seminars, author training sessions, and academic conferences as part of its commitment to enrich and support the scholarly community. CUJS often stages academic events (e.g., conferences, editor training, and editor competitions), and I believe there are great opportunities for CUJS and MDPI to collaborate accordingly.
Meeting with National Science Library, Chinese Academy of Sciences (NSLC)
Stefan Tochev (CEO, MDPI), Dr. Giulia Stefenelli (Chair of Scientific Officers, MDPI), Anita Sun (PR Manager, MDPI) and Dr. Guoshi Liu (Managing Director, MDPI) at the National Science Library, Chinese Academy of Sciences.
We also visited the NSLC Director, Xiwen Liu, and colleagues Ying Jin, Zhesi Shen, and Sichao Tong. Following our introductions, we gave a presentation on the history and editorial process at MDPI, discussing specific details related to MDPI’s business and data. We highlighted the status of our IOAP collaborations in China and the makeup of our author base, specifically in China, and drew attention to the fact that MDPI has published research by authors from every country in the world. We then discussed the design indicators, calculation methods and implementation purposes of the ‘Early Warning Journal List’ and how we can have open communication to provide any data regarding MDPI journals. I am pleased to report that we reached a consensus on future communications, and am grateful to NSLC for hosting us in their offices.
In-person meetings with stakeholders provide an invaluable opportunity to communicate what MDPI is about and the various ways in which we serve the scholarly community. While digital marketing and online communication are essential, they are no replacement for the understanding and trust that come about through in-person interactions.
The Numbers
As at September 2023, China holds the largest position in MDPI’s global market, ranking as the largest contributor to the total number of papers published by MDPI.
At this point in time, there were more than 847,000 China mainland scholars who have published with MDPI, 51 of whom are Section-Editors-in-Chief (SEiC) of MDPI journals, with seven serving as Editors-in-Chief (EiCs) for journals such as Air, Big Data and Cognitive Computing, Blockchains, Future, Nanoenergy Advances, and Targets.
Our growth and presence in China are a true testament to the service we provide to the scholarly community, and to the relationships we foster through collaborative activities. We look forward to continuing to support the growth of the scholarly community in China, providing a valuable and trusted experience with MDPI.
Closing Thoughts
Final Reflections on our MDPI Offices in Beijing and Wuhan
Stefan Tochev (CEO, MDPI), Dr. Constanze Schelhorn (Indexing Manager, MDPI), Jiale Shang (Admin, Tongzhou, MDPI) at Beijing Capital International Airport, Beijing.
I spent approximately two weeks visiting some of our offices in China, and the first word that comes to mind when describing my experience is ‘hospitality.’ My colleagues and I were met with enthusiasm and delight at the airport by the Tongzhou Admin team (thank you, Jiale Shang, and thank you, Eric Wang, for keeping us organized on this trip!) and were taken care of with great attention. From hotels to transportation, dinners, and meetings, our stay was catered for perfectly.
Perhaps this is where MDPI’s focus on customers and service originates. At our core, we are a service company that provides a publishing platform for its authors. It’s therefore no surprise that authors consistently rate their experience with MDPI very highly.
95% of submitting authors rate their overall experience with the MDPI publication process as Excellent or Good (Springer Nature report 90%).
91% of submitting authors rate their overall experience with the MDPI peer review process as Excellent or Good.
Speed/Efficiency and Editorial Relationship are two key reasons underlying this high satisfaction score. ‘Editorial Relationship’ can be further explored, but in the past month, the most commonly noted aspects were the professionalism, kindness, availability, communicativeness, and personalized assistance provided by our editorial staff throughout the process. These attributes are at the core of our work across all our offices and continents.
Hospitality and Service
Just as our Chinese colleagues strove to keep us engaged by showing us the city sights (thank you, Thea Pan, and Jason Wu from the Wuhan Marketing team!) and sharing a variety of wonderful meals, our editorial staff are committed to serving our authors throughout their publishing journey. Our aim is to place the author at the centre of everything we do, eager to welcome our ‘guests’ and provide them with a pleasant publishing experience.
I asked my colleague Francis Wu (Senior Publisher, Wuhan office) where this hospitality originates. He responded that it is part of Chinese culture. I reflected long and deep on this answer. China is a vast country, and when visitors arrive, hosts want to ensure they feel welcomed and taken care of in order to maximize their time and visit. I can’t think of a better analogy for how I would want our authors to feel when they visit MDPI for their publishing needs. A company culture that prioritizes service, something that goes beyond products and productivity, and focuses on the overall experience. Over 6,000 people, across all MDPI offices, are ready, willing and able to go the extra mile for their colleagues and their customers. This is something I am truly proud of.
Chief Executive Officer
MDPI AG
28 September 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Breast Cancer”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Breast Cancer” shown below:
1. “Applying Deep Learning for Breast Cancer Detection in Radiology”
by Ella Mahoro and Moulay A. Akhloufi
Curr. Oncol. 2022, 29(11), 8767–8793; https://doi.org/10.3390/curroncol29110690
Available online: https://www.mdpi.com/1718-7729/29/11/690
2. “Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?”
by Liqin Yao, Gang Jia, Lingeng Lu and Wenxue Ma
Curr. Oncol. 2022, 29(7), 4902–4913; https://doi.org/10.3390/curroncol29070389
Available online: https://www.mdpi.com/1718-7729/29/7/389
3. “Optimizing Adjuvant Treatment Recommendations for Older Women with Biologically Favorable Breast Cancer: Short-Course Radiation or Long-Course Endocrine Therapy?”
by Susan G. R. McDuff and Rachel C. Blitzblau
Curr. Oncol. 2023, 30(1), 392–400; https://doi.org/10.3390/curroncol30010032
Available online: https://www.mdpi.com/1718-7729/30/1/32
4. “Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2− Advanced Breast Cancer Patients: An Italian Managed Access Program”
by Nicoletta Staropoli, Elena Geuna, Gaetana Rinaldi, Giancarlo Bisagni, Vieri Scotti, Giovanni Faggioni, Laura Vannini, Carlo Arcara, Gabriella Moretti, Marco Gunnellini et al.
Curr. Oncol. 2022, 29(9), 6635–6641; https://doi.org/10.3390/curroncol29090521
Available online: https://www.mdpi.com/1718-7729/29/9/521
5. “Are Columnar Cell Lesions the Earliest Non-Obligate Precursor in the Low-Grade Breast Neoplasia Pathway?”
by Sarah Strickland and Gulisa Turashvili
Curr. Oncol. 2022, 29(8), 5664–5681; https://doi.org/10.3390/curroncol29080447
Available online: https://www.mdpi.com/1718-7729/29/8/447
6. “Efficacy and Accuracy of Using Magnetic Seed for Preoperative Non-Palpable Breast Lesions Localization: Our Experience with Magseed”
by Anna D’Angelo, Charlotte Marguerite Lucille Trombadori, Flavia Caprini, Stefano Lo Cicero, Valentina Longo, Francesca Ferrara, Simone Palma, Marco Conti, Antonio Franco, Lorenzo Scardina et al.
Curr. Oncol. 2022, 29(11), 8468–8474; https://doi.org/10.3390/curroncol29110667
Available online: https://www.mdpi.com/1718-7729/29/11/667
7. “Prevalence and Persistence of Anxiety and Depression over Five Years since Breast Cancer Diagnosis—The NEON-BC Prospective Study”
by Catarina Lopes, Luisa Lopes-Conceição, Filipa Fontes, Augusto Ferreira, Susana Pereira, Nuno Lunet and Natália Araújo
Curr. Oncol. 2022, 29(3), 2141–2153; https://doi.org/10.3390/curroncol29030173
Available online: https://www.mdpi.com/1718-7729/29/3/173
8. “Preoperative Radio(Chemo)Therapy in Breast Cancer: Time to Switch the Perspective?”
by Angel Montero and Raquel Ciérvide
Curr. Oncol. 2022, 29(12), 9767–9787; https://doi.org/10.3390/curroncol29120768
Available online: https://www.mdpi.com/1718-7729/29/12/768
28 September 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Oncology Nursing”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Oncology Nursing” shown below:
1. “Equity-Oriented Healthcare: What It Is and Why We Need It in Oncology”
by Tara C. Horrill, Annette J. Browne and Kelli I. Stajduhar
Curr. Oncol. 2022, 29(1), 186–192; https://doi.org/10.3390/curroncol29010018
Available online: https://www.mdpi.com/1718-7729/29/1/18
2. “A Continuing Educational Program Supporting Health Professionals to Manage Grief and Loss”
by Mary Jane Esplen, Jiahui Wong, Mary L. S. Vachon and Yvonne Leung
Curr. Oncol. 2022, 29(3), 1461–1474; https://doi.org/10.3390/curroncol29030123
Available online: https://www.mdpi.com/1718-7729/29/3/123
3. “Risk Stratification and Cancer Follow-Up: Towards More Personalized Post-Treatment Care in Canada”
by Robin Urquhart, Wendy Cordoba, Jackie Bender, Colleen Cuthbert, Julie Easley, Doris Howell, Julia Kaal, Cynthia Kendell, Samantha Radford and Jonathan Sussman
Curr. Oncol. 2022, 29(5), 3215–3223; https://doi.org/10.3390/curroncol29050261
Available online: https://www.mdpi.com/1718-7729/29/5/261
4. “Oncology Healthcare Professionals’ Mental Health during the COVID-19 Pandemic”
by Leeat Granek and Ora Nakash
Curr. Oncol. 2022, 29(6), 4054–4067; https://doi.org/10.3390/curroncol29060323
Available online: https://www.mdpi.com/1718-7729/29/6/323
5. “Lessons Learned from the Implementation of a Person-Centred Digital Health Platform in Cancer Care”
by Saima Ahmed, Karine LePage, Renata Benc, Guy Erez, Alon Litvin, Annie Werbitt, Gabrielle Chartier, Carly Berlin and Carmen G. Loiselle
Curr. Oncol. 2022, 29(10), 7171–7180; https://doi.org/10.3390/curroncol29100564
Available online: https://www.mdpi.com/1718-7729/29/10/564
27 September 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Psychosocial Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Psychosocial Oncology” shown below:
1. “The Chemo-Gut Pilot Study: Associations between Gut Microbiota, Gastrointestinal Symptoms, and Psychosocial Health Outcomes in a Cross-Sectional Sample of Young Adult Cancer Survivors”
by Julie M. Deleemans, Faye Chleilat, Raylene A. Reimer, Mohamad Baydoun, Katherine-Ann Piedalue, Dana E. Lowry, Jan-Willem Henning and Linda E. Carlson
Curr. Oncol. 2022, 29(5), 2973-2994; https://doi.org/10.3390/curroncol29050243
Available online: https://www.mdpi.com/1718-7729/29/5/243
2. “The Psychosocial Impact of COVID-19 on Older Adults with Cancer: A Rapid Review”
by Ridhi Verma, Heather M. Kilgour and Kristen R. Haase
Curr. Oncol. 2022, 29(2), 589-601; https://doi.org/10.3390/curroncol29020053
Available online: https://www.mdpi.com/1718-7729/29/2/53
3. “Assessing the Relationship between Socioeconomic Status, Race, and Psychological Distress in Cancer Survivors: A Population Based Study”
by Ikechukwu Chidobem, Fan Tian, Chisom Mgbodile, Francis Mgbodile, Tahereh Orouji Jokar, Esther Ogbuokiri and Nazia Khan
Curr. Oncol. 2022, 29(4), 2575-2582; https://doi.org/10.3390/curroncol29040211
Available online: https://www.mdpi.com/1718-7729/29/4/211
4. “Psychosocial Implications of COVID-19 on Head and Neck Cancer”
by Sarah M. Dermody and Andrew G. Shuman
Curr. Oncol. 2022, 29(2), 1062-1068; https://doi.org/10.3390/curroncol29020090
Available online: https://www.mdpi.com/1718-7729/29/2/90
5. “Biopsychosocial Markers of Body Image Concerns in Patients with Head and Neck Cancer: A Prospective Longitudinal Study”
by Justine G. Albert, Christopher Lo, Zeev Rosberger, Saul Frenkiel, Michael Hier, Anthony Zeitouni, Karen Kost, Alex Mlynarek, Martin Black, Christina MacDonald et al.
Curr. Oncol. 2022, 29(7), 4438-4454; https://doi.org/10.3390/curroncol29070353
Available online: https://www.mdpi.com/1718-7729/29/7/353
6. “Psychological Problems among Head and Neck Cancer Patients in Relation to Utilization of Healthcare and Informal Care and Costs in the First Two Years after Diagnosis”
by Florie E. van Beek, Femke Jansen, Rob J. Baatenburg de Jong, Johannes A. Langendijk, C. René Leemans, Johannes H. Smit, Robert P. Takes, Chris H. J. Terhaard, José A. E. Custers, Judith B. Prins et al.
Curr. Oncol. 2022, 29(5), 3200-3214; https://doi.org/10.3390/curroncol29050260
Available online: https://www.mdpi.com/1718-7729/29/5/260
7. “Screening for Distress and Health Outcomes in Head and Neck Cancer”
by Bryan Gascon, Aliza A. Panjwani, Olivia Mazzurco and Madeline Li
Curr. Oncol. 2022, 29(6), 3793-3806; https://doi.org/10.3390/curroncol29060304
Available online: https://www.mdpi.com/1718-7729/29/6/304
8. “Oncology Healthcare Professionals’ Mental Health during the COVID-19 Pandemic”
by Leeat Granek and Ora Nakash
Curr. Oncol. 2022, 29(6), 4054-4067; https://doi.org/10.3390/curroncol29060323
Available online: https://www.mdpi.com/1718-7729/29/6/323
26 September 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Hematology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Hematology” below:
1. “Primary Diffuse Large B-Cell Lymphoma of the Urinary Bladder: Update on a Rare Disease and Potential Diagnostic Pitfalls”
by Magda Zanelli, Francesca Sanguedolce, Maurizio Zizzo, Andrea Palicelli, David Pellegrini, Sabrina Farinacci, Alessandra Soriano, Elisabetta Froio, Luigi Cormio, Giuseppe Carrieri et al.
Curr. Oncol. 2022, 29(2), 956–968; https://doi.org/10.3390/curroncol29020081
Available online: https://www.mdpi.com/1718-7729/29/2/81
2. “Comprehensive Laboratory Diagnostic Workup for Patients with Suspected Intraocular Lymphoma including Flow Cytometry, Molecular Genetics and Cytopathology”
by Evgenii Shumilov, Paolo Mazzeo, Martin S. Zinkernagel, Myriam Legros, Naomi Porret, Lorenz Romagna, Detlef Haase, Georg Lenz, Urban Novak, Yara Banz et al.
Curr. Oncol. 2022, 29(2), 766–776; https://doi.org/10.3390/curroncol29020065
Available online: https://www.mdpi.com/1718-7729/29/2/65
3. “Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients”
by Isacco Ferrarini, Francesca Gandini, Ettore Zapparoli and Antonella Rigo
Curr. Oncol. 2022, 29(4), 2792–2797; https://doi.org/10.3390/curroncol29040227
Available online: https://www.mdpi.com/1718-7729/29/4/227
4. “The Use of Virtual Care in Patients with Hematologic Malignancies: A Scoping Review”
by Adam Suleman, Abi Vijenthira, Alejandro Berlin, Anca Prica and Danielle Rodin
Curr. Oncol. 2022, 29(2), 892–900; https://doi.org/10.3390/curroncol29020076
Available online: https://www.mdpi.com/1718-7729/29/2/76
by Margaret E. Stalker and Tomer M. Mark
Curr. Oncol. 2022, 29(7), 4464–4477; https://doi.org/10.3390/curroncol29070355
Available online: https://www.mdpi.com/1718-7729/29/7/355
6. “Concurrent Waldenstrom’s Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation”
by Peter A. DeRosa, Kyle C. Roche, Victor E. Nava, Sunita Singh, Min-Ling Liu and Anita Agarwal
Curr. Oncol. 2022, 29(7), 4587–4592; https://doi.org/10.3390/curroncol29070363
Available online: https://www.mdpi.com/1718-7729/29/7/363
7. “Diffuse Large B Cell Lymphoma Arising in Patients with Preexisting Hodgkin Lymphoma”
by Emilio Bellitti, Pierluigi Masciopinto, Pellegrino Musto, Elena Arcuti, Luca Mastracci, Giuseppina Opinto, Sabino Ciavarella, Attilio Guarini, Gerardo Cazzato, Giorgina Specchia et al.
Curr. Oncol. 2022, 29(9), 6115–6124; https://doi.org/10.3390/curroncol29090480
Available online: https://www.mdpi.com/1718-7729/29/9/480
8. “Total Body Irradiation for Hematopoietic Stem Cell Transplantation: What Can We Agree on?”
by Mitchell Sabloff, Steven Tisseverasinghe, Mustafa Ege Babadagli and Rajiv Samant
Curr. Oncol. 2021, 28(1), 903–917; https://doi.org/10.3390/curroncol28010089
Available online: https://www.mdpi.com/1718-7729/28/1/89
9. “Primary Vitreoretinal Lymphoma: Current Diagnostic Laboratory Tests and New Emerging Molecular Tools”
by Beatrice Melli, Pietro Gentile, Davide Nicoli, Enrico Farnetti, Stefania Croci, Fabrizio Gozzi, Elena Bolletta, Luca De Simone, Francesca Sanguedolce, Andrea Palicelli et al.
Curr. Oncol. 2022, 29(10), 6908–6921; https://doi.org/10.3390/curroncol29100543
Available online: https://www.mdpi.com/1718-7729/29/10/543
10. “Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment”
by Matthew Ho, Alexander Xiao, Dongni Yi, Saurabh Zanwar and Giada Bianchi
Curr. Oncol. 2022, 29(11), 8975–9005; https://doi.org/10.3390/curroncol29110705
Available online: https://www.mdpi.com/1718-7729/29/11/705
26 September 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Surgical Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Surgical Oncology” below:
1. “Outcomes of Enhanced Recovery after Surgery (ERAS) in Gynecologic Oncology: A Review”
by Steven P. Bisch and Gregg Nelson
Curr. Oncol. 2022, 29(2), 631–640; https://doi.org/10.3390/curroncol29020056
Available online: https://www.mdpi.com/1718-7729/29/2/56
2. “Systemic Therapy and Its Surgical Implications in Patients with Resectable Liver Colorectal Cancer Metastases. A Report from the Western Canadian Gastrointestinal Cancer Consensus Conference”
by Shahid Ahmed, Nicholas Bosma, Michael Moser, Shahida Ahmed, Bryan Brunet, Janine Davies, Corinne Doll, Dorie-Anna Dueck, Christina A. Kim, Shuying Ji et al.
Curr. Oncol. 2022, 29(3), 1796–1807; https://doi.org/10.3390/curroncol29030147
Available online: https://www.mdpi.com/1718-7729/29/3/147
3. “Challenges in Geriatric Oncology—A Surgeon’s Perspective”
by Ruth Parks and Kwok-Leung Cheung
Curr. Oncol. 2022, 29(2), 659–674; https://doi.org/10.3390/curroncol29020058
Available online: https://www.mdpi.com/1718-7729/29/2/58
4. “The Prediction of Survival after Surgical Management of Bone Metastases of the Extremities—A Comparison of Prognostic Models”
by Ofir Gal Ben, Terrence Chi Fang Soh, Sarah Vaughan, Viswanath Jayasanker, Ashish Mahendra and Sanjay Gupta
Curr. Oncol. 2022, 29(7), 4703–4716; https://doi.org/10.3390/curroncol29070373
Available online: https://www.mdpi.com/1718-7729/29/7/373
5. “Minimally Invasive Surgery for Cervical Cancer in Light of the LACC Trial: What Have We Learned?”
by Omar Touhami and Marie Plante
Curr. Oncol. 2022, 29(2), 1093–1106; https://doi.org/10.3390/curroncol29020093
Available online: https://www.mdpi.com/1718-7729/29/2/93
6. “A Qualitative Study of Patient and Healthcare Provider Perspectives on Building Multiphasic Exercise Prehabilitation into the Surgical Care Pathway for Head and Neck Cancer”
by Julia T. Daun, Rosie Twomey, Joseph C. Dort, Lauren C. Capozzi, Trafford Crump, George J. Francis, T. Wayne Matthews, Shamir P. Chandarana, Robert D. Hart, Christiaan Schrag et al.
Curr. Oncol. 2022, 29(8), 5942–5954; https://doi.org/10.3390/curroncol29080469
Available online: https://www.mdpi.com/1718-7729/29/8/469
7. “Surgical Treatment of Distal Cholangiocarcinoma”
by Leva Gorji and Eliza W. Beal
Curr. Oncol. 2022, 29(9), 6674–6687; https://doi.org/10.3390/curroncol29090524
Available online: https://www.mdpi.com/1718-7729/29/9/524
8. “Upfront Chemotherapy Followed by Stereotactic Body Radiation Therapy with or without Surgery in Older Patients with Localized Pancreatic Cancer: A Single Institution Experience and Review of the Literature”
by Abhinav V. Reddy, Shuchi Sehgal, Colin S. Hill, Lei Zheng, Jin He, Joseph M. Herman, Jeffrey Meyer and Amol K. Narang
Curr. Oncol. 2022, 29(1), 308–320; https://doi.org/10.3390/curroncol29010028
Available online: https://www.mdpi.com/1718-7729/29/1/28
9. “The Role of Surgical Approaches in the Multi-Modal Management of Adult Craniopharyngiomas”
by Christopher S. Hong and Sacit Bulent Omay
Curr. Oncol. 2022, 29(3), 1408–1421; https://doi.org/10.3390/curroncol29030118
Available online: https://www.mdpi.com/1718-7729/29/3/118
10. “Surgical Management of Craniovertebral Junction Schwannomas: A Systematic Review”
by Paolo Palmisciano, Gianluca Ferini, Gina Watanabe, Andie Conching, Christian Ogasawara, Gianluca Scalia, Othman Bin-Alamer, Ali S. Haider, Maurizio Passanisi, Rosario Maugeri et al.
Curr. Oncol. 2022, 29(7), 4842–4855; https://doi.org/10.3390/curroncol29070384
Available online: https://www.mdpi.com/1718-7729/29/7/384
25 September 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Palliative and Supportive Care”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Palliative and Supportive Care” below:
1. “Satisfaction with Telemedicine for Cancer Pain Management: A Model of Care and Cross-Sectional Patient Satisfaction Study”
by Marco Cascella, Sergio Coluccia, Mariacinzia Grizzuti, Maria Cristina Romano, Gennaro Esposito, Anna Crispo and Arturo Cuomo
Curr. Oncol. 2022, 29(8), 5566–5578; https://doi.org/10.3390/curroncol29080439
Available online: https://www.mdpi.com/1718-7729/29/8/439
2. “Point of Care Molecular Testing: Community-Based Rapid Next-Generation Sequencing to Support Cancer Care”
by Brandon S. Sheffield, Andrea Beharry, Joanne Diep, Kirstin Perdrizet, Marco A. J. Iafolla, William Raskin, Shaan Dudani, Mary Anne Brett, Blerta Starova, Brian Olsen et al.
Curr. Oncol. 2022, 29(3), 1326–1334; https://doi.org/10.3390/curroncol29030113
Available online: https://www.mdpi.com/1718-7729/29/3/113
3. “Effect of COVID-19 Pandemic on Hepatocellular Carcinoma Diagnosis: Results from a Tertiary Care Center in North-West Italy”
by Davide Giuseppe Ribaldone, Gian Paolo Caviglia, Silvia Gaia, Emanuela Rolle, Alessandra Risso, Daniela Campion, Paola Rita Brunocilla, Giorgio Maria Saracco and Patrizia Carucci
Curr. Oncol. 2022, 29(3), 1422–1429; https://doi.org/10.3390/curroncol29030119
Available online: https://www.mdpi.com/1718-7729/29/3/119
4. “The Psychosocial Impact of COVID-19 on Older Adults with Cancer: A Rapid Review”
by Ridhi Verma, Heather M. Kilgour and Kristen R. Haase
Curr. Oncol. 2022, 29(2), 589–601; https://doi.org/10.3390/curroncol29020053
Available online: https://www.mdpi.com/1718-7729/29/2/53
5. “The Use of Virtual Care in Patients with Hematologic Malignancies: A Scoping Review”
by Adam Suleman, Abi Vijenthira, Alejandro Berlin, Anca Prica and Danielle Rodin
Curr. Oncol. 2022, 29(2), 892–900; https://doi.org/10.3390/curroncol29020076
Available online: https://www.mdpi.com/1718-7729/29/2/76
6. “Patient and Physician Satisfaction with Telemedicine in Cancer Care in Saskatchewan: A Cross-Sectional Study”
by Hurria Gondal, Tahir Abbas, Heather Choquette, Duc Le, Haji Ibraheem Chalchal, Nayyer Iqbal and Shahid Ahmed
Curr. Oncol. 2022, 29(6), 3870–3880; https://doi.org/10.3390/curroncol29060309
Available online: https://www.mdpi.com/1718-7729/29/6/309
7. “Tailoring the Evidence for Exercise Oncology within Breast Cancer Care”
by Chad W. Wagoner, Lauren C. Capozzi and S. Nicole Culos-Reed
Curr. Oncol. 2022, 29(7), 4827–4841; https://doi.org/10.3390/curroncol29070383
Available online: https://www.mdpi.com/1718-7729/29/7/383
8. “Treatment of Older Adult Patients with Glioblastoma: Moving towards the Inclusion of a Comprehensive Geriatric Assessment for Guiding Management”
by Manik Chahal, Brian Thiessen and Caroline Mariano
Curr. Oncol. 2022, 29(1), 360–376; https://doi.org/10.3390/curroncol29010032
Available online: https://www.mdpi.com/1718-7729/29/1/32
9. “Challenges in Geriatric Oncology—A Surgeon’s Perspective”
by Ruth Parks and Kwok-Leung Cheung
Curr. Oncol. 2022, 29(2), 659–674; https://doi.org/10.3390/curroncol29020058
Available online: https://www.mdpi.com/1718-7729/29/2/58
10. “Understanding the Post-Treatment Concerns of Cancer Survivors with Five Common Cancers: Exploring the Alberta Results from the Pan-Canadian Transitions Study”
by Claire Link, Andrea DeIure and Linda Watson
Curr. Oncol. 2022, 29(4), 2662–2680; https://doi.org/10.3390/curroncol29040218
Available online: https://www.mdpi.com/1718-7729/29/4/218
22 September 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Cell Therapy”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Cell Therapy” below:
1. “A Portrait of SARS-CoV-2 Infection in Patients Undergoing Hematopoietic Cell Transplantation: A Systematic Review of the Literature”
by Adrian J. M. Bailey, Aidan M. Kirkham, Madeline Monaghan, Risa Shorr, C. Arianne Buchan, Christopher Bredeson and David S. Allan
Curr. Oncol. 2022, 29(1), 337-349; https://doi.org/10.3390/curroncol29010030
Available online: https://www.mdpi.com/1718-7729/29/1/30
2. “A Scoping Review on Outcomes and Outcome Measurement Instruments in Rehabilitative Interventions for Patients with Haematological Malignancies Treated with Allogeneic Stem Cell Transplantation”
by Anastasios I. Manettas, Panagiotis Tsaklis, Dario Kohlbrenner and Lidwine B. Mokkink
Curr. Oncol. 2022, 29(7), 4998-5025; https://doi.org/10.3390/curroncol29070397
Available online: https://www.mdpi.com/1718-7729/29/7/397
3. “Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada”
by Graeme Ball, Christopher Lemieux, David Cameron and Matthew D. Seftel
Curr. Oncol. 2022, 29(3), 2021-2045; https://doi.org/10.3390/curroncol29030164
Available online: https://www.mdpi.com/1718-7729/29/3/164
4. “Abstracts of the Cell Therapy Transplant Canada 2022 Annual Conference”
by Stephanie A. Maier, Tobias Berg, Susan Berrigan, Jonathan Bramson, Chris Bredeson, Guy Cantin, Andrew Daly, Gwynivere A. Davies, Mahmoud Elsawy, Alejandro Garcia-Horton et al.
Curr. Oncol. 2022, 29(12), 9970-10017; https://doi.org/10.3390/curroncol29120783
Available online: https://www.mdpi.com/1718-7729/29/12/783
5. “Access to Hematopoietic Stem Cell Transplant in Canada for Patients with Acute Myeloid”
by Oluwatobiloba Morakinyo, Oliver Bucher and Kristjan Paulson
Curr. Oncol. 2022, 29(8), 5198-5208; https://doi.org/10.3390/curroncol29080412
Available online: https://www.mdpi.com/1718-7729/29/8/412
6. “Donor Age and Non-Relapse Mortality: Study of Their Association after HLA-Matched Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome”
by Yasmine Kadri, Michelle Phan, Nadia Bambace, Léa Bernard, Sandra Cohen, Jean-Sébastien Delisle, Thomas Kiss, Sylvie Lachance, Denis-Claude Roy, Guy Sauvageau et al.
Curr. Oncol. 2022, 29(8), 5955-5962; https://doi.org/10.3390/curroncol29080470
Available online: https://www.mdpi.com/1718-7729/29/8/470
22 September 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Medical Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Medical Oncology” below:
1. “Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria”
by Philippe d’Abadie, Stephan Walrand, Renaud Lhommel, Michel Hesse, Ivan Borbath and François Jamar
Curr. Oncol. 2022, 29(4), 2422-2434; https://doi.org/10.3390/curroncol29040196
Available online: https://www.mdpi.com/1718-7729/29/4/196
2. “Health Literacy and Clinical Trial Participation in French Cancer Patients: A National Survey”
by Youssoufa M. Ousseine, Anne-Déborah Bouhnik and Julien Mancini
Curr. Oncol. 2022, 29(5), 3118-3129; https://doi.org/10.3390/curroncol29050253
Available online: https://www.mdpi.com/1718-7729/29/5/253
3. “5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice”
by Takuo Yamai, Kenji Ikezawa, Yasuharu Kawamoto, Takeru Hirao, Sena Higashi, Kazuma Daiku, Shingo Maeda, Yutaro Abe, Makiko Urabe, Yugo Kai et al.
Curr. Oncol. 2022, 29(4), 2644-2649; https://doi.org/10.3390/curroncol29040216
Available online: https://www.mdpi.com/1718-7729/29/4/216
4. “Novel, First-in-Human, Oral PCLX-001 Treatment in a Patient with Relapsed Diffuse Large B-Cell Lymphoma”
by Randeep Sangha, Neal M. Davies, Afshin Namdar, Michael Chu, Jennifer Spratlin, Erwan Beauchamp, Luc G. Berthiaume and John R. Mackey
Curr. Oncol. 2022, 29(3), 1939-1946; https://doi.org/10.3390/curroncol29030158
Available online: https://www.mdpi.com/1718-7729/29/3/158
5. “Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events”
by Arezou Teimouri, Laura V. Minard, Samantha N. Scott, Amanda Daniels and Stephanie Snow
Curr. Oncol. 2022, 29(5), 3104-3117; https://doi.org/10.3390/curroncol29050252
Available online: https://www.mdpi.com/1718-7729/29/5/252
6. “Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline”
by Phillip Blanchette, Duvaraga Sivajohanathan, John Bartlett, Andrea Eisen, Harriet Feilotter, Rossanna Pezo, Gulisa Turashvili and Phillip Williams
Curr. Oncol. 2022, 29(4), 2599-2615; https://doi.org/10.3390/curroncol29040213
Available online: https://www.mdpi.com/1718-7729/29/4/213
7. “Gynecologic Symptoms among Hormone Receptor-Positive Breast Cancer Patients on Oral Endocrine Therapy: A Cross-Sectional Study”
by Alexandra Moskalewic, Amy Di Tomaso, Jacob J. Kachura, Samantha Scime, Rosane Nisenbaum, Ronita Lee, Rashida Haq, Christine Derzko and Christine Brezden-Masley
Curr. Oncol. 2022, 29(3), 1813-1827; https://doi.org/10.3390/curroncol29030149
Available online: https://www.mdpi.com/1718-7729/29/3/149
8. “The Clinical Impact of Neoadjuvant Endocrine Treatment on Luminal-like Breast Cancers and Its Prognostic Significance: Results from a Single-Institution Prospective Cohort Study”
by Covadonga Martí, Laura Yébenes, José María Oliver, Elisa Moreno, Laura Frías, Alberto Berjón, Adolfo Loayza, Marcos Meléndez, María José Roca, Vicenta Córdoba et al.
Curr. Oncol. 2022, 29(4), 2199-2210; https://doi.org/10.3390/curroncol29040179
Available online: https://www.mdpi.com/1718-7729/29/4/179
9. “Routine Screening for Central and Primary Adrenal Insufficiency during Immune-Checkpoint Inhibitor Therapy: An Endocrinology Perspective for Oncologists”
by Irena Druce, Karine Tawagi, Julie L. V. Shaw, Andrea Ibrahim, Heather Lochnan and Michael Ong
Curr. Oncol. 2022, 29(7), 4665-4677; https://doi.org/10.3390/curroncol29070370
Available online: https://www.mdpi.com/1718-7729/29/7/370
15 September 2023
Current Oncology | World Lymphoma Awareness Day in 2023—“We Can’t Wait”

World Lymphoma Awareness Day (WLAD) takes place annually on September 15th. It is organized by the Lymphoma Coalition and was established in 2004 with the purpose of promoting public understanding of the various subtypes of lymphoma. Its primary objectives include educating people about recognizing symptoms, encouraging early diagnosis, and emphasizing the importance of timely treatment.
For World Lymphoma Awareness Day 2023, Current Oncology (ISSN: 1718-7729) has gathered open access academic research on the topic of lymphoma. We hope to share new scientific knowledge in the field of lymphoma with the world on this special day.
1. “CD5-Negative, CD10-Negative Low-Grade B-Cell Lymphoproliferative Disorders of the Spleen”
by John J. Schmieg, Jeannie M. Muir, Nadine S. Aguilera and Aaron Auerbach
Curr. Oncol. 2021, 28(6), 5124–5147; https://doi.org/10.3390/curroncol28060430
Available online: https://www.mdpi.com/1718-7729/28/6/430
2. “How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen”
by José Cabeçadas, Victor E. Nava, Joao L. Ascensao and Maria Gomes da Silva
Curr. Oncol. 2021, 28(6), 4611–4633; https://doi.org/10.3390/curroncol28060390
Available online: https://www.mdpi.com/1718-7729/28/6/390
3. “A Review on Splenic Diffuse Red Pulp Small B-Cell Lymphoma”
by Elif Yilmaz, Arashpreet Chhina, Victor E. Nava and Anita Aggarwal
Curr. Oncol. 2021, 28(6), 5148–5154; https://doi.org/10.3390/curroncol28060431
Available online: https://www.mdpi.com/1718-7729/28/6/431
4. “Low-Grade Primary Splenic CD10-Positive Small B-Cell Lymphoma/Follicular Lymphoma”
by Rami Abdulbaki, Parastou Tizro, Victor E. Nava, Maria Gomes da Silva and João L. Ascensão
Curr. Oncol. 2021, 28(6), 4821–4831; https://doi.org/10.3390/curroncol28060407
Available online: https://www.mdpi.com/1718-7729/28/6/407
5. “Comprehensive Laboratory Diagnostic Workup for Patients with Suspected Intraocular Lymphoma including Flow Cytometry, Molecular Genetics and Cytopathology”
by Evgenii Shumilov, Paolo Mazzeo, Martin S. Zinkernagel, Myriam Legros, Naomi Porret, Lorenz Romagna, Detlef Haase, Georg Lenz, Urban Novak, Yara Banz et al.
Curr. Oncol. 2022, 29(2), 766–776; https://doi.org/10.3390/curroncol29020065
Available online: https://www.mdpi.com/1718-7729/29/2/65
6. “Intravascular Large B-Cell Lymphoma: A Review with a Focus on the Prognostic Value of Skin Involvement”
by Thomas Breakell, Heidi Waibel, Stefan Schliep, Barbara Ferstl, Michael Erdmann, Carola Berking and Markus V. Heppt
Curr. Oncol. 2022, 29(5), 2909–2919; https://doi.org/10.3390/curroncol29050237
Available online: https://www.mdpi.com/1718-7729/29/5/237
7. “Management of Marginal Zone Lymphoma: A Canadian Perspective”
by Anthea Peters, Mary-Margaret Keating, Anna Nikonova, Sarah Doucette and Anca Prica
Curr. Oncol. 2023, 30(2), 1745–1759; https://doi.org/10.3390/curroncol30020135
Available online: https://www.mdpi.com/1718-7729/30/2/135
8. “Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada”
by Graeme Ball, Christopher Lemieux, David Cameron and Matthew D. Seftel
Curr. Oncol. 2022, 29(3), 2021–2045; https://doi.org/10.3390/curroncol29030164
Available online: https://www.mdpi.com/1718-7729/29/3/164
9. “Novel, First-in-Human, Oral PCLX-001 Treatment in a Patient with Relapsed Diffuse Large B-Cell Lymphoma”
by Randeep Sangha, Neal M. Davies, Afshin Namdar, Michael Chu, Jennifer Spratlin, Erwan Beauchamp, Luc G. Berthiaume and John R. Mackey
Curr. Oncol. 2022, 29(3), 1939–1946; https://doi.org/10.3390/curroncol29030158
Available online: https://www.mdpi.com/1718-7729/29/3/158
10. “Novel Mutations in a Lethal Case of Lymphomatous Adult T Cell Lymphoma with Cryptic Myocardial Involvement”
by Taraneh Hashemi Zonouz, Rami Abdulbaki, Bidhan C. Bandyopadhyay and Victor E. Nava
Curr. Oncol. 2021, 28(1), 818–824; https://doi.org/10.3390/curroncol28010079
Available online: https://www.mdpi.com/1718-7729/28/1/79
14 September 2023
Current Oncology | Official Social Media Accounts Go Live
We are pleased to announce the official social media of Current Oncology:
- Twitter: https://twitter.com/CurrentOncology
- Facebook: https://www.facebook.com/CurrentOncologyMDPI
- LinkedIn: https://www.linkedin.com/company/current-oncology-mdpi
You are more than welcome to connect with us!
6 September 2023
Recap of Awards Granted to Scholars in 2022

MDPI is committed to supporting the academic community, nurturing talent and advancing science. Awards are an important part of the research landscape and play a vital role in helping academics gain recognition, especially young researchers as they embark on new research avenues.
In 2022, our journals presented a total number of 394 Awards, including Travel Awards, Young Investigator Awards, Best PhD Thesis Awards, Best Paper Awards, and Outstanding Reviewer Awards, with several winners announced for some of the awards. The total prize sum amounted to just under 580,000 Swiss francs (CHF), or approximately 650,000 US dollars. Overall, more than 720 scholars were awarded.
The majority of the awards were dedicated to young researchers in relatively early stages of their careers. This encompassed 66 of the afore-mentioned Travel Awards, 60 Young Investigator Awards, supporting research projects and conference attendance, as well as 51 Best PhD Thesis Awards. Additionally, 113 Best Paper Awards were given by our journals. The selection committees were entrusted with identifying the most impactful and novel research and review articles published in their journal within a given year.
MDPI will continue its support and recognition for the academic community moving forward, sponsoring new awards across disciplines. To learn more about all the awardees and their research projects in your field of study, please visit the following pages:
To explore more MDPI awards, please click here.
5 September 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Neuro-Oncology”
As Current Oncology (ISSN: 1718-7729) is open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Neuro-Oncology” shown below:
1. “State of the Art in Combination Immuno/Radiotherapy for Brain Metastases: Systematic Review and Meta-Analysis”
by Masoumeh Najafi, Amin Jahanbakhshi, Marzieh Gomar, Cinzia Iotti, Lucia Giaccherini, Omid Rezaie, Francesco Cavallieri, Letizia Deantonio, Lilia Bardoscia, Andrea Botti et al.
Curr. Oncol. 2022, 29(5), 2995–3012; https://doi.org/10.3390/curroncol29050244
Available online: https://www.mdpi.com/1718-7729/29/5/244
2. “Delayed Effect of Dendritic Cells Vaccination on Survival in Glioblastoma: A Systematic Review and Meta-Analysis”
by Salvatore Cozzi, Masoumeh Najafi, Marzieh Gomar, Patrizia Ciammella, Cinzia Iotti, Corrado Iaccarino, Massimo Dominici, Giacomo Pavesi, Chiara Chiavelli, Ali Kazemian et al.
Curr. Oncol. 2022, 29(2), 881–891; https://doi.org/10.3390/curroncol29020075
Available online: https://www.mdpi.com/1718-7729/29/2/75
3. “Classification of Brain Tumor from Magnetic Resonance Imaging Using Vision Transformers Ensembling”
by Sudhakar Tummala, Seifedine Kadry, Syed Ahmad Chan Bukhari and Hafiz Tayyab Rauf
Curr. Oncol. 2022, 29(10), 7498–7511; https://doi.org/10.3390/curroncol29100590
Available online: https://www.mdpi.com/1718-7729/29/10/590
4. “Brain Metastases among Cancer Patients Diagnosed from 2010–2017 in Canada: Incidence Proportion at Diagnosis and Estimated Lifetime Incidence”
by Jiaqi L. Liu, Emily V. Walker, Yuba Raj Paudel, Faith G. Davis and Yan Yuan
Curr. Oncol. 2022, 29(3), 2091–2105; https://doi.org/10.3390/curroncol29030169
Available online: https://www.mdpi.com/1718-7729/29/3/169
5. “Treatment of Older Adult Patients with Glioblastoma: Moving towards the Inclusion of a Comprehensive Geriatric Assessment for Guiding Management”
by Manik Chahal, Brian Thiessen and Caroline Mariano
Curr. Oncol. 2022, 29(1), 360–376; https://doi.org/10.3390/curroncol29010032
Available online: https://www.mdpi.com/1718-7729/29/1/32
6. “Focused Delivery of Chemotherapy to Augment Surgical Management of Brain Tumors”
by Yusuf Mehkri, Samuel Woodford, Kevin Pierre, Abeer Dagra, Jairo Hernandez, Mohammad Reza Hosseini Siyanaki, Mohammed Azab and Brandon Lucke-Wold
Curr. Oncol. 2022, 29(11), 8846–8861; https://doi.org/10.3390/curroncol29110696
Available online: https://www.mdpi.com/1718-7729/29/11/696
7. “Somatostatin Receptor Theranostics for Refractory Meningiomas”
by Betty Salgues, Thomas Graillon, Tatiana Horowitz, Olivier Chinot, Laetitia Padovani, David Taïeb and Eric Guedj
Curr. Oncol. 2022, 29(8), 5550–5565; https://doi.org/10.3390/curroncol29080438
Available online: https://www.mdpi.com/1718-7729/29/8/438
8. “Newly Diagnosed Multifocal GBM: A Monocentric Experience and Literature Review”
by Valentina Baro, Giulia Cerretti, Michela Todoverto, Alessandro Della Puppa, Franco Chioffi, Francesco Volpin, Francesco Causin, Fabio Busato, Pasquale Fiduccia, Andrea Landi et al.
Curr. Oncol. 2022, 29(5), 3472–3488; https://doi.org/10.3390/curroncol29050280
Available online: https://www.mdpi.com/1718-7729/29/5/280
9. “Prospective Evaluation of Kidney Function in Long-Term Survivors of Pediatric CNS Tumors”
by Natalia Stepien, Viktoria Handler, Johannes Gojo, Amedeo A. Azizi, Lisa Mayr, Chryssa Grylli, Daniela Schwarz, Monika Chocholous, Irene Slavc, Michael Boehm et al.
Curr. Oncol. 2022, 29(8), 5306–5315; https://doi.org/10.3390/curroncol29080421
Available online: https://www.mdpi.com/1718-7729/29/8/421
10. “Laser Interstitial Thermal Therapy in Grade 2/3 IDH1/2 Mutant Gliomas: A Preliminary Report and Literature Review”
by Gabrielle W. Johnson, Rowland H. Han, Matthew D. Smyth, Eric C. Leuthardt and Albert H. Kim Curr. Oncol. 2022, 29(4), 2550–2563; https://doi.org/10.3390/curroncol29040209
Available online: https://www.mdpi.com/1718-7729/29/4/209
5 September 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Gynecologic Oncology”
As Current Oncology (ISSN: 1718-7729) is open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Gynecologic Oncology” shown below:
1. “Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2”
by Lauren Clarfield, Laura Diamond and Michelle Jacobson
Curr. Oncol. 2022, 29(3), 2132–2140; https://doi.org/10.3390/curroncol29030172
Available online: https://www.mdpi.com/1718-7729/29/3/172
2. “Minimally Invasive Surgery for Cervical Cancer in Light of the LACC Trial: What Have We Learned?”
by Omar Touhami and Marie Plante
Curr. Oncol. 2022, 29(2), 1093–1106; https://doi.org/10.3390/curroncol29020093
Available online: https://www.mdpi.com/1718-7729/29/2/93
3. “Outcomes of Enhanced Recovery after Surgery (ERAS) in Gynecologic Oncology: A Review”
by Steven P. Bisch and Gregg Nelson
Curr. Oncol. 2022, 29(2), 631–640; https://doi.org/10.3390/curroncol29020056
Available online: https://www.mdpi.com/1718-7729/29/2/56
4. “The Path to Eliminating Cervical Cancer in Canada: Past, Present and Future Directions”
by Hannah Caird, Jonathan Simkin, Laurie Smith, Dirk Van Niekerk and Gina Ogilvie
Curr. Oncol. 2022, 29(2), 1117–1122; https://doi.org/10.3390/curroncol29020095
Available online: https://www.mdpi.com/1718-7729/29/2/95
5. “Advances in Radiation Oncology for the Treatment of Cervical Cancer”
by Mame Daro Faye and Joanne Alfieri
Curr. Oncol. 2022, 29(2), 928–944; https://doi.org/10.3390/curroncol29020079
Available online: https://www.mdpi.com/1718-7729/29/2/79
6. “Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis”
by Antonia Pagkali, Ioannis Mamais, Adamantios Michalinos and Aris P. Agouridis
Curr. Oncol. 2022, 29(1), 321–336; https://doi.org/10.3390/curroncol29010029
Available online: https://www.mdpi.com/1718-7729/29/1/29
7. “Cervical Cancer Prevention and High-Risk HPV Self-Sampling Awareness and Acceptability among Women Living with HIV: A Qualitative Investigation from the Patients’ and Providers’ Perspectives”
by Daisy Le, Annie Coriolan Ciceron, Min Jeong Jeon, Laura Isabel Gonzalez, Jeanne A. Jordan, Jose Bordon and Beverly Long
Curr. Oncol. 2022, 29(2), 516–533; https://doi.org/10.3390/curroncol29020047
Available online: https://www.mdpi.com/1718-7729/29/2/47
8. “Gynecologic Symptoms among Hormone Receptor-Positive Breast Cancer Patients on Oral Endocrine Therapy: A Cross-Sectional Study”
by Alexandra Moskalewicz, Amy Di Tomaso, Jacob J. Kachura, Samantha Scime, Rosane Nisenbaum, Ronita Lee, Rashida Haq, Christine Derzko and Christine Brezden-Masley
Curr. Oncol. 2022, 29(3), 1813–1827; https://doi.org/10.3390/curroncol29030149
Available online: https://www.mdpi.com/1718-7729/29/3/149
30 August 2023
MDPI Insights: The CEO's Letter #3 - Sustainability and Co-opetition

Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
Our Commitment to Sustainability
As a pioneer in academic open access publishing since 1996, MDPI has always been dedicated to facilitating scientific exchange across all disciplines. Our approach to open science is guided by principles such as Open Access (OA), Timeliness and Efficiency, Simplicity, High-Quality Service, Flexibility, and a commitment to Sustainability. This commitment involves preserving published papers for the long term and supporting the future of science through partnerships, sponsorships, and awards.
In this edition of the CEO Letter, I will delve into MDPI’s various sustainability initiatives. As a leader in OA publishing, we are able to provide the public with a significant amount of environment-related content at no cost.
MDPI and the Sustainable Development Goals (SDGs)
In 2020, the SDG Publishers Compact was launched to accelerate implementation of the SDGs by promoting content that informs, develops, and inspires action. MDPI joined this initiative in 2021 and subsequently launched the MDPI SDG Hub in 2022, offering free access to recent research within the scope of each of the 17 SDGs. We also support authors from underrepresented communities by waiving publication charges for selected SDG-related papers. Detailed sustainability practices and supported publications are available in the report under each Goal page.
“More than 80% of MDPI articles and reviews published in 2022 relate to the Sustainable Development Goals.” [source: InCites, Accessed on 21.08.2023]
As at August 2023, MDPI boasts 14 journals dedicated to sustainability-related topics. Our first journal in this area, Sustainability, has published over 29,000 articles on the SDGs, accumulating over 240,000 citations (source: InCites, as at 1 January 2023). These journals serve as vital platforms for researchers to share insights and address environmental challenges. In addition:
MDPI journals specializing in sustainability-related topics:
- 2009: Sustainability
- 2012: Resources
- 2013: Climate
- 2014: Environments
- 2016: Recycling
- 2019: Clean Technologies
- 2020: Sustainable Chemistry
- 2021: Wind, Biomass, Conservation, Pollutants, Solar
- 2022: Waste, Microplastics
Read more:
Impactful Research
Highly Cited Articles in Sustainability
In 2022, content published in Sustainability and indexed in Journal Citation Reports (JCR) received nearly 190,000 citations. This highlights the fact that Sustainability publishes highly cited research articles related to environmental sciences and SDG-related topics such as climate action.
We are pleased to share that Sustainability received a 2022 CiteScore of 5.8, marking a 16% increase from the 2021 metric. Specifically, the CiteScore positions Sustainability as follows: Q1 (27 out of 163) in the “Environmental Science (miscellaneous)” category, and Q1 (101 out of 779) in the “Geography Planning and Development” category. For additional journal statistics, please visit here.
“Sustainability received a 2022 CiteScore of 5.8”
While MDPI journals such as Climate and Atmosphere have a distinct focus on atmosphere pollution and its impact on climate processes, journals like Sustainability, Environments, Water, Remote Sensing, and IJERPH publish content related to climate change. These journals have published over 32,300 articles related to SDG 13: Climate Action.
Highly Cited Papers in Sustainability
Below are several highly cited papers published in Sustainability over the past three years. Citation metrics are current as at 15 August 2023.
1. “A Global Assessment: Can Renewable Energy Replace Fossil Fuels by 2050?”Authors: Jerry L. Holechek, Hatim M. E. Geli, Mohammed N. Sawalhah, and Raul Valdez
Sustainability 2022, 14(8), 4792; https://doi.org/10.3390/su14084792
Citations: Crossref (97), Scopus (91), Web of Science (82), Google Scholar (125)
This paper addresses one of the most significant challenges of climate change – achieving Net Zero Carbon by 2050. The meta-analysis suggests that while difficult, this transition is possible through the concerted application of pathways, lifestyle changes, and global cooperation.
2. “Anxiety and the Ecological Crisis: An Analysis of Eco-Anxiety and Climate Anxiety”Author: Panu Pihkala
Sustainability 2020, 12(19), 7836; https://doi.org/10.3390/su12197836
Citations: Crossref (144), Scopus (121), Web of Science (159), Google Scholar (382)
This paper has received substantial media attention, including coverage by The Guardian, BBC, Vice, and CNBC. An interview with Dr. Panu Pihkala, a leading interdisciplinary researcher on the topic, can be found on MDPI’s podcast: Insight Faster, Episode 1.
3. “Impact of Climate Change on Agriculture and Its Mitigation Strategies: A Review”Authors: Gurdeep Singh Malhi, Manpreet Kaur, and Prashant Kaushik
Sustainability 2021, 13(3), 1318; https://doi.org/10.3390/su13031318
Citations: Crossref (207), Scopus (221), Web of Science (186), Google Scholar (355)
This paper reviews literature on climate change, addressing its causes, future projections, impact on agriculture, including plant physiology, growth, productivity, pest infestation, and the economic implications of mitigation strategies.
4. “Impacts of Plastic Pollution on Ecosystem Services, Sustainable Development Goals, and Need to Focus on Circular Economy and Policy Interventions”Authors: Rakesh Kumar, Anurag Verma, Arkajyoti Shome, Rama Sinha, Srishti Sinha, Prakash Kumar Jha, Ritesh Kumar, Pawan Kumar, Shubham, Shreyas Das, Prabhakar Sharma, and P. V. Vara Prasad
Sustainability 2021, 13(17), 9963; https://doi.org/10.3390/su13179963
Citations: Crossref (134), Scopus (136), Web of Science (113), Google Scholar (184)
This review aims to assess the adverse effects of plastic pollution on ecosystems, link the management of plastic with the SDGs, and propose policy measures using transdisciplinary approaches. Empowering communities to reduce plastic use is crucial. Addressing global plastic pollution is a priority.
Sustainability is an international, cross-disciplinary, open access journal that explores environmental, cultural, economic, and social sustainability of human beings. It provides a forward-looking platform for research on sustainability and sustainable development, and is published semi-monthly online by MDPI. Sustainability is affiliated with The Canadian Urban Transit Research & Innovation Consortium (CUTRIC) and The International Council for Research and Innovation in Building and Construction (CIB).
Read more:
- Testimonials: See what our editors and authors say about Sustainability.
Inside MDPI
President of Ireland Authors Editorial in MDPI Journal Sustainability
It’s a very special occasion when the president of a country takes the initiative to write an editorial for a journal. Michael D. Higgins, President of the Republic of Ireland, has contributed his insights to a forthcoming Special Issue in Sustainability:
This Special Issue, focusing on “making sustainable development happen” at grassroots levels, allows for perspectives from, and on, the major world faiths, exploring how challenges have been conceptualised and addressed, in addition to case studies of faith-based sustainability initiatives in practice.
The experience of faith institutions and communities in translating theological and moral commitments to sustainable development into action is now a topic we must examine with urgency; one on which I am so glad this Special Issue focuses.
As President of Ireland, I very much support this Special Issue of Sustainability. It is my great hope that the contents of the papers contained herein will assist in making sustainable development happen at grassroots levels across the world so that we can cooperate together, people of faith and of none, to ensure a just, inclusive and sustainable future for all on our fragile planet.
Read the completed editorial here:
Special Issue “Faith and Sustainable Development: Exploring Practice, Progress and Challenges among Faith Communities and Institutions”: Foreword by the President of Ireland
Author: Michael D. Higgins
Sustainability 2023, 15(12), 9683; https://doi.org/10.3390/su15129683
Coming Together for Science
The World Sustainability Forum 2023
The World Sustainability Forum (WSF) is a biennial MDPI event focused on sustainability. WSF 2023 marks the tenth anniversary of the conference series, taking place on 14 September. For the first time, the event will be hosted as a 24-hour conference across three locations – Singapore, Basel in Switzerland, and Toronto in Canada – alongside virtual streaming.
This unique format allows us to span three time zones, providing live coverage of critical sustainability-related topics throughout the day:
- The Singapore Hub, chaired by Professor Horn Mun Cheah and Associate Professor Renee Tan, will explore “Sustainability for Social and Community Impact”.
- The Basel Hub, chaired by Prof. Dr. Anet Režek Jambrak and Dr. Lela Mélon, will delve into “Sustainability in the industry, and at university and corporate settings”.
- The Toronto Hub, led by Dr. Umberto Berardi, will discuss “The Sustainable Built Environment”.
MDPI Sustainability Foundation: Recognizing Excellence in Sustainability Research
The MDPI Sustainability Foundation supports researchers through two sustainability-focused awards:
- The World Sustainability Award, amounting to USD 100,000, is given to senior researchers.
- The Emerging Sustainability Leader Award, valued at USD 20,000, sponsored by the journal Sustainability, is presented to early-career researchers.
The winners of the Sustainability Foundation will be formally awarded during the WSF2023 on 14 September. Interviews with the award winners and finalists are available below.
2023 World Sustainability Award Winners
Interviews with 2023 Emerging Sustainability Leader Award Finalists
- Dr. Bahareh Kamranzad
- Dr. Youjin Kim
- Dr. Julia Lohmann
As a hybrid event, WSF23 provides scholars with the option to attend in person at one of the conference sites or, for a more sustainable approach, virtually. All sessions will be recorded and archived for future access. Registration is open until 3 September 2023, with in-person and virtual tickets available here.
Read more:
Closing Thoughts
“Co-opetition”: Collaboration Plus Healthy Competition – A Visit to Elsevier
I firmly believe in fostering collaboration and at the same time promoting healthy competition within the academic publishing industry. The market offers ample room for publishers and related companies to provide valuable services and products that enrich the academic community. While MDPI is recognized for its efficient and streamlined processes –thanks to our over 6,000 colleagues, in-house tools, and initiatives that support the author journey – our ethos has always involved learning from and collaborating with other organizations.
MDPI’s Interaction with Elsevier
In January 2023, I had a brief conversation with Judy Verses, President of Global Academic and Government Markets at Elsevier, following her participation in a panel discussion at the Academic Publishers Europe event in Berlin. One of the highlights for me was Judy’s insight into the impact of research, particularly her emphasis on the role of collaboration, including policy and showing the impact of research to influence on funding decisions.
“Such collaborations drive forward-looking strategies to elevate our support for the scholarly community”
Judy and I resumed our discussion in August, when I visited Elsevier's office to review current projects, such as our recent agreement with Science Direct and the continued indexing of MDPI journals in Scopus (indexing database owned by Elsevier). We also explored possible opportunities for the future, including a potential collaboration to expand MDPI’s Scilit data infrastructure. This endeavour aims to aggregate and provide access to scholarly metadata encompassing journal articles, conference papers, books, preprints, and more. While these discussions are ongoing, the underlying principle remains that such collaborations drive forward-looking strategies to elevate our services and support for the scholarly community.
It was great that Judy and I acknowledged the merits of 'co-opetition,' a concept based of the belief that fostering cooperation alongside healthy competition can lead to shared advancements for both individual companies and the industry at large.
‘Fully OA’ Organizations Dedicated to Open Access
MDPI proudly aligns with the ‘Fully OA’ group, a collaborative initiative comprising nine organizations dedicated to Open Access. Our monthly meetings, including an OASPA representative, serve as platforms to share non-confidential information, resources, and projects. These gatherings also facilitate discussions on topics relevant to fully OA organizations. Occasionally, joint actions spring from these interactions, such as collaborative blog posts on pertinent subjects and joint statements, such as a recent response to the House Appropriations Committee.
This display of cooperation among competing entities forms a strategic alliance focused on nurturing the best interests of the OA publishing model.
As I wrap up this third edition of the CEO Letter, I encourage you to seize opportunities for collaboration and contribute to advancing our shared academic culture. As the African proverb has it, “If you want to go fast, go alone; if you want to go far, go together.”
Chief Executive Officer
MDPI AG
22 August 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Genitourinary Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top highly cited papers in the Section “Genitourinary Oncology” shown below:
1. “Current Advances in Immune Checkpoint Inhibition and Clinical Genomics in Upper Tract Urothelial Carcinoma: State of the Art”
by Gianluigi Califano, Idir Ouzaid, Paul Laine-Caroff, Arthur Peyrottes, Claudia Collà Ruvolo, Benjamin Pradère, Vincent Elalouf, Vincent Misrai, Jean-François Hermieu, Shahrokh F. Shariat et al.
Curr. Oncol. 2022, 29(2), 687–697; https://doi.org/10.3390/curroncol29020060
Available online: https://www.mdpi.com/1718-7729/29/2/60
2. “Nondetectable Prostate Carcinoma (pT0) after Radical Prostatectomy: A Narrative Review”
by Nikolaos Kalampokis, Nikolaos Grivas, Markos Karavitakis, Ioannis Leotsakos, Ioannis Katafigiotis, Marcio Covas Moschovas, Henk van der Poel and the European Association of Urology (EAU) Young Academic Urologists (YAU) Robotic Urology Working Group
Curr. Oncol. 2022, 29(3), 1309–1315; https://doi.org/10.3390/curroncol29030111
Available online: https://www.mdpi.com/1718-7729/29/3/111
3. “Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study”
by Elodie Dang, Alexandre Vallée, Coralie Lepage-Seydoux, Karine Sejean, Brigitte Bonan, Christine Abraham, Philippe Beuzeboc and Raffaele Ratta
Curr. Oncol. 2022, 29(2), 945–955; https://doi.org/10.3390/curroncol29020080
Available online: https://www.mdpi.com/1718-7729/29/2/80
4. “Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies”
by Ioannis A. Voutsadakis
Curr. Oncol. 2022, 29(3), 1390–1407; https://doi.org/10.3390/curroncol29030117
Available online: https://www.mdpi.com/1718-7729/29/3/117
5. “Trop-2 in Upper Tract Urothelial Carcinoma”
by Eisuke Tomiyama, Kazutoshi Fujita, Kosuke Nakano, Ken Kuwahara, Takafumi Minami, Taigo Kato, Koji Hatano, Atsunari Kawashima, Motohide Uemura, Tetsuya Takao et al.
Curr. Oncol. 2022, 29(6), 3911–3921; https://doi.org/10.3390/curroncol29060312
Available online: https://www.mdpi.com/1718-7729/29/6/312
6. “Diagnostic and Therapeutic Challenges in a Patient with Synchronous Very High-Risk Prostate Adenocarcinoma and Anal Carcinoma”
by Jonathan Wallach, Irini Youssef, Andrea Leaf and David Schwartz
Curr. Oncol. 2022, 29(1), 377–382; https://doi.org/10.3390/curroncol29010033
Available online: https://www.mdpi.com/1718-7729/29/1/33
7. “Genomics and Immunomics in the Treatment of Urothelial Carcinoma”
by Veronica Mollica, Francesco Massari, Alessandro Rizzo, Roberto Ferrara, Arjun K. Menta and Jacob J. Adashek
Curr. Oncol. 2022, 29(5), 3499–3518; https://doi.org/10.3390/curroncol29050283
Available online: https://www.mdpi.com/1718-7729/29/5/283
8. “Next Wave of Targets in the Treatment of Advanced Renal Cell Carcinoma”
by Luisa M. Cardenas, Jasna E. Deluce, Shahrukh Khan, Omar Gulam, Saman Maleki Vareki, Ricardo Fernandes and Aly-Khan A. Lalani
Curr. Oncol. 2022, 29(8), 5426–5441; https://doi.org/10.3390/curroncol29080429
Available online: https://www.mdpi.com/1718-7729/29/8/429
9. “Clinical Lymph Node Involvement as a Predictor for Cancer-Specific Survival in Patients with Penile Squamous Cell Cancer”
by Makoto Kawase, Kimiaki Takagi, Kei Kawada, Takashi Ishida, Masayuki Tomioka, Torai Enomoto, Shota Fujimoto, Tomoki Taniguchi, Hiroki Ito, Koji Kameyama et al.
Curr. Oncol. 2022, 29(8), 5466–5474; https://doi.org/10.3390/curroncol29080432
Available online: https://www.mdpi.com/1718-7729/29/8/432
10. “The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature”
by Hana Studentova, Nikol Rusarova, Andrea Ondruskova, Anezka Zemankova, Vladimir Student Jr., Daniela Skanderova and Bohuslav Melichar
Curr. Oncol. 2022, 29(8), 5475–5488; https://doi.org/10.3390/curroncol29080433
Available online: https://www.mdpi.com/1718-7729/29/8/433
22 August 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Thoracic Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top highly cited papers in the Section “Thoracic Oncology” shown below:
1. “ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date”
by Sébastien Gendarme, Olivier Bylicki, Christos Chouaid and Florian Guisier
Curr. Oncol. 2022, 29(2), 641–658; https://doi.org/10.3390/curroncol29020057
Available online: https://www.mdpi.com/1718-7729/29/2/57
2. “Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology”
by Hamid Mithoowani and Michela Febbraro
Curr. Oncol. 2022, 29(3), 1828–1839; https://doi.org/10.3390/curroncol29030150
Available online: https://www.mdpi.com/1718-7729/29/3/150
3. “Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence”
by Ilaria Attili, Antonio Passaro, Pasquale Pisapia, Umberto Malapelle and Filippo de Marinis
Curr. Oncol. 2022, 29(1), 255–266; https://doi.org/10.3390/curroncol29010024
Available online: https://www.mdpi.com/1718-7729/29/1/24
4. “Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer”
by Diana N. Ionescu, Tracy L. Stockley, Shantanu Banerji, Christian Couture, Cheryl A. Mather, Zhaolin Xu, Normand Blais, Parneet K. Cheema, Quincy S.-C. Chu, Barbara Melosky et al.
Curr. Oncol. 2022, 29(7), 4981–4997; https://doi.org/10.3390/curroncol29070396
Available online: https://www.mdpi.com/1718-7729/29/7/396
5. “Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with EGFR Gene Mutation–Case Report and a Literature Review”
by Anna Rekowska, Piotr Rola, Magdalena Wójcik-Superczyńska, Izabela Chmielewska, Paweł Krawczyk and Janusz Milanowski
Curr. Oncol. 2022, 29(5), 3531–3539; https://doi.org/10.3390/curroncol29050285
Available online: https://www.mdpi.com/1718-7729/29/5/285
6. “Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer”
by Shelley Kuang, Andrea S. Fung, Kirstin A. Perdrizet, Kaitlin Chen, Janice J. N. Li, Lisa W. Le, Michael Cabanero, Ola Abu Al Karsaneh, Ming S. Tsao, Josh Morganstein et al.
Curr. Oncol. 2022, 29(7), 4428–4437; https://doi.org/10.3390/curroncol29070352
Available online: https://www.mdpi.com/1718-7729/29/7/352
7. “Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy”
by Balázs Jóri, Markus Falk, Iris Hövel, Peggy Weist, Markus Tiemann, Lukas C. Heukamp and Frank Griesinger
Curr. Oncol. 2022, 29(9), 6628–6634; https://doi.org/10.3390/curroncol29090520
Available online: https://www.mdpi.com/1718-7729/29/9/520
8. “HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature”
by Laurent Mathiot, Guillaume Herbreteau, Siméon Robin, Charlotte Fenat, Jaafar Bennouna, Christophe Blanquart, Marc Denis and Elvire Pons-Tostivint
Curr. Oncol. 2022, 29(5), 3748–3758; https://doi.org/10.3390/curroncol29050300
Available online: https://www.mdpi.com/1718-7729/29/5/300
18 August 2023
MDPI’s 2022 Young Investigator Awards in Medicine and Pharmacology—Winners Announced

MDPI’s Young Investigator Awards recognize promising young researchers, acknowledge their contributions, and enhance communication among scientists. We are proud to present the winners for the year 2022 in medicine and pharmacology. The winners were selected by the journals’ Award Evaluation Committee.
We would like to warmly congratulate the awarded young investigators for their outstanding contributions. MDPI will continue to provide support and recognition to the academic community.
- Yuyan Jiang, Stanford University, USA
- Billy Wai-Lung Ng, Chinese University of Hong Kong, China
- Ashleigh Poh, The Olivia Newton-John Cancer Research Institute, Australia
- Miranda Fidler-Benaoudia, University of Calgary, Canada
- Bishal Gyawali, Queen’s University, Canada
- Shahnawaz Anwer, Hong Kong Polytechnic University, Hong Kong
- Jan Bednarsch, Universitätsmedizin Berlin, Germany
- Anda Mihaela Naciu, Fondazione Policlinico Universitario Campus Bio-Medico, Italy
- Jerome Lechien, University of Mons, Belgium
- Daniele Bertoglio, University of Antwerp, Belgium
- Gregor Fuhrmann, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany
- Haley Adcox, Virginia Commonwealth University, USA
About MDPI Awards:
In order to support the academic community, especially young researchers, and enhance communication among scientists, MDPI journals regularly offer various awards to researchers in specific fields. These awards, serving as a source of inspiration and a form of recognition, help to promote the influence of talented individuals who have made outstanding achievements and are making significant contributions to the advancement of their fields.
For more MDPI awards, please click here.
18 August 2023
MDPI’s 2022 Travel Awards in Medicine and Pharmacology—Winners Announced

We are proud to recognize the winners of MDPI’s 2022 Travel Awards in medicine and pharmacology category for their outstanding presentations.
MDPI journals regularly offer Travel Awards to encourage talented junior scientists to present their research at academic conferences in specific fields, which helps to enhance their influence.
The winners mentioned below were carefully selected by the journal editors based on an outline of their research and the work to be presented at an academic conference.
We would like to congratulate the winners of the 2022 Travel Awards and wish them success with their future research endeavors. MDPI will continue to enhance communication among scientists.
- Filip Jansåker, Lund University, Lund, Sweden
- Vanessa Silva, University of Trás-os-Montes and Alto Douro, Portugal
- Diego de Miguel Perez, Icahn School of Medicine at Mount Sinai, USA
- Luigi Russo, Italian Institute of Technology (IIT), Italy
- Sneha Sethi, University of Adelaide, Australia
- Xiyin Wang, Indiana University School of Medicine, USA
- Sonia Nath, University of Adelaide, Australia
- Konstantina Kritikou, Carol Davila University of Medicine and Pharmacy, Romania
- Adrien Holzgreve, The University Hospital of Munich, Germany
- Antonella Padella, Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l., Italy
- Susanna Cooper, St. George’s University of London, UK
- Renée Tillie, Maastricht University Medical Center, the Netherlands
- Max Lennart Eckstein, University of Bayreuth, Germany
- Lorenzo Bertani, University of Pisa, Italy
- Yuxue Cao, University of Queensland, Australia
- Flávia Sousa, Italian Institute of Technology, Italy
About MDPI Awards:
In order to support the academic community, especially young researchers, and enhance communication among scientists, MDPI journals regularly offer various awards to researchers in specific fields. These awards, serving as a source of inspiration and form ot recognition, help to promote the influence of talented individuals who have made outstanding achievements and are making significant contributions to their fields.
See more MDPI awards, please click here.
18 August 2023
MDPI’s 2022 Outstanding Reviewer Awards in Medicine and Pharmacology—Winners Announced

In order to acknowledge our reviewers, who so generously dedicate their time to reviewing papers and demonstrate diligence, professionalism, and timeliness when reviewing manuscripts, MDPI journals regularly offer outstanding reviewer awards to scholars who participate in the peer-review process.
We are proud to recognize the winners for the year 2022 in medicine and pharmacology for their outstanding contributions among the extensive competition by presenting them with an Outstanding Reviewer Award.
We would like to take this opportunity to congratulate all of the winners on their achievements. MDPI will continue to provide support and recognition to the academic community.
- Maxime Pichon, Centre Hospitalier Universitaire de Poitiers, France
- Violeta Popovici, Ovidius University of Constanta, Romania
- Yosra A. Helmy, University of Kentucky, USA
- Antonio G. Solimando, Aldo Moro University of Bari, Italy
- Linlin Guo, The Ohio State University Medical Center, USA
- Ravindra Deshpande, Wake Forest School of Medicine, USA
- Songli Zhu, Fred Hutchinson Cancer Research Center, USA
- Antonella Argentiero, IRCCS Istituto Tumori “Giovanni Paolo II” of Bari, Italy
- Camelia Coada, Alma Mater Studiorum-University of Bologna, Italy
- Chenghui Li, University of Arkansas for Medical Sciences, USA
- Laurentiu Pop, University of Texas Southwestern Medical Center, USA
- Muhammad Fazal Ijaz, Dongguk University, Republic of Korea
- Rafał Watrowski, University of Freiburg, Germany
- Ruben C. Petreaca, The Ohio State University, USA
- Ruchi Roy, Rush University Medical Center, USA
- Salvatore Cocuzza, University of Catania, Italy
- Santosh Kumar Singh, Morehouse School of Medicine, USA
- Sergei Boichuk, Kazan State Medical University, Russia
- Simon John Christoph Soerensen, Stanford University, USA
- Takuya Koie, Gifu University, Japan
- Teresa Rubio-Tomás, Foundation for Research and Technology Hellas, Greece
- Teruki Nii, Kyushu University, Japan
- Tomasz Marjanski, Medical University of Gdansk, Poland
- Kristen Haase, The University of British Columbia, Canada
- Ravi Ramjeesingh, Nova Scotia Cancer Centre and Dalhousie University, Canada
- Makoto Endo, Kyushu University, Japan
- Tefera Tadesse, Addis Ababa University, Ethiopia
- Ravi Ramjeesingh, Nova Scotia Cancer Centre and Dalhousie University, Canada
- Ryuichi Ohta, Unnan City Hospital, Japan
- Henry Sutanto, Cardiovascular Research Institute Maastricht, the Netherlands
- José-María Sánchez-González, University of Seville, Spain
- Emmanouil Kapetanakis, General Hospital of Piraeus “Tzaneio”, Greece
- Eleonora Topino, Libera Università Maria Santissima Assunta (LUMSA), Italy
- Rodolfo Reda, Sapienza University of Rome, Italy
- Giulio Francesco Romiti, Sapienza University of Rome, Italy
- Maria Gabriella Melchiorre, IRCCS INRCA—National Institute of Health and Science on Ageing, Italy
- James Walter, 1Hines VA Hospital, USA; 2 Loyola Medical Center, USA
- Vasiliki Tsigkou, Sotiria Hospital, Greece
- Flavia Zacconi, Pontificia Universidad Católica de Chile, Chile
- Bhupendra Prajapati, Ganpat University, India
- Van-An Duong, Gachon University, Republic of Korea
- Ashish Agrawal, Indian Institute of Technology (BHU), India
- Aydin Eresen, University of California Irvine, USA
About MDPI Awards:
In order to support the academic community, especially young researchers, and enhance communication among scientists, MDPI journals regularly offer various awards to researchers in specific fields. These awards, serving as a source of inspiration and form of recognition, help to promote the influence of talented individuals who have made outstanding achievements and are making significant contributions to their fields.
See more MDPI awards, please click here.
18 August 2023
MDPI’s 2022 Best PhD Thesis Awards in Medicine and Pharmacology—Winners Announced

MDPI’s Best PhD Thesis Awards aim to recognize young scholars who are deemed to have produced the most outstanding PhD thesis in their fields of research and to encourage them to continue their outstanding work and further contributions to their field.
We would like to congratulate the winners of the 2022 Best PhD Thesis Awards in medicine and pharmacology and wish them success with their future research endeavors. MDPI will continue to enhance communication among scientists.
- “Uncovering Novel Prognostic and Predictive Epigenetic Biomarkers in Malignant Testicular Germ Cell Tumors”
by João Pedro da Silva Machado Lobo, University of Porto, Portugal
- “Metastatic Recurrence in Colorectal Cancer Arises from Residual EMP1+ Cells”
by Adrià Cañellas Socias, University of Barcelona, Spain
- “Investigating Novel Aspects of the Blood–Brain Barrier Using High-Resolution Electron Microscopy”
by Shireen Mentor, University of Cape Town, South Africa
- “An Epidemiological Approach to Study The Interplay between Genome, Epigenome and Exposome in Women”
by Roberta Magnano San Lio, University of Catania, Italy
- “Intravitreal Liposomes as Ocular Drug Delivery Systems: Vitreal Interactions, Retinal Permeation and Drug Release Characteristics”
by Shirin Tavakoli, University of Helsinki, Finland
- “Microbiome-Mediated Colonization Resistance: Defense against Enteropathogens and Multi-Drug Resistant Organisms”
by Quinten Ducarmon, Leiden University Medical Center, the Netherlands
About MDPI Awards:
In order to support the academic community, especially young researchers, and enhance communication among scientists, MDPI journals offer various awards to researchers in specific fields. These awards, serving as a source of inspiration and form of recognition, help to promote the influence of talented individuals who have made outstanding achievements and are making significant contributions to their fields.
For more MDPI awards, please click here.
18 August 2023
MDPI’s Best Paper Awards in Medicine and Pharmacology—Winners Announced in 2022

The purpose of our Best Paper Awards is to promote and recognize the most impactful contributions published within MDPI journals.
The editors of each journal carefully selected review and research papers through a rigorous evaluative process based on criteria such as the scientific merit, overall impact, and quality of presentation of the papers published in the journal.
We are honored to present the winners for the year 2022 in medicine and pharmacology, who were selected amongst extensive competition, and congratulate the authors for their outstanding scientific publications. MDPI will continue to provide support and recognition to the academic community.
- “Development and Challenges of Antimicrobial Peptides for Therapeutic Applications”
by Charles H. Chen and Timothy K. Lu
Antibiotics 2020, 9(1), 24; https://doi.org/10.3390/antibiotics9010024
- “Antimicrobial Usage and Resistance in Companion Animals: A Cross-Sectional Study in Three European Countries”
by Philip Joosten, Daniela Ceccarelli, Evelien Odent, Steven Sarrazin, Haitske Graveland, Liese Van Gompel, Antonio Battisti, Andrea Caprioli, Alessia Franco, Jaap A. Wagenaar et al.
Antibiotics 2020, 9(2), 87; https://doi.org/10.3390/antibiotics9020087
- “Management of Peri-Implantitis Lesions without the Use of Systemic Antibiotics: A Systematic Review”
by Ahsen Khan, Ankit Goyal, Scott D. Currell and Dileep Sharma
Dent. J. 2020, 8(3), 106; https://doi.org/10.3390/dj8030106
- “Associations among Primary Stability, Histomorphometric Findings, and Bone Density: A Prospective Randomized Study after Alveolar Ridge Preservation with a Collagen Cone”
by Sigmar Schnutenhaus, Werner Götz, Jens Dreyhaupt, Heike Rudolph, Ralph G. Luthardt and Cornelia Edelmann
Dent. J. 2020, 8(4), 112; https://doi.org/10.3390/dj8040112
- “Novel Prefrontal Synthesis Intervention Improves Language in Children with Autism”
by Andrey Vyshedskiy, Edward Khokhlovich, Rita Dunn, Alexander Faisman, Jonah Elgart, Lisa Lokshina, Yuriy Gankin, Simone Ostrovsky, Lauren deTorres, Stephen M. Edelson et al.
Healthcare 2020, 8(4), 566; https://doi.org/10.3390/healthcare8040566
- “The Effects of Long-Term 40-Hz Physioacoustic Vibrations on Motor Impairments in Parkinson’s Disease: A Double-Blinded Randomized Control Trial”
by Abdullah Mosabbir, Quincy J. Almeida and Heidi Ahonen
Healthcare 2020, 8(2), 113; https://doi.org/10.3390/healthcare8020113
- “Racial Disparities-Associated COVID-19 Mortality among Minority Populations in the US”
by Donald J. Alcendor
J. Clin. Med. 2020, 9(8), 2442; https://doi.org/10.3390/jcm9082442
- “Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence”
by Celestino Sardu, Jessica Gambardella, Marco Bruno Morelli, Xujun Wang, Raffaele Marfella and Gaetano Santulli
J. Clin. Med. 2020, 9(5), 1417; https://doi.org/10.3390/jcm9051417
- “Estimation of the Transmission Risk of the 2019-nCoy and Its Implication for Public Health Interventions”
by Biao Tang, Xia Wang, Qian Li, Nicola Luigi Bragazzi, Sanyi Tang, Yanni Xiao and Jianhong Wu
J. Clin. Med. 2020, 9(2), 462; https://doi.org/10.3390/jcm9020462
- “Molecular and Cellular Mechanisms Affected in ALS”
by Laura Le Gall, Ekene Anakor, Owen Connolly, Udaya G. Vijayakumar, William J. Duddy and Stephanie Duguez
J. Pers. Med. 2020, 10(3), 101; https://doi.org/10.3390/jpm10030101
- “Postulated Adjuvant Therapeutic Strategies for COVID-19”
by Anderson O. Ferreira, Hudson C. Polonini and Eli C. F. Dijkers
J. Pers. Med. 2020, 10(3), 80; https://doi.org/10.3390/jpm10030080
- “Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models”
by Vincenzo Quagliariello, Margherita Passariello, Domenica Rea, Antonio Barbieri, Martina Iovine, Annamaria Bonelli, Antonietta Caronna, Gerardo Botti, Claudia De Lorenzo and Nicola Maurea
J. Pers. Med. 2020, 10(4), 179; https://doi.org/10.3390/jpm10040179
- "Manufacturing Considerations for the Development of Lipid Nanoparticles Using Microfluidics”
by Carla B. Roces, Gustavo Lou, Nikita Jain, Suraj Abraham, Anitha Thomas, Gavin W. Halbert and Yvonne Perrie
Pharmaceutics 2020, 12(11), 1095; https://doi.org/10.3390/pharmaceutics12111095
- “Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing”
by Sawittree Sahakijpijarn, Chaeho Moon, John J. Koleng, Dale J. Christensen and Robert O. Williams III
Pharmaceutics 2020, 12(11), 1002; https://doi.org/10.3390/pharmaceutics12111002
- “Skin Wound Healing Process and New Emerging Technologies for Skin Wound Care and Regeneration”
by Erika Maria Tottoli, Rossella Dorati, Ida Genta, Enrica Chiesa, Silvia Pisani and Bice Conti
Pharmaceutics 2020, 12(8), 735; https://doi.org/10.3390/pharmaceutics12080735
- “The Role of Hospital and Community Pharmacists in the Management of COVID-19: Towards an Expanded Definition of the Roles, Responsibilities, and Duties of the Pharmacist”
by Nicola Luigi Bragazzi, Muhammad Mansour, Alessandro Bonsignore and Rosagemma Ciliberti
Pharmacy 2020, 8(3), 140; https://doi.org/10.3390/pharmacy8030140
- “Association of a Novel Medication Risk Score with Adverse Drug Events and Other Pertinent Outcomes Among Participants of the Programs of All-Inclusive Care for the Elderly”
by David L. Bankes, Hubert Jin, Stephanie Finnel, Veronique Michaud, Calvin H. Knowlton, Jacques Turgeon and Alan Stein
Pharmacy 2020, 8(2), 87; doi.org/10.3390/pharmacy8020087
About MDPI Awards:
In order to support the academic community, especially young researchers, and enhance communication among scientists, MDPI journals regularly offer various awards to researchers in specific fields. These awards, serving as a source of inspiration and form of recognition, help to promote the influence of talented individuals who have made outstanding achievements and are making significant contributions to their fields.
See more MDPI awards, please click here.
15 August 2023
Meet Us at the 29th Annual Meeting of Japan Society of Gene and Cell Therapy, 11–13 September 2023, Osaka, Japan

MDPI will attend the 29th Annual Meeting of Japan Society of Gene and Cell Therapy. This event will be held at the Osaka International Convention Center for three days from Monday, 11 September, to Wednesday, 13 September 2023.
The theme of this meeting is “Gene Therapy Making a Leap Forward – A Bridge to the Future through Cooperation between Industry, Government and Academia”. Gene and cell therapy has so far been centered on blood diseases, cancers, and metabolic disorders, but gene therapy for spinal muscular atrophy, an intractable neurological disease, was also launched in the US and Japan. Regulations must be well discussed with government agencies, PMDA, and other agencies. The Society will develop a meaningful program to enable sufficient discussions between stakeholders. In addition, a session will be organized by the Scientific Program Committee, a new committee established by the Japan Society of Gene and Cell Therapy.
The following MDPI journals will be represented:
- IJMS;
- CIMB;
- Antioxidants;
- Cancers;
- Current Oncology;
- Metabolites;
- SynBio;
- Biologics;
- Genes;
- Hemato.
If you plan on attending this conference, please feel free to stop by our booth and speak with us. Our delegates look forward to meeting you in person and answering any questions that you may have.
For more information about the conference, please visit https://www.c-linkage.co.jp/jsgct2023/en/index_en.html.
27 July 2023
MDPI Insights: The CEO's Letter #2 - Open Peer-Review and IJERPH

Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
Open Peer Review Reports
Continuing the topic of openness from my inaugural monthly CEO letter, in these Opening Thoughts, I highlight the growth and importance of open peer-review reports at MDPI. Open peer reports align with the principles of open science, making the publishing process more transparent and facilitating rigorous peer review.
MDPI journals operate an open peer-review option by default, allowing authors to publish review reports and author responses (often referred to as open reports) together with the published paper. Publishing the reviewer reports and author responses together with the article provides greater transparency and trust for readers, as this allows them to track the editorial decision-making process. Open peer-review also encourages reviewers and editors to provide high-quality comments, as these will be made public if the article is accepted for publication.
Start and Growth of Open Peer Review at MDPI
The MDPI journal Life was a pioneer in offering this opportunity to its authors in 2014. The first MDPI article with peer-review reports openly published was a review by the Nobel Laureate Werner Arber, in which the review reports were published as supplementary material. By 2018, open peer-review was available across all MDPI journals. As such, MDPI authors have embraced the open peer-review model, providing a steady increase in the number of MDPI articles. As of 2023, approximately one-third (34.0%) of MDPI articles were published with open review reports.
As at July 2023, the percentage of MDPI articles published with open peer review has increased to 36.2% of the total papers published in 2023 so far, indicating ongoing growth in adoption.
Open peer review continues to play a critical role in the assessment of the peer-review process in Life. For further insights, please see the recent editorial by Dr. Pabulo Henrique Rampelotto, the former Editor-in-Chief of Life, who spearheaded the implementation of the open peer-review process.
Benefits of Open Peer Review
The benefits of open peer review include increased transparency, trust and constructive feedback. To promote open communication further and increase the robustness of the peer-review process, we encourage reviewers to sign their reports so that their name appears on the review report (this process is referred to as open identity). The default option is for reviewers to remain anonymous; however, by signing the reports, reviewers receive direct credit for their contribution to the peer-review process and show their commitment towards open science.
As the leading open access publisher, MDPI remains committed to promoting open peer-review and encourages authors to choose this approach. Our goal is to provide a rigorous and transparent peer-review process that benefits the scientific community, and we believe that open peer-review is a vital step in fostering openness and collaboration in scientific communication.
Impactful Research
MDPI Papers Cited in the News – IJERPH edition
Every month, our corporate marketing team compiles data from Altmetrics to create a list of MDPI papers that have been cited in the news. This list continues to grow as renowned news outlets regularly reference research published by MDPI in their articles.
During 2022, a total of 111,965 MDPI research papers were mentioned in prominent news outlets such as National Geographic, The Washington Post, Forbes, The Guardian, the BBC, CNN, Time, and Harvard Business Review.
Highly Cited Journal Publications
IJERPH, known for publishing impactful research, received the most news mentions among all MDPI journals in 2022, based on Altmetrics data:
- International Journal of Environmental Research and Public Health: 3509 mentions
- Nutrients: 2698 mentions
- International Journal of Molecular Sciences: 1701 mentions
- Journal of Clinical Medicine: 1131 mentions
- Viruses: 1111 mentions
These numbers show the recognition and impact of the articles published in IJERPH. For a more detailed view of the journal’s most cited and viewed papers, you can visit here. In total, IJERPH has garnered over 28,000 mentions in prominent news outlets, and as at July 2023, an impressive count of over 17,000 papers cited 10 times or more. These figures highlight the impactful contribution of IJERPH publications to the scientific community.
Example of Recent Mentions
During May and June 2023, a noteworthy selection of articles from IJERPH was cited in news articles, including:
The Washington Post: “Bringing nature inside can improve your health. Here’s how to do it.”
IJERPH paper: “Physiological Benefits of Viewing Nature: A Systematic Review of Indoor Experiments”
Harvard Business Review: “How to Take Better Breaks at Work, According to Research”
IJERPH paper: “Canine-Assisted Therapy Improves Well-Being in Nurses”
National Geographic: “Lyme disease is spreading fast—but a vaccine may be on the way”
IJERPH paper: “Range Expansion of Tick Disease Vectors in North America: Implications for Spread of Tick-Borne Disease”
Inside MDPI
MDPI Develops an Artificial Intelligence Tool to Enhance the Peer-Review Process
At MDPI, we believe that rigorous peer-review is the corner-stone of high-quality academic publishing. We are grateful to the scholars who generously dedicate their time to peer-review articles submitted to MDPI journals. Their contributions are invaluable to the advancement of science.
Peer-review is a critical part of the publication process, ensuring that MDPI upholds the highest quality standards for the papers we publish. Every manuscript submitted to our journals undergoes a comprehensive peer-review process conducted by subject-matter experts.
To further enhance our peer-review process, our Data Analytics team has developed an Artificial Intelligence (AI) tool designed to support the selection of reviewers. This proprietary tool utilizes Natural Language Processing (NLP), a specially designed AI language model, to extract information from the title and abstract of submitted papers. It then searches our database for similar manuscripts and suggests potential reviewers based on this analysis. Integrated with MDPI's submission system (SuSy), the AI tool cross-references the suggested candidates with our reviewer database to verify their invitation status and availability.
The goal of this tool is to provide better targeted peer-review invitations, reducing the number of emails sent for each paper and increasing the efficiency of our editorial staff.
In the near future, our Data Analytics team plans to deploy similar AI projects to improve other critical aspects of our services, offering an enhanced experience to our authors and readers.
Click here to learn about MDPI’s review process, including procedures, responsibilities, and benefits.
Read more:
Coming Together for Science
The Future of IJERPH
On 5 July 2023, Prof. Dr. Paul B. Tchounwou, the founding Editor-in-Chief of IJERPH, along with five Section Editors in Chief (Prof. Dr. Germán Vicente-Rodríguez, Prof. Dr. Karl Goodkin, Prof. Dr. William A. Toscano, Prof. Dr. Jimmy T. Efird, and Prof. Dr. William Douglas Evans), gathered in Basel to discuss the future of the journal. The meeting provided an opportunity to address the recent decision by The Web of Science to delist IJERPH due to the journal failing the Content Relevance criterion, and propose best strategies that will ensure high scientific rigor as well as a clear scope and aim of IJERPH, going forward.
While the delisting is disappointing for IJERPH, as well as for our authors, academic editors, and the entire scientific community supporting our journal, we see it as an opportunity to reflect and prepare for the future direction of the journal.
Since its launch in 2004, IJERPH’s vision and mission have evolved to be more complete and comprehensive in engaging scientific communities. In light of this, we will refresh the journal’s aims and scope, ensuring they align with the organic expansion of IJERPH. Additionally, we will restructure the journal sections into broader categories, encouraging collaborative research and transdisciplinary approaches for authors. This is designed to foster collaboration and knowledge exchange among diverse fields, contributing to a holistic understanding of health promotion and disease prevention. We are confident that these next steps will enhance the scientific strength and societal impact of our journal.
Journal Achievements
In addition to the productive discussions, we took the time to celebrate some of the remarkable achievements of IJERPH, which I highlight below:
- Founded by Prof. Dr. Paul B. Tchounwou in 2004
- Indexed in PubMed in 2008
- Received its first Impact Factor in 2012
- Published its 5000th paper in 2017
- Over 60,000 papers published as at June 30, 2023
- 131,628,173 paper views in 2018–2022
- Over 28,000 mentions in prominent news outlets
- 17,000 papers cited 10 times or more as at June 30, 2023
- No.1 journal in the 2022 Google Scholar Metrics in the category of Public Health
- Awarded several editions of Young Investigator Awards, Travel Awards, and Outstanding Reviewer Awards since 2018.
These achievements showcase the journal’s significant contributions to the field and its impact on global health. We are proud of the exceptional work accomplished by the IJERPH team and look forward to building upon this success in the years to come.
Closing Thoughts
MDPI’s Impact in Spain
During the past month, I had the opportunity to visit our new office building in Barcelona, where I met with our local colleagues to discuss the ways we serve the scholarly community, particularly in Spain. The multi-functional office plays a vital role in supporting various business needs, including editorial, design, conference management, data analytics, journal relationship management, publishing partnerships, and collaborations with societies.
Spain holds a significant position in MDPI’s global market, ranking as the fourth-largest contributor to the total number of papers published by MDPI as at July 2023, ranking next to Italy, the USA, and China, with Germany completing the top five.
The Numbers
Out of the 1,680,000 total MDPI articles published as at 25 July, almost 80,000 articles are contributed by Spanish authors, representing nearly 40,000 unique authors affiliated with Spanish institutions. Remarkably, over 6,300 of these authors hold editorial board member (EBM) positions within MDPI journals, with 30 of them serving as Editors-in-Chief (EiCs).
Our commitment to working with institutions is very evident in Spain, where we have successfully established over 40 Institutional Open Access Programs (IOAP) with esteemed institutions such as the University of Barcelona, the Autonomous University of Barcelona, Pompeu Fabra University, the University of Navarre, and Complutense University of Madrid.
Over the past five years, we have successfully organized eight in-person conferences in Barcelona, attracting over 1,150 registrations, with two forthcoming events scheduled for 2024. Barcelona's excellent connectivity to international airports makes it easily accessible to participants from around the world. Its welcoming atmosphere provides us with the perfect environment for knowledge-sharing, networking, and contributing to the local economy.
Our growth and presence in Spain are a true testament to the incredible service we provide to the scholarly community and the relationships we foster through responsive and collaborative communication. We look forward to continuing to support Spanish scholars, providing them a valuable and trusted experience with MDPI, the leader in open access publishing.
Testimonials
I close this letter as I did in the first edition, by sharing testimonials from our stakeholders. Here are a few IJERPH testimonials from a Spanish guest editor and an author:
Guest Editor
“I want to thank the kindness, attention and professionalism of the MDPI team throughout the editorial process of the Special Issue. I believe that it is a very professional and quality editorial process.”
- Professor Víctor Arufe-Giráldez, University of A Coruña
Special Issue in International Journal of Environmental Research and Public Health: Physical Activity in Childhood and Adolescence
Special Issue in International Journal of Environmental Research and Public Health: Physical Education: Present and Future
__
Author
“I want to thank the rigor of the revisions made to the manuscripts to improve their quality, the support to the authors for the editor assignment system they have and the follow-up they carry out, for the speed in answering and in carrying out the entire process of the revision, and for doing all this at an affordable price.”
- Dr. María Paz García-Caro, University of Granada
Article in International Journal of Environmental Research and Public Health: Factors Associated with Suicide Attempts and Suicides in the General Population of Andalusia (Spain)
Chief Executive Officer
MDPI AG
18 July 2023
Current Oncology | Special Issue Mentor Program
We are pleased to announce the launch of a new initiative—the Current Oncology Special Issue Mentor Program.
This program will enable early career researchers (who must hold a Ph.D. in a related field) to experience editing a Special Issue in MDPI journals under the mentorship of our experienced Editorial Board Members or other experienced scientists. The mentor program will provide an excellent opportunity to gain editorial experience and to cultivate an ability to edit scientific research.
The mentee’s responsibilities include:
- Proposing a Special Issue title and assisting the GE mentor to prepare a summary (around 200–400 words) and 3–10 keywords describing the background, importance, and goal of the issue;
- Writing a brief promotion plan for the Special Issue;
- Preparing a list of scholars that may be interested and personally e-mail the invitations on behalf of GEs;
- Writing an editorial for the online Special Issue together with the mentor.
The mentor’s responsibilities include:
- Conducting a final check before the Special Issue is published online;
- Performing editorial control of the Special Issue and quality control of the publications in a timely manner;
- Providing suggestions to younger scholars if they have any doubts or concerns regarding submissions;
- Organizing video calls with young scholars and the Editorial Office regularly to discuss problems and improvement suggestions for the Special Issue;
- Making and submitting decisions for the submissions with the assistance of mentees.
Certificates and awards:
After the Special Issue closes, the Editorial Office will provide official certificates for all mentors and mentees.
If you are interested in this opportunity, please send your Special Issue proposal to the Current Oncology Editorial Office ([email protected]) and we will discuss the process in further detail.
In addition to the new Special Issue Mentor Program, Current Oncology (ISSN: 1718-7729) will continue to welcome all Special Issue proposals focusing on hot research topics.
13 July 2023
Prof. Dr. Shahid Ahmed Appointed Editor-in-Chief of Current Oncology | Acknowledgement to Prof. Dr. Sharlene Gill
We are pleased to announce that Prof. Dr. Shahid Ahmed has been appointed Editor-in-Chief of Current Oncology (ISSN: 1718-7729). Under Prof. Dr. Ahmed’s stewardship, Current Oncology will continue to provide the best editorial services and contribute to the development of the clinical oncology community.
![]() |
Name: Prof. Dr. Shahid Ahmed |
Prof. Dr. Shahid Ahmed is a medical oncologist at the Saskatchewan Cancer Agency, Saskatchewan, Canada, and Professor of Oncology at the University of Saskatchewan, Canada. In addition to patient care, he has been actively involved in medical education and research. He has a Ph.D. in community and population health sciences. His research interests include real-world and health service research in gastrointestinal and breast cancer. Prof. Dr. Ahmed holds several research grants and has been actively involved in collaborative research and clinical trials. Furthermore, he has presented his works at several international meetings and published more than 100 articles in peer-reviewed journals.
The following is a short Q&A with Prof. Dr. Shahid Ahmed, who shared his vision for the journal with us, as well as his views on the research area and open access publishing:
1. What appealed to you about the journal that made you want to take on the role as its Editor-in-Chief?
I am honored and enthusiastic to serve as incoming Editor-in-Chief of Current Oncology. Since its establishment in 1994, Current Oncology has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. Current Oncology is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of Current Oncology. I would like to extend my gratitude to our current Editor-in-Chief, Prof. Dr. Sharlene Gill, for her dedication and hard work, along with Editorial Board Members, Section Editors-in-Chief, associate editors, authors, reviewers, and other editorial staff for their ongoing support and commitment in advancement of Current Oncology.
2. What is your vision for the journal?
Current Oncology has established itself as a quality peer-reviewed journal in the oncology community. It has a broad scope and is inclusive in publishing articles in translational, clinical, and real-world evidence in the cancer care continuum. My vision is to increase Current Oncology’s profile in the cancer research community with a rigorous peer review process completed in a timely manner and provide cancer researchers a preferred platform for their high-quality impactful research.
3. What does the future of this field of research look like?
Over the past two decades, with a better understanding of tumor biology and the identification of newer actionable targets, the treatment paradigm for most cancers has changed. However, there remain many challenging areas with unmet needs to improve outcome and reduce the disease burden. For example, in 2023, the 5-year survival of individuals with pancreatic cancer is still about 10%. The members of the global research community are working collectively to generate new cancer knowledge for better outcomes. With the increasing use of molecular biology and cancer genetics in the management of cancer, we anticipate more research focusing on newer validated screening tools for early diagnosis of cancer. The incorporation of artificial intelligence and other digital tools in the use of cancer databases will inform cancer research and further facilitate personalized medicine. We will see increasing use of precision and molecular medicine in tailoring cancer diagnosis, treatment, and prevention, along with a tumor-agnostic approach using various targeted therapies to reduce cancer burden and transform most stage 4 cancers into chronic diseases.
4. What do you think of the development of open access in the publishing field?
Open access to scientific papers is an important step in disseminating research. It improves access to new knowledge for everyone, including researchers and readers from developing countries, and provides opportunities for better collaboration for high-impact research.
Prof. Dr. Shahid Ahmed is taking over from Prof. Dr. Sharlene Gill, the former Editor-in-Chief, who will remain on the Editorial Board of Current Oncology. During the five-year tenure of Prof. Dr. Gill, the journal has had great success, seeing a sustained increase in both the number of publications and the journal’s impact. Prof. Dr. Gill shared with us her experience of serving as the Editor-in-Chief for Current Oncology and expressed her confidence about the future of the journal:
“It has been a pleasure and honor to serve as the Editor-in-Chief for Current Oncology over the past 5 years. I am proud of the journal’s Canadian roots and what it has accomplished as an international platform to disseminate high-quality, peer-reviewed cancer research and review publications. This has been possible due to the efforts of our academic Editorial Board Members and the MDPI editorial team who work diligently to ensure a rigorous and efficient publication process for our authors and readers. Thank you for this wonderful opportunity, and I step down confident that Current Oncology will continue to excel under the leadership of Prof. Dr. Shahid Ahmed as our incoming Editor-in-Chief.”
We are extremely grateful to Prof. Dr. Sharlene Gill for her hard work and support in helping the journal realize its potential, and warmly welcome Prof. Dr. Shahid Ahmed as the new Editor-in-Chief. We look forward to his contribution and to the continued success of Current Oncology.
11 July 2023
MDPI’s Newly Launched Journals in June 2023
With the first issue released in June 2023, five new MDPI journals disseminating multi-disciplinary science are due to launch, which will cover the subjects of medicine & pharmacology, biology and physical sciences.
The newly launched journals will be overseen by professional Editorial Board Members and Editors to ensure an accurate and rapid publication, rigorous peer review and broad visibility.
Please feel free to browse and discover more about the new journals below.
Journal | Founding Editor-in-Chief | Journal topics (selected) |
![]() |
Prof. Dr. Jun Ma, Peking University, China| Editorial | view inaugural issue | growth and development; diet and nutrients; school health promotion policies and practices; child health and care; adolescent health and wellbeing | view journal scope | submit an article |
![]() |
Prof. Dr. Bernd Rehm, Griffith University, Australia | Editorial | view inaugural issue | DNA and gene synthesis; synthetic transcription factors; protein engineering; viral engineering; metabolic engineering | view journal scope | submit an article |
![]() |
Prof. Dr. Varsha Gandhi, University of Texas MD Anderson Cancer Center, USA | Editorial | view inaugural issue | lymphatics; cancers associated with lymphocytes and lymphoblasts; lymphatic tissues; lymphoma; lymphoid leukemia | view journal scope | submit an article |
![]() |
Dr. Bradley Turner, University of Melbourne, Australia | Editorial | view inaugural issue | multiple sclerosis; amyotrophic lateral sclerosis; primary lateral sclerosis; atherosclerosis; systemic sclerosis | view journal scope | submit an article |
![]() |
Prof. Dr. Clemens Burda, Case Western Reserve University, USA | Editorial | view inaugural issue | Gamma ray, X-ray, and UV–Vis spectroscopies; NIR/mid-infrared/Raman spectroscopy; microwave and THz spectroscopy; high-resolution gas-phase atomic, molecular, and cluster spectroscopy; MS, NMR, and EPR spectroscopy | view journal scope | submit an article |
We wish to thank everyone who has supported the development of open access publishing. You are welcome to submit an application to the New Journal Committee ([email protected]) if you would like to create more new journals.
4 July 2023
Current Oncology | 2021–2022 Highly Cited Papers in Web of Science
We are delighted to present the 2021–2022 highly cited papers in the Web of Science, a curated list of high-quality articles from Current Oncology (ISSN: 1718-7729), as shown below.
“Immune Checkpoint Inhibitors in Cancer Therapy”
by Yavar Shiravand, Faezeh Khodadadi, Seyyed Mohammad Amin Kashani, Seyed Reza Hosseini-Fard, Shadi Hosseini, Habib Sadeghirad, Rahul Ladwa, Ken O’Byrne and Arutha Kulasinghe
Curr. Oncol. 2022, 29(5), 3044–3060; https://doi.org/10.3390/curroncol29050247
Available online: https://www.mdpi.com/1718-7729/29/5/247
Cited by 52 | Viewed by 8369
“Immunotherapy in Gastric Cancer”
by Anica Högner and Markus Moehler
Curr. Oncol. 2022, 29(3), 1559–1574; https://doi.org/10.3390/curroncol29030131
Available online: https://www.mdpi.com/1718-7729/29/3/131
Cited by 27 | Viewed by 6908
“Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology”
by Hamid Mithoowani and Michela Febbraro
Curr. Oncol. 2022, 29(3), 1828–1839; https://doi.org/10.3390/curroncol29030150
Available online: https://www.mdpi.com/1718-7729/29/3/150
Cited by 21 | Viewed by 9126
“Circulating Exosomal microRNAs as Predictive Biomarkers of Neoadjuvant Chemotherapy Response in Breast Cancer”
by Valentina K. Todorova, Stephanie D. Byrum, Allen J. Gies, Cade Haynie, Hunter Smith, Nathan S. Reyna and Issam Makhoul
Curr. Oncol. 2022, 29(2), 613–630; https://doi.org/10.3390/curroncol29020055
Available online: https://www.mdpi.com/1718-7729/29/2/55
Cited by 16 | Viewed by 3544
3 July 2023
MDPI Insights: The CEO's Letter #1 - Open Access and Impactful Research

Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
The Future is Open, and MDPI is Leading the Way
I strongly believe in a future that embraces openness, where open source, open information, and open access (OA) take center stage. This belief that led me to join MDPI in 2020, and I am honored to have recently been appointed as Chief Executive Officer (CEO). In this capacity, and operating in close liaison with Dr. Lin and MDPI’s senior management, I shall work to build on Dr. Lin’s achievements of the past quarter-century. In this role, I will focus on communication initiatives to promote MDPI's remarkable work and continue to build our company as a trusted leader in OA publishing. For over two decades, MDPI has been at the forefront of reshaping the academic publishing landscape, with OA surpassing subscription-based publishing in 2020. This trajectory is deeply rooted in our history and reflects our unwavering commitment and vision for an open future.
1 Million Published Articles
2023 began with a remarkable achievement for MDPI, as we became the first OA publisher to reach the milestone of 1 million published articles. This represents 2.7 million unique authors who have trusted us with their work, or about a third of all researchers worldwide. As the world's most cited OA publisher, we are proud in sharing these significant milestones.
Our mission remains unchanged: to make science open and accessible to all. We understand the importance of knowledge access, empowering researchers to stay at the forefront of a rapidly changing world. Our diverse range of journals covers a wide spectrum of disciplines, offering cutting-edge insights, trusted tools, and crucial knowledge to address global challenges.
Liberating Science
As the world’s leading OA publisher, MDPI is actively liberating science. We are committed to eliminating the frustrations researchers and the general public face when accessing information, ensuring it is not locked behind paywalls. We firmly believe that everyone has a right to information, and our commitment to open access publishing drives our work.
In this inaugural edition of Insights: The CEO's Letter, I draw inspiration from the upcoming 20th anniversary of the Berlin Declaration on Open Access. Its stated mission reminds us that true impact is achieved when knowledge is widely and readily available to society:
"Our mission of disseminating knowledge is only half complete if the information is not made widely and readily available to society”
Impactful Research
MDPI Publishes Impactful Research: Recognized by Leading Indexing Databases
MDPI journals are indexed in every single top database in the world.
As of June 2023, we have 214 journals indexed within Web of Science, 223 indexed within Scopus, 87 indexed within PubMed and PMC, and 17 indexed within MEDLINE, and these numbers increase every month. We constantly strive to expand the coverage of our journals within leading multi-disciplinary and scope-specific databases, resulting in an incredibly broad range of journals that are indexed within a variety of databases. MDPI has active relationships with approximately 65 well-known databases around the world, and we continue to expand our portfolio every year so that your work can be found, cited, and referenced with ease.
Continued Growth of MDPI Journals
The 2022 Scopus and Web of Science journal citation metrics were officially released in June, and I am pleased to report that 31 MDPI journals received their first CiteScore, taking the total number of journals with a CiteScore to 216. The number of MDPI journals receiving an Impact Factor (IF) also continues to grow with 111 receiving their first, by being covered in the ESCI, bringing our total number of journals with an IF to 208 of which 41 journals received an IF above 4.0. Looking at 2022 CiteScores in the Scopus database, 80% of MDPI journals have a score that ranks them in Q1 or Q2 in at least one subject category.
Publishing impactful science would not be possible without all of our authors, editors and reviewers. Thank you for your contribution and continued support! Together we share the latest scientific insights faster and ensure that your work is accessible to all.
Read more
Inside MDPI
Preprints.org: Clarivate adds the Preprint Citation Index to the Web of Science
At MDPI, we are dedicated to driving the advancement of science. Through our initiative, Preprints.org, researchers can publish their work and gain valuable feedback from the broader research community, ensuring rapid progress in their respective fields. This is particularly crucial during times of health and climate challenges, where timely dissemination of findings is essential.
Increased Visibility for Preprints
I am pleased to share that Clarivate recognizes the significance of preprints and has taken a crucial step to enhance their visibility. Clarivate has added the Preprint Citation Index to the Web of Science, encompassing preprints published not only on Preprints.org but also on other reputable repositories.
Looking ahead, the future of preprints appears promising, bolstered by the recent indexing announcement from the Web of Science. As a result, preprints will receive increased visibility, serving as a valuable resource for staying informed about the latest research developments.
Read more
What are Preprints?
The Pros and Cons of Preprints
Preprints and COVID-19
Preprints—The Future of Open Access Publishing?
Coming Together for Science
The First International Conference on Antioxidants: Sources, Methods, Health Benefits and Industrial Applications
In this edition of ‘Coming Together for Science,’ I am pleased to highlight the First International Conference on Antioxidants organized by our conference team in the beautiful city of Barcelona, Spain. The conference attracted over 130 attendees, who engaged in 42 talks, and 89 poster presentations spread across several sessions.
Working Together
Under the leadership of Prof. Dr. Alessandra Napolitano (Department of Chemical Sciences, University of Naples ‘Federico II’, Naples, Italy) and Prof. Dr. Rosa M. Lamuela Raventos (Department of Nutrition, Food Sciences and Gastronomy, University of Barcelona, Spain) as chairs, and supported by the committee members, 10 invited keynote speakers, poster presenters, and all the attendees, this dedicated group of academics came together to discuss the natural sources, methodologies, health benefits, and industrial applications of antioxidants.
Especially noteworthy is the positive feedback received from attendees, with 94% rating the overall organization of the conference as good or excellent. I particularly love the picture above, capturing the gathering of some of the participants. You can browse through more photos in the event gallery located here.
Managing Events With Sciforum
If you are considering hosting your own academic event, I highly recommend checking out Sciforum, MDPI's event management platform. Sciforum simplifies the entire process, making it easy to host your own event by allowing you to focus on what really matters: Science!
Read more
Closing Thoughts
Stefan Tochev, Dr. Shu-Kun Lin, Dr. Eric O. Freed, Peter Roth, Wynne Wang, Allison Yang
Viruses and Editorial Quality: Acknowledging the Dedication of our Viruses Journal Team
During a June meeting with Dr. Eric O. Freed, the founding and current Editor-in-Chief of our journal Viruses, I was reminded of the exceptional dedication of our editorial board. Meeting with Eric is a pleasure, as he has a strong commitment and clear vision for the journal. Over the course of two days, we gained a deep understanding of the journal’s expectations and focus on strategic growth, editorial board representation, and engagement.
I am pleased to share that Viruses holds a CiteScore of 7.1 (an increase of 7.57% versus the 2021 metric) and an Impact Factor of 4.7. You can view the journal statistics here. Viruses publishes highly cited papers, and is indexed in renowned databases such as Scopus, SCIE (Web of Science), PubMed, and others, and maintains affiliations with prestigious societies. Moreover, the Viruses team has recently announced an exciting upcoming event titled ‘Viruses 2024 – A World of Viruses,’ scheduled to take place in Barcelona, Spain, from 14–16 February 2024.
Testimonials
If you notice my enthusiasm regarding our editorial service, it’s because the surveys and testimonials we receive speak volumes about the experiences of our authors, reviewers, and guest editors who collaborate with MDPI. The purpose of these letters is to highlight the exceptional work that we do and the experiences we create for the scholars – thus, let me end with this testimonial from an author:
“It was a great pleasure to publish in Viruses Special Issue [Emerging Viruses in Aquaculture]. The submission process was easy. Guest editors were very helpful and provided all the guidance and support as needed. The handling of the manuscript by the Editorial Team was very fast, efficient, and professional. The reviewer’s comments were insightful, and the publication processes were remarkably rapid.”
– Ms. Magdalena Stachnik, Państwowy Instytut Weterynaryjny | PIWet
Article in Viruses: Emerging Viral Pathogens in Sturgeon Aquaculture in Poland: Focus on Herpesviruses and Mimivirus Detection
Chief Executive Officer
MDPI AG
29 June 2023
Meet Us at the ESMO Congress 2023, 20–24 October 2023, Madrid, Spain

MDPI will attend the ESMO Congress 2023 as an exhibitor. This conference will be held in Madrid, Spain, from 20 to 24 October 2023.
The ESMO Congress is the most influential oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world. They will disseminate the latest cutting-edge data, provide high-quality education and unparalleled networking opportunities for oncologists and other stakeholders from all around the world.
The following MDPI journals will be represented:
- Cancers;
- JCM;
- Cells;
- Diagnostics;
- Medical Sciences;
- Biomedicines;
- Geriatrics;
- Current Oncology;
- Hemato;
- Onco;
- CIMB;
- Healthcare.
If you are attending this conference, please feel free to start a conversation with us at our booth #724. Our delegates look forward to meeting you in person and answering any questions that you may have.
For more information about the conference, please visit https://www.esmo.org/meeting-calendar/esmo-congress-2023.
28 June 2023
2022 Impact Factors for MDPI Journals
The 2022 citation metrics have been released in the Journal Citation Reports (JCR), and we’re pleased to announce the following results for MDPI journals:
We are thrilled to announce that 90% of our ranked MDPI journals, specifically 86 out of 96 (captured in the table below), are performing above average in Q1 or Q2. This year, Clarivate has expanded its Impact Factor (IF) awards to include journals in the Emerging Sources Citation Index (ESCI) and the Arts and Humanities Citation Index (AHCI), providing greater transparency for the full set of journals indexed in the Web of Science Core Collection. As a result, 111 of MDPI journals have received their first IF in 2023, with 37 journals surpassing an IF of 3.0. In total, 208 MDPI journals have been honored with an IF.
Clarivate explains that by "expanding the coverage but holding to highly selective standards, the [Impact Factor] is now a reliable indicator of trustworthiness, as well as a measure of scholarly impact, at the journal level."
Please visit our blog post where we discuss the release of the latest citation metrics with our Indexing Manager, Dr. Constanze Schelhorn, to find out what's different this time around and how to make use of different metrics available.
Journal | Impact Factor | Rank Quartile | Category |
Vaccines | 7.8 | Q1 | Immunology |
Medicine, Research & Experimental | |||
Antioxidants | 7.0 | Q1 | Food Science & Technology |
Biochemistry & Molecular Biology | |||
Chemistry, Medicinal | |||
Cells | 6.0 | Q2 | Cell Biology |
Nutrients | 5.9 | Q1 | Nutrition & Dietetics |
International Journal of Molecular Sciences | 5.6 | Q1 | Biochemistry & Molecular Biology |
Q2 | Chemistry, Multidisciplinary | ||
Journal of Theoretical and Applied Electronic Commerce Research | 5.6 | Q2 | Business |
Biomolecules | 5.5 | Q1 | Biochemistry & Molecular Biology |
Biosensors | 5.4 | Q1 | Chemistry, Analytical |
Instruments & Instrumentation | |||
Q2 | Nanoscience & Nanotechnology | ||
Fractal and Fractional | 5.4 | Q1 | Mathematics, Interdisciplinary Applications |
Marine Drugs | 5.4 | Q1 | Chemistry, Medicinal |
Pharmacology & Pharmacy | |||
Pharmaceutics | 5.4 | Q1 | Pharmacology & Pharmacy |
Nanomaterials | 5.3 | Q1 | Physics, Applied |
Q2 | Chemistry, Multidisciplinary | ||
Materials Science, Multidisciplinary | |||
Nanoscience & Nanotechnology | |||
Cancers | 5.2 | Q2 | Oncology |
Foods | 5.2 | Q1 | Food Science & Technology |
Polymers | 5.0 | Q1 | Polymer Science |
Remote Sensing | 5.0 | Q1 | Geosciences, Multidisciplinary |
Q2 | Remote Sensing | ||
Imaging Science & Photographic Technology | |||
Environmental Sciences | |||
Antibiotics | 4.8 | Q1 | Pharmacology & Pharmacy |
Q2 | Infectious Diseases | ||
Drones | 4.8 | Q2 | Remote Sensing |
Journal of Functional Biomaterials | 4.8 | Q2 | Engineering, Biomedical |
Materials Science, Biomaterials | |||
Biomedicines | 4.7 | Q1 | Pharmacology & Pharmacy |
Q2 | Biochemistry & Molecular Biology | ||
Medicine, Research & Experimental | |||
Journal of Fungi | 4.7 | Q2 | Mycology |
Microbiology | |||
Viruses | 4.7 | Q2 | Virology |
Bioengineering | 4.6 | Q2 | Engineering, Biomedical |
Gels | 4.6 | Q1 | Polymer Science |
Molecules | 4.6 | Q2 | Chemistry, Multidisciplinary |
Biochemistry & Molecular Biology | |||
Pharmaceuticals | 4.6 | Q2 | Pharmacology & Pharmacy |
Chemistry, Medicinal | |||
Toxics | 4.6 | Q1 | Toxicology |
Q2 | Environmental Sciences | ||
Biomimetics | 4.5 | Q1 | Engineering, Multidisciplinary |
Q2 | Materials Science, Biomaterials | ||
Microorganisms | 4.5 | Q2 | Microbiology |
Plants | 4.5 | Q1 | Plant Sciences |
Biology | 4.2 | Q2 | Biology |
Chemosensors | 4.2 | Q2 | Instruments & Instrumentation |
Chemistry, Analytical | |||
Electrochemistry | |||
Membranes | 4.2 | Q2 | Engineering, Chemical |
Materials Science, Multidisciplinary | |||
Chemistry, Physical | |||
Polymer Science | |||
Toxins | 4.2 | Q1 | Toxicology |
Q2 | Food Science & Technology | ||
Metabolites | 4.2 | Q2 | Biochemistry & Molecular Biology |
Batteries | 4.0 | Q2 | Electrochemistry |
Materials Science, Multidisciplinary | |||
Q3 | Energy & Fuels | ||
Catalysts | 3.9 | Q2 | Chemistry, Physical |
Journal of Clinical Medicine | 3.9 | Q2 | Medicine, General & Internal |
Land | 3.9 | Q2 | Environmental Studies |
Sensors | 3.9 | Q2 | Instruments & Instrumentation |
Chemistry, Analytical | |||
Engineering, Electrical & Electronic | |||
Sustainability | 3.9 | Q2 | Environmental Sciences (SCIE) |
Environmental Studies (SSCI) | |||
Q3 | Green & Sustainable Science & Technology (SCIE) | ||
Green & Sustainable Science & Technology (SSCI) | |||
Buildings | 3.8 | Q2 | Construction & Building Technology |
Engineering, Civil | |||
Agronomy | 3.7 | Q1 | Agronomy |
Q2 | Plant Sciences | ||
Fermentation | 3.7 | Q2 | Biotechnology & Applied Microbiology |
Pathogens | 3.7 | Q2 | Microbiology |
Agriculture | 3.6 | Q1 | Agronomy |
Diagnostics | 3.6 | Q2 | Medicine, General & Internal |
Genes | 3.5 | Q2 | Genetics & Heredity |
Journal of Intelligence | 3.5 | Q2 | Psychology, Multidisciplinary |
Lubricants | 3.5 | Q2 | Engineering, Mechanical |
Processes | 3.5 | Q2 | Engineering, Chemical |
Coatings | 3.4 | Q2 | Materials Science, Coatings & Films |
Physics, Applied | |||
Q3 | Materials Science, Multidisciplinary | ||
ISPRS International Journal of Geo-Information | 3.4 | Q2 | Geography, Physical |
Q3 | Computer Science, Information Systems | ||
Remote Sensing | |||
Materials | 3.4 | Q2 | Metallurgy & Metallurgical Engineering |
Physics, Applied | |||
Physics, Condensed Matter | |||
Q3 | Materials Science, Multidisciplinary | ||
Chemistry, Physical | |||
Micromachines | 3.4 | Q2 | Instruments & Instrumentation |
Physics, Applied | |||
Chemistry, Analytical | |||
Q3 | Nanoscience & Nanotechnology | ||
Water | 3.4 | Q2 | Water Resources |
Environmental Sciences | |||
Brain Sciences | 3.3 | Q3 | Neurosciences |
Energies | 3.2 | Q3 | Energy & Fuels |
Fire | 3.2 | Q1 | Forestry |
Q2 | Ecology | ||
Life | 3.2 | Q2 | Biology |
Current Issues in Molecular Biology | 3.1 | Q3 | Biochemistry & Molecular Biology |
Horticulturae | 3.1 | Q1 | Horticulture |
Animals | 3.0 | Q1 | Agriculture, Dairy & Animal Science |
Veterinary Sciences | |||
Insects | 3.0 | Q1 | Entomology |
Atmosphere | 2.9 | Q3 | Meteorology & Atmospheric Sciences |
Environmental Sciences | |||
Electronics | 2.9 | Q2 | Engineering, Electrical & Electronic |
Physics, Applied | |||
Q3 | Computer Science, Information Systems | ||
Forests | 2.9 | Q1 | Forestry |
Inorganics | 2.9 | Q2 | Chemistry, Inorganic & Nuclear |
Journal of Marine Science and Engineering | 2.9 | Q1 | Engineering, Marine |
Q2 | Oceanography | ||
Engineering, Ocean | |||
Metals | 2.9 | Q2 | Metallurgy & Metallurgical Engineering |
Q3 | Materials Science, Multidisciplinary | ||
Tropical Medicine and Infectious Disease | 2.9 | Q2 | Tropical Medicine |
Parasitology | |||
Q3 | Infectious Diseases | ||
Universe | 2.9 | Q2 | Astronomy & Astrophysics |
Physics, Particles & Fields | |||
Healthcare | 2.8 | Q2 | Health Policy & Services (SSCI) |
Q3 | Health Care Sciences & Services (SCIE) | ||
Applied Sciences | 2.7 | Q2 | Engineering, Multidisciplinary |
Physics, Applied | |||
Q3 | Chemistry, Multidisciplinary | ||
Materials Science, Multidisciplinary | |||
Crystals | 2.7 | Q2 | Crystallography |
Q3 | Materials Science, Multidisciplinary | ||
Entropy | 2.7 | Q2 | Physics, Multidisciplinary |
Magnetochemistry | 2.7 | Q2 | Chemistry, Inorganic & Nuclear |
Q3 | Chemistry, Physical | ||
Materials Science, Multidisciplinary | |||
Symmetry | 2.7 | Q2 | Multidisciplinary Sciences |
Actuators | 2.6 | Q2 | Instruments & Instrumentation |
Engineering, Mechanical | |||
Aerospace | 2.6 | Q1 | Engineering, Aerospace |
Behavioral Sciences | 2.6 | Q2 | Psychology, Multidisciplinary |
Current Oncology | 2.6 | Q3 | Oncology |
Machines | 2.6 | Q2 | Engineering, Mechanical |
Q3 | Engineering, Electrical & Electronic | ||
Medicina | 2.6 | Q3 | Medicine, General & Internal |
Separations | 2.6 | Q3 | Chemistry, Analytical |
Minerals | 2.5 | Q2 | Mining & Mineral Processing |
Mineralogy | |||
Geochemistry & Geophysics | |||
Children | 2.4 | Q2 | Pediatrics |
Diversity | 2.4 | Q2 | Biodiversity Conservation |
Q3 | Ecology | ||
Journal of Cardiovascular Development and Disease | 2.4 | Q3 | Cardiac & Cardiovascular Systems |
Mathematics | 2.4 | Q1 | Mathematics |
Photonics | 2.4 | Q3 | Optics |
Veterinary Sciences | 2.4 | Q1 | Veterinary Sciences |
Fishes | 2.3 | Q2 | Marine & Freshwater Biology |
Fisheries | |||
Axioms | 2.0 | Q2 | Mathematics, Applied |
Systems | 1.9 | Q2 | Social Sciences, Interdisciplinary |
Tomography | 1.9 | Q3 | Radiology, Nuclear Medicine & Medical Imaging |
Note: The Journal of Personalized Medicine's Impact Factor was omitted in the original release and will be assigned separately. Please find the data on the journal webpage in due course.
Source: 2022 Journal Impact Factors, Journal Citation Reports TM (Clarivate, 2023)
21 April 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Gastrointestinal Oncology”
As Current Oncology (ISSN: 1718-7729) is of open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top highly cited papers of the Section “Gastrointestinal Oncology” shown below:
1. “Immunotherapy in Gastric Cancer”
by Anica Högner and Markus Moehler
Curr. Oncol. 2022, 29(3), 1559–1574; https://doi.org/10.3390/curroncol29030131
Available online: https://www.mdpi.com/1718-7729/29/3/131
2. “Imaging Spectrum of Intrahepatic Mass-Forming Cholangiocarcinoma and Its Mimickers: How to Differentiate Them Using MRI”
by Jelena Djokic Kovač, Aleksandra Janković, Aleksandra Đikić-Rom, Nikica Grubor, Andrija Antić and Vladimir Dugalić
Curr. Oncol. 2022, 29(2), 698–723; https://doi.org/10.3390/curroncol29020061
Available online: https://www.mdpi.com/1718-7729/29/2/61
3. “Endobiliary Radiofrequency Ablation Combined with Gemcitabine and Cisplatin in Patients with Unresectable Extrahepatic Cholangiocarcinoma”
by Tadahisa Inoue, Itaru Naitoh, Rena Kitano, Mayu Ibusuki, Yuji Kobayashi, Yoshio Sumida, Yukiomi Nakade, Kiyoaki Ito and Masashi Yoneda
Curr. Oncol. 2022, 29(4), 2240–2251; https://doi.org/10.3390/curroncol29040182
Available online: https://www.mdpi.com/1718-7729/29/4/182
4. “Effect of COVID-19 Pandemic on Hepatocellular Carcinoma Diagnosis: Results from a Tertiary Care Center in North-West Italy”
by Davide Giuseppe Ribaldone, Gian Paolo Caviglia, Silvia Gaia, Emanuela Rolle, Alessandra Risso, Daniela Campion, Paola Rita Brunocilla, Giorgio Maria Saracco and Patrizia Carucci
Curr. Oncol. 2022, 29(3), 1422–1429; https://doi.org/10.3390/curroncol29030119
Available online: https://www.mdpi.com/1718-7729/29/3/119
5. “Implication of ERBB2 as a Predictive Tool for Survival in Patients with Pancreatic Cancer in Histological Studies”
by Miguel A. Ortega, Leonel Pekarek, Oscar Fraile-Martinez, Cielo Garcia-Montero, Miguel A. Saez, Angel Asúnsolo, Miguel A. Alvarez-Mon, Jorge Monserrat, Lidia Ruiz-Llorente, Natalio García-Honduvilla et al.
Curr. Oncol. 2022, 29(4), 2442–2453; https://doi.org/10.3390/curroncol29040198
Available online: https://www.mdpi.com/1718-7729/29/4/198
6. “Immunotherapy in Squamous Cell Cancer of the Esophagus”
by Peter Thuss-Patience and Alexander Stein
Curr. Oncol. 2022, 29(4), 2461–2471; https://doi.org/10.3390/curroncol29040200
Available online: https://www.mdpi.com/1718-7729/29/4/200
7. “Tumor Stroma Ratio and Its Significance in Locally Advanced Colorectal Cancer”
by Luz Sullivan, Richard R. Pacheco, Michel Kmeid, Anne Chen and Hwajeong Lee
Curr. Oncol. 2022, 29(5), 3232–3241; https://doi.org/10.3390/curroncol29050263
Available online: https://www.mdpi.com/1718-7729/29/5/263
8. “Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes”
by Nicolas Voizard, Tiffany Ni, Alex Kiss, Robyn Pugash, Michael Jonathon Raphael, Natalie Coburn and Elizabeth David
Curr. Oncol. 2022, 29(1), 209–220; https://doi.org/10.3390/curroncol29010020
Available online: https://www.mdpi.com/1718-7729/29/1/20
9. “An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer”
by Alessandra Anna Prete, Letizia Procaccio, Francesca Bergamo, Cosimo Rasola, Floriana Nappo, Vittorina Zagonel and Sara Lonardi
Curr. Oncol. 2022, 29(2), 544–550; https://doi.org/10.3390/curroncol29020049
Available online: https://www.mdpi.com/1718-7729/29/2/49
10. “In Silico Identification and Validation of Cuproptosis-Related LncRNA Signature as a Novel Prognostic Model and Immune Function Analysis in Colon Adenocarcinoma”
by Yue Wang, Xulong Huang, Siyu Chen, Huajuan Jiang, Huanan Rao, Lijie Lu, Feiyan Wen and Jin Pei
Curr. Oncol. 2022, 29(9), 6573–6593; https://doi.org/10.3390/curroncol29090517
Available online: https://www.mdpi.com/1718-7729/29/9/517
21 April 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Head and Neck Oncology”
As Current Oncology (ISSN: 1718-7729) is of open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top highly cited papers of the Section “Head and Neck Oncology” shown below:
1. “Osseous Union after Mandible Reconstruction with Fibula Free Flap Using Manually Bent Plates vs. Patient-Specific Implants: A Retrospective Analysis of 89 Patients”
by Michael Knitschke, Sophia Sonnabend, Fritz Christian Roller, Jörn Pons-Kühnemann, Daniel Schmermund, Sameh Attia, Philipp Streckbein, Hans-Peter Howaldt and Sebastian Böttger
Curr. Oncol. 2022, 29(5), 3375–3392; https://doi.org/10.3390/curroncol29050274
Available online: https://www.mdpi.com/1718-7729/29/5/274
2. “Rates of Smoking Cessation at 6 and 12 Months after a Clinical Tobacco Smoking Cessation Intervention in Head and Neck Cancer Patients in Northern Ontario, Canada”
by Stacey A. Santi, Michael S. C. Conlon, Margaret L. Meigs, Stacey M. Davidson, Kyle Mispel-Beyer and Deborah P. Saunders
Curr. Oncol. 2022, 29(3), 1544–1558; https://doi.org/10.3390/curroncol29030130
Available online: https://www.mdpi.com/1718-7729/29/3/130
3. “Co-Occurrence of EBV-Positive Mucocutaneous Ulcer (EBV-MCU) and CLL/SLL in the Head and Neck Region”
by Patricia Bott, Ilske Oschlies, Andreas Radeloff and Maureen Loewenthal
Curr. Oncol. 2022, 29(4), 2749–2767; https://doi.org/10.3390/curroncol29040224
Available online: https://www.mdpi.com/1718-7729/29/4/224
4. “Prognostic and Predictive Relevance of Tumor-Infiltrating Lymphocytes in Squamous Cell Head–Neck Cancer Patients Treated with Radical Radiotherapy/Chemo-Radiotherapy”
by Ioannis M. Koukourakis, Anastasia G. Gkegka, Erasmia Xanthopoulou, Christos Nanos, Alexandra Giatromanolaki and Michael I. Koukourakis
Curr. Oncol. 2022, 29(6), 4274–4284; https://doi.org/10.3390/curroncol29060342
Available online: https://www.mdpi.com/1718-7729/29/6/342
5. “Impact of Nutrition Counseling in Head and Neck Cancer Sufferers Undergoing Antineoplastic Therapy: A Randomized Controlled Pilot Study”
by Wangshu Dai, Shu-An Wang, Kongcheng Wang, Chen Chen, Juan Wang, Xiaotian Chen and Jing Yan
Curr. Oncol. 2022, 29(10), 6947–6955; https://doi.org/10.3390/curroncol29100546
Available online: https://www.mdpi.com/1718-7729/29/10/546
6. “Outcomes of Early Transition of Low-Risk Thyroid Cancer Patients from Specialist to Primary Care”
by Patricia Nguyen, Parsa Azizi-Mehr, Carol Townsley and Afshan Zahedi
Curr. Oncol. 2022, 29(10), 7672–7679; https://doi.org/10.3390/curroncol29100606
Available online: https://www.mdpi.com/1718-7729/29/10/606
7. “Influence of Tumor Site on Survival in Young Patients with Head and Neck Squamous Cell Carcinoma”
by Claudius Steffen, Iris Piwonski, Max Heiland, Carmen Stromberger, Grzegorz Kofla, Christian Doll, Annekatrin Coordes and Benedicta Beck-Broichsitter
Curr. Oncol. 2022, 29(2), 969–980; https://doi.org/10.3390/curroncol29020082
Available online: https://www.mdpi.com/1718-7729/29/2/82
8. “Retrospective Analysis of the Development of Human Thyroglobulin during Pregnancy in Patients with Treated Non-Recurrent Differentiated Thyroid Cancer”
by Justus Baumgarten, Christian Happel, Daniel Groener, Jennifer Staudt, Benjamin Bockisch, Amir Sabet, Frank Grünwald and Thomas Rink
Curr. Oncol. 2022, 29(6), 4012–4019; https://doi.org/10.3390/curroncol29060320
Available online: https://www.mdpi.com/1718-7729/29/6/320
9. “The Management and Outcomes of Patients with Extra-Pulmonary Neuroendocrine Neoplasms and Brain Metastases”
by Zainul-Abedin Kapacee, Jennifer Allison, Mohammed Dawod, Xin Wang, Melissa Frizziero, Bipasha Chakrabarty, Prakash Manoharan, Catherine McBain, Was Mansoor, Angela Lamarca et al.
Curr. Oncol. 2022, 29(7), 5110–5125; https://doi.org/10.3390/curroncol29070405
Available online: https://www.mdpi.com/1718-7729/29/7/405
10. “A Qualitative Study of Patient and Healthcare Provider Perspectives on Building Multiphasic Exercise Prehabilitation into the Surgical Care Pathway for Head and Neck Cancer”
by Julia T. Daun, Rosie Twomey, Joseph C. Dort, Lauren C. Capozzi, Trafford Crump, George J. Francis, T. Wayne Matthews, Shamir P. Chandarana, Robert D. Hart, Christiaan Schrag et al.
Curr. Oncol. 2022, 29(8), 5942–5954; https://doi.org/10.3390/curroncol29080469
Available online: https://www.mdpi.com/1718-7729/29/8/469
30 March 2023
Meet Us at the 29th Congress of the European Association for Cancer Research, 12–15 June 2023, Torino, Italy

Conference: 29th Congress of the European Association for Cancer Research
Date: 12–15 June 2023
Place: Torino, Italy
MDPI will be attending the 29th Congress of the European Association for Cancer Research, held in Torino, Italy, from 12 to 15 June 2023. This conference aims to achieve an in-depth exchange of the latest research results in the field of basic research, clinical application, cutting-edge technology, and industrial development in the field of cancer research over the year. During this conference, MDPI will welcome researchers from different backgrounds to visit and share their latest ideas with us.
The following MDPI journals will be represented:
- Cells;
- Cancers;
- Children;
- CIMB;
- Current Oncology;
- Diagnostics;
- Geriatrics;
- Healthcare;
- JCM;
- Medical Sciences.
If you are attending this conference, please feel free to start a conversation with us. Our delegates look forward to meeting you in person and answering any questions that you may have. For more information about the conference, please visit https://www.eacr2023.org/.
29 March 2023
Current Oncology | Top Cited Papers in 2022
1. “Immune Checkpoint Inhibitors in Cancer Therapy”
by Yavar Shiravand, Faezeh Khodadadi, Seyyed Mohammad Amin Kashani, Seyed Reza Hosseini-Fard, Shadi Hosseini, Habib Sadeghirad, Rahul Ladwa, Ken O’Byrne and Arutha Kulasinghe
Curr. Oncol. 2022, 29(5), 3044–3060; https://doi.org/10.3390/curroncol29050247
Available online: https://www.mdpi.com/1718-7729/29/5/247
2. “Immunotherapy in Gastric Cancer”
by Anica Högner and Markus Moehler
Curr. Oncol. 2022, 29(3), 1559–1574; https://doi.org/10.3390/curroncol29030131
Available online: https://www.mdpi.com/1718-7729/29/3/131
3. “Circulating Exosomal microRNAs as Predictive Biomarkers of Neoadjuvant Chemotherapy Response in Breast Cancer”
by Valentina K. Todorova, Stephanie D. Byrum, Allen J. Gies, Cade Haynie, Hunter Smith, Nathan S. Reyna and Issam Makhoul
Curr. Oncol. 2022, 29(2), 613–630; https://doi.org/10.3390/curroncol29020055
Available online: https://www.mdpi.com/1718-7729/29/2/55
4. “Autophagy Agents in Clinical Trials for Cancer Therapy: A Brief Review”
by Samiha Mohsen, Philip T. Sobash, Ghada Fahad Algwaiz, Noor Nasef, Safaa Abed Al-Zeidaneen and Nagla Abdel Karim
Curr. Oncol. 2022, 29(3), 1695–1708; https://doi.org/10.3390/curroncol29030141
Available online: https://www.mdpi.com/1718-7729/29/3/141
5. “Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology”
by Hamid Mithoowani and Michela Febbraro
Curr. Oncol. 2022, 29(3), 1828–1839; https://doi.org/10.3390/curroncol29030150
Available online: https://www.mdpi.com/1718-7729/29/3/150
6. “A Portrait of SARS-CoV-2 Infection in Patients Undergoing Hematopoietic Cell Transplantation: A Systematic Review of the Literature”
by Adrian J. M. Bailey, Aidan M. Kirkham, Madeline Monaghan, Risa Shorr, C. Arianne Buchan, Christopher Bredeson and David S. Allan
Curr. Oncol. 2022, 29(1), 337–349; https://doi.org/10.3390/curroncol29010030
Available online: https://www.mdpi.com/1718-7729/29/1/30
7. “Exosomal Non-Coding RNAs: New Insights into the Biology of Hepatocellular Carcinoma”
by Qian Zhang, Hanlin Li, Yang Liu, Jian Li, Chunling Wu and Hua Tang
Curr. Oncol. 2022, 29(8), 5383–5406; https://doi.org/10.3390/curroncol29080427
Available online: https://www.mdpi.com/1718-7729/29/8/427
8. “Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence”
by Ilaria Attili, Antonio Passaro, Pasquale Pisapia, Umberto Malapelle and Filippo de Marinis
Curr. Oncol. 2022, 29(1), 255–266; https://doi.org/10.3390/curroncol29010024
Available online: https://www.mdpi.com/1718-7729/29/1/24
9. “Current Advances in Immune Checkpoint Inhibition and Clinical Genomics in Upper Tract Urothelial Carcinoma: State of the Art”
by Gianluigi Califano, Idir Ouzaid, Paul Laine-Caroff, Arthur Peyrottes, Claudia Collà Ruvolo, Benjamin Pradère, Vincent Elalouf, Vincent Misrai, Jean-François Hermieu, Shahrokh F. Shariat et al.
Curr. Oncol. 2022, 29(2), 687–697; https://doi.org/10.3390/curroncol29020060
Available online: https://www.mdpi.com/1718-7729/29/2/60
10. “Endometrial Cancer: Transitioning from Histology to Genomics”
by Cristina Mitric and Marcus Q. Bernardini
Curr. Oncol. 2022, 29(2), 741–757; https://doi.org/10.3390/curroncol29020063
Available online: https://www.mdpi.com/1718-7729/29/2/63
11. “Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article”
by Chieh-Hsun Chen, Hsin-Su Yu and Sebastian Yu
Curr. Oncol. 2022, 29(4), 2871–2886; https://doi.org/10.3390/curroncol29040234
Available online: https://www.mdpi.com/1718-7729/29/4/234
12. “Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond”
by Maple Ye Feng, Landon L. Chan and Stephen Lam Chan
Curr. Oncol. 2022, 29(8), 5489–5507; https://doi.org/10.3390/curroncol29080434
Available online: https://www.mdpi.com/1718-7729/29/8/434
13. “Delayed Effect of Dendritic Cells Vaccination on Survival in Glioblastoma: A Systematic Review and Meta-Analysis”
by Salvatore Cozzi, Masoumeh Najafi, Marzieh Gomar, Patrizia Ciammella, Cinzia Iotti, Corrado Iaccarino, Massimo Dominici, Giacomo Pavesi, Chiara Chiavelli, Ali Kazemian et al.
Curr. Oncol. 2022, 29(2), 881–891; https://doi.org/10.3390/curroncol29020075
Available online: https://www.mdpi.com/1718-7729/29/2/75
14. “Point of Care Molecular Testing: Community-Based Rapid Next-Generation Sequencing to Support Cancer Care”
by Brandon S. Sheffield, Andrea Beharry, Joanne Diep, Kirstin Perdrizet, Marco A. J. Iafolla, William Raskin, Shaan Dudani, Mary Anne Brett, Blerta Starova, Brian Olsen et al.
Curr. Oncol. 2022, 29(3), 1326–1334; https://doi.org/10.3390/curroncol29030113
Available online: https://www.mdpi.com/1718-7729/29/3/113
15. “Applications of Artificial Intelligence in Screening, Diagnosis, Treatment, and Prognosis of Colorectal Cancer”
by Hang Qiu, Shuhan Ding, Jianbo Liu, Liya Wang and Xiaodong Wang
Curr. Oncol. 2022, 29(3), 1773–1795; https://doi.org/10.3390/curroncol29030146
Available online: https://www.mdpi.com/1718-7729/29/3/146
29 March 2023
Current Oncology | Top Cited Papers in 2021
1. “Local Chemotherapy as an Adjuvant Treatment in Unresectable Squamous Cell Carcinoma: What Do We Know So Far?”
by Luigi Bennardo, Francesco Bennardo, Amerigo Giudice, Maria Passante, Stefano Dastoli, Pietro Morrone, Eugenio Provenzano, Cataldo Patruno and Steven Paul Nisticò
Curr. Oncol. 2021, 28(4), 2317–2325; https://doi.org/10.3390/curroncol28040213
Available online: https://www.mdpi.com/1718-7729/28/4/213
2. “COVID-19 Pandemic Stressors and Psychological Symptoms in Breast Cancer Patients”
by Véronique Massicotte, Hans Ivers and Josée Savard
Curr. Oncol. 2021, 28(1), 294–300; https://doi.org/10.3390/curroncol28010034
Available online: https://www.mdpi.com/1718-7729/28/1/34
3. “The Out-of-Pocket Cost Burden of Cancer Care—A Systematic Literature Review”
by Nicolas Iragorri, Claire de Oliveira, Natalie Fitzgerald and Beverley Essue
Curr. Oncol. 2021, 28(2), 1216–1248; https://doi.org/10.3390/curroncol28020117
Available online: https://www.mdpi.com/1718-7729/28/2/117
4. “Artificial Intelligence in Colorectal Cancer Screening, Diagnosis and Treatment. A New Era”
by Athanasia Mitsala, Christos Tsalikidis, Michail Pitiakoudis, Constantinos Simopoulos and Alexandra K. Tsaroucha
Curr. Oncol. 2021, 28(3), 1581–1607; https://doi.org/10.3390/curroncol28030149
Available online: https://www.mdpi.com/1718-7729/28/3/149
5. “Synovial Sarcoma: A Clinical Review”
by Aaron M. Gazendam, Snezana Popovic, Sohaib Munir, Naveen Parasu, David Wilson and Michelle Ghert
Curr. Oncol. 2021, 28(3), 1909–1920; https://doi.org/10.3390/curroncol28030177
Available online: https://www.mdpi.com/1718-7729/28/3/177
6. “Virtual Oncology Appointments during the Initial Wave of the COVID-19 Pandemic: An International Survey of Patient Perspectives”
by Jonathan M. Loree, Hallie Dau, Nevena Rebić, Alyssa Howren, Louise Gastonguay, Helen McTaggart-Cowan, Sharlene Gill, Kanwal Raghav and Mary A. De Vera
Curr. Oncol. 2021, 28(1), 671–677; https://doi.org/10.3390/curroncol28010065
Available online: https://www.mdpi.com/1718-7729/28/1/65
7. “Current Overview of Treatment for Metastatic Bone Disease”
by Shinji Tsukamoto, Akira Kido, Yasuhito Tanaka, Giancarlo Facchini, Giuliano Peta, Giuseppe Rossi and Andreas F. Mavrogenis
Curr. Oncol. 2021, 28(5), 3347–3372; https://doi.org/10.3390/curroncol28050290
Available online: https://www.mdpi.com/1718-7729/28/5/290
8. “Extramammary Paget’s Disease: Diagnosis, Pathogenesis, and Treatment with Focus on Recent Developments”
by Shoichiro Ishizuki and Yoshiyuki Nakamura
Curr. Oncol. 2021, 28(4), 2969–2986; https://doi.org/10.3390/curroncol28040260
Available online: https://www.mdpi.com/1718-7729/28/4/260
9. “Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults”
by D. Gwyn Bebb, Shantanu Banerji, Normand Blais, Patrice Desmeules, Sharlene Gill, Andrea Grin, Harriet Feilotter, Aaron R. Hansen, Martin Hyrcza, Monika Krzyzanowska et al.
Curr. Oncol. 2021, 28(1), 523–548; https://doi.org/10.3390/curroncol28010053
Available online: https://www.mdpi.com/1718-7729/28/1/53
10. “The Feasibility and Effects of a Telehealth-Delivered Home-Based Prehabilitation Program for Cancer Patients during the Pandemic”
by Fiona Wu, Oloruntobi Rotimi, Roberto Laza-Cagigas and Tarannum Rampal
Curr. Oncol. 2021, 28(3), 2248–2259; https://doi.org/10.3390/curroncol28030207
Available online: https://www.mdpi.com/1718-7729/28/3/207
11. “Proton Pump Inhibitors and Oncologic Treatment Efficacy: A Practical Review of the Literature for Oncologists”
by Angel A. T. Uchiyama, Pedro A. I. A. Silva, Moisés S. M. Lopes, Cheng T. Yen, Eliza D. Ricardo, Taciana Mutão, Jefferson R. Pimenta, Larissa M. Machado, Denis S. Shimba and Renata D. Peixoto
Curr. Oncol. 2021, 28(1), 783–799; https://doi.org/10.3390/curroncol28010076
Available online: https://www.mdpi.com/1718-7729/28/1/76
12. “Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer”
by Samitha Andrahennadi, Amer Sami, Mita Manna, Mehrnoosh Pauls and Shahid Ahmed
Curr. Oncol. 2021, 28(3), 1803–1822; https://doi.org/10.3390/curroncol28030168
Available online: https://www.mdpi.com/1718-7729/28/3/168
13. “Psychosocial Distress in Adult Patients Awaiting Cancer Surgery during the COVID-19 Pandemic”
by David Forner, Sarah Murnaghan, Geoffrey Porter, Ross J. Mason, Paul Hong, S. Mark Taylor, James Bentley, Gregory Hirsch, Christopher W. Noel, Matthew H. Rigby et al.
Curr. Oncol. 2021, 28(3), 1867–1878; https://doi.org/10.3390/curroncol28030173
Available online: https://www.mdpi.com/1718-7729/28/3/173
14. “Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients”
by Sébastien Perreault, Rose Chami, Rebecca J. Deyell, Dina El Demellawy, Benjamin Ellezam, Nada Jabado, Daniel A. Morgenstern, Aru Narendran, Poul H. B. Sorensen, Jonathan D. Wasserman et al.
Curr. Oncol. 2021, 28(1), 346–366; https://doi.org/10.3390/curroncol28010038
Available online: https://www.mdpi.com/1718-7729/28/1/38
15. “Detection of Cervical Cancer Cells in Whole Slide Images Using Deformable and Global Context Aware Faster RCNN-FPN”
by Xia Li, Zhenhao Xu, Xi Shen, Yongxia Zhou, Binggang Xiao and Tie-Qiang Li
Curr. Oncol. 2021, 28(5), 3585–3601; https://doi.org/10.3390/curroncol28050307
Available online: https://www.mdpi.com/1718-7729/28/5/307
16. “Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects”
by Grace Lassiter, Cole Bergeron, Ryan Guedry, Julia Cucarola, Adam M. Kaye, Elyse M. Cornett, Alan D. Kaye, Giustino Varrassi, Omar Viswanath and Ivan Urits
Curr. Oncol. 2021, 28(1), 640–660; https://doi.org/10.3390/curroncol28010063
Available online: https://www.mdpi.com/1718-7729/28/1/63
17. “Advancing the Field of Pediatric Exercise Oncology: Research and Innovation Needs”
by Amanda Wurz, Emma McLaughlin, Carolina Chamorro Viña, Sarah L. Grimshaw, Lotta Hamari, Miriam Götte, Sabine Kesting, Francesca Rossi, Patrick van der Torre, Gregory M. T. Guilcher et al.
Curr. Oncol. 2021, 28(1), 619–629; https://doi.org/10.3390/curroncol28010061
Available online: https://www.mdpi.com/1718-7729/28/1/61
18. “The Advances and Challenges of NK Cell-Based Cancer Immunotherapy”
by Synat Kang, Xuefeng Gao, Li Zhang, Erna Yang, Yonghui Li and Li Yu
Curr. Oncol. 2021, 28(2), 1077–1093; https://doi.org/10.3390/curroncol28020105
Available online: https://www.mdpi.com/1718-7729/28/2/105
19. “Real-World Palbociclib Use in HR+/HER2− Advanced Breast Cancer in Canada: The IRIS Study”
by Katie Mycock, Lin Zhan, Gavin Taylor-Stokes, Gary Milligan and Debanjali Mitra
Curr. Oncol. 2021, 28(1), 678–688; https://doi.org/10.3390/curroncol28010066
Available online: https://www.mdpi.com/1718-7729/28/1/66
20. “Total Body Irradiation for Hematopoietic Stem Cell Transplantation: What Can We Agree on?”
by Mitchell Sabloff, Steven Tisseverasinghe, Mustafa Ege Babadagli and Rajiv Samant
Curr. Oncol. 2021, 28(1), 903–917; https://doi.org/10.3390/curroncol28010089
Available online: https://www.mdpi.com/1718-7729/28/1/89
29 March 2023
Meet Us at the 19th World Congress of Basic & Clinical Pharmacology 2023, 2–7 July 2023, Glasgow, Scotland

This conference organized by the British Pharmacological Society and International Union of Basic and Clinical Pharmacologists (IUPHAR) will be held in Glasgow, Scotland, from 2 July to 7 July 2023. The topic of the conference focuses on pharmacology and drug discovery, research, and development, and the conference will include six days of symposia, keynote lectures, workshops, and debates. Discover the latest in pharmacology research and developments across 10 content themes.
Pharmaceuticals (ISSN: 1424-8247) is a peer-reviewed, open access journal of medicinal chemistry and related drug sciences, published monthly online by MDPI. Pharmaceuticals will participate in this event as an exhibitor together with nine other MDPI journals, among which Pharmaceuticals, Journal of Personalized Medicine and Biomedicines will have journal representatives at our booth.
The following MDPI journals will be represented:
- Pharmaceuticals (leading journal);
- Biomedicines;
- JPM;
- JCM;
- Marine Drugs;
- Children;
- Current Oncology;
- BioMedInformatics;
- JoX;
- Rheumato.
If you are attending this conference, please feel free to start a conversation with us at our booth #A22. Our delegates look forward to meeting you in person and answering any questions that you may have. For more information about the conference, please visit https://wcp2023.org/ or contact the Pharmaceuticals Editorial Office at [email protected].
16 March 2023
Meet Us at the Chinese Academic Conference on Tumor Biomarker, 7–9 April 2023, Shanghai, China

MDPI will be attending the Chinese Academic Conference on Tumor Biomarker, held in Shanghai, China, from 7 to 9 April 2023. This conference aims to achieve an in-depth exchange of the latest research results in the field of basic research, clinical application, cutting-edge technology, and industrial development in the field of tumor markers over the year. During this conference, MDPI will welcome researchers from different backgrounds to visit and share their latest inspirations with us.
The following MDPI journals will be represented:
- Biomedicines;
- Cancers;
- Cells;
- Diagnostics;
- Current Oncology;
- JPM;
- JCM;
- Onco;
- CIMB;
- BioMedInformatics.
If you plan on attending this conference, feel free to stop by our booth, #B155. Our delegates look forward to meeting you in person to answer any questions you may have.
For more information about the conference, please follow the link below: https://biomarker2022.sciconf.cn/cn/web/index/13496.
13 March 2023
MDPI’s Newly Launched Journals in December 2022
As a leading open access publisher, MDPI provides scholars with a high-quality and rich academic exchange platform by continuously expanding into new and exciting research areas.
In December 2022, MDPI launched five new journals, covering multiple subjects such as life sciences, biology, medicine and pharmacology, social sciences and humanities. These new journals are being edited by established scholars across the world.
Journal |
Founding Editor-in-Chief |
Journal Topics (Selected) |
Prof. Dr. Fabio Gresta, University of Messina, Italy| Editorial | view inaugural issue |
grass/forage/turf production; grassland management; pasture monitoring; grazing and livestock; grass agro-ecosystems| view journal scope | submit an article |
|
Prof. Dr. Christos G. Athanassiou, University of Thessaly, Greece| Editorial | view inaugural issue |
pesticides; fungicides; herbicides; fertilizers; soil conditioners| view journal scope | submit an article |
|
Prof. Dr. Stephen H. Safe, Texas A&M University, USA| Editorial | view inaugural issue |
receptor structure; receptor function; receptor signaling; receptor expression and regulation; receptor interactions with drugs| view journal scope | submit an article |
|
Dr. Jean Jacques Vanden Eynde, University of Mons-UMONS, Belgium| Editorial | view inaugural issue |
drug discovery; medicinal chemistry; preclinical and clinical research; marketed drugs; intellectual property and regulatory affairs| view journal scope | submit an article |
|
Prof. Dr. Heather Kanuka, University of Alberta, Canada| Editorial | view inaugural issue |
higher education; tertiary education; policy and practice in higher education; educational leadership in higher education; educational administration and management in higher education| view journal scope | submit an article |
If you are interested in creating more open access journals with us to publish cutting-edge research, please send your journal proposal application to [email protected].
7 March 2023
Displaying Co-Authors’ Email Addresses on the Webpage of Published Papers
MDPI is pleased to announce that we now display the co-authors’ email addresses in addition to the corresponding author’s email address on the webpage of published papers, protected by Captcha. For more information about this change, please visit the journal’s instructions for authors page.
We believe this change will facilitate academic discussions and advance our cause of open science and research. The corresponding authors are responsible for communicating with their co-authors and indicating in our system (https://susy.mdpi.com/) if co-authors would prefer for their email addresses not to be displayed.
16 February 2023
Increasing Visibility for Preprints.org – Clarivate adds the Preprint Citation Index to the Web of Science

On 9 February 2023, Clarivate, a global leader in providing trusted insights and analytics, added the Preprint Citation Index to the Web of Science platform, streamlining the research process by allowing researchers to locate and link to preprints alongside other trusted content in the database.
The Preprint Citation Index will act as a bridge to connect cutting-edge preprints with peer-reviewed journal articles published within the Web of Science Core Collection. Alerts can be easily set to monitor new research across several repositories and authors will also be able to include preprints on their Web of Science Research Profile to more accurately display their various research outputs.
As of its launch, the Preprint Citation Index will provide nearly two million preprints from various repositories, including MDPI’s own Preprints.org.
MDPI's Preprints Platform – Preprints.org
To advance Open Science and the fast dissemination of research, MDPI offers researchers a free multidisciplinary preprint platform. Preprints.org accepts submissions from all research areas and offers authors high visibility, permanent archiving, article-level Metrics and immediately citable content by assigning a Digital Object Identifier (DOI) to all preprints.
During submission to any MDPI journal, authors have the option to share their research as a preprint. After an initial screening, the manuscript is available online in 48 hours or less. Once online, preprints can be downloaded, shared, commented on, and cited, providing authors maximum visibility.
We invite you to join the ranks of the over 100k researchers using Preprints.org and share your research.
For more information, please visit Preprints.org.
22 December 2022
Special Issue Mentor Program
We are pleased to announce the launch of a new initiative—the MDPI Special Issue Mentor Program.
This program will enable early career researchers (who must hold a Ph.D. in a related field) to experience editing a Special Issue in MDPI journals, under the mentorship of our experienced Editorial Board Members or other experienced scientists. The mentor program will provide an excellent opportunity for early career scientists to gain editorial experience, and to cultivate their ability to edit scientific research.
The mentee’s responsibilities include:
- Proposing a Special Issue title and assisting the mentor in preparing a summary (around 200–400 words) and 3–10 keywords describing the background, importance, and goal of the Issue;
- Writing a brief promotion plan for the Special Issue;
- Preparing a list of scholars who may be interested in the Issue and personally e-mailing invitations on behalf of Guest Editors;
- Writing an editorial for the online Special Issue together with the mentor.
The mentor’s responsibilities include:
- Conducting a final check before the Special Issue is published online;
- Performing editorial control of the Special Issue and quality control of the publications, both of which must be carried out in a timely manner;
- Providing suggestions to younger scholars if they have any doubts or concerns regarding submissions;
- Organizing video calls with young scholars and the Editorial Office regularly to discuss problems and improvement suggestions for the Special Issue;
- Making and submitting decisions regarding submissions with the assistance of mentees.
Certificates and awards:
After the Special Issue closes, the Editorial Office will provide official certificates for all the mentors and early career researchers.
If you are interested in this opportunity, please send your Special Issue proposal to the Editorial Office of a journal you choose, and we will discuss the process (i.e., mentor collaboration, Special Issue topic feasibility analysis, etc.) in further detail. The full list of MDPI journals is as follows: https://www.mdpi.com/about/journals.
In addition to the new Special Issue Mentor Program, we will continue to welcome all Special Issue proposals focusing on hot research topics.
15 December 2022
Current Oncology | New Section “Oncology Nursing” Established
The Current Oncology (ISSN: 1718-7729) editorial team is pleased to announce the launch of a new Section, “Oncology Nursing”. The aim of this Section is to publish high-quality manuscripts that will contribute to the work and education of oncology nurses. We are interested in manuscripts of relevance to oncology nursing care across the cancer trajectory (including prevention, diagnosis, treatment, rehabilitation, survivorship, end of life, and bereavement). All age groups, cancer types, and practice locations are relevant.
Manuscripts can have a focus on research, practice, education, administration, or policy. Topics could include but are not limited to the following:
- Care of inpatient, outpatient, or community-based populations;
- Care of individuals in rural and remote locations;
- Use of virtual approaches to provide oncology nursing care;
- Care for disadvantaged or marginalized populations;
- Symptom assessment and control;
- Patient education;
- Oncology nursing education;
- Innovations in oncology nursing care;
- Nurse-led approaches in oncology care;
- Fostering self-care management in cancer patients.
Prof. Dr. Margaret Fitch (University of Toronto, Canada) is serving as the Editor-in-Chief for this Section. We are currently recruiting Editorial Board Members, Guest Editors, and Topical Advisory Panel Members for this new Section. If you would like to build a platform to provide the scientific community in your area an opportunity to work on an interconnected set of papers on an innovative topic(s), please do not hesitate to join us.
You are welcome to apply to be a Guest Editor or join the Topical Advisory Panel at the following links:
- https://www.mdpi.com/journalproposal/sendproposalspecialissue/curroncol;
- https://www.mdpi.com/journal/curroncol/topical_advisory_panel_application.
Please do not hesitate to contact the Editorial Office ([email protected]) for further details and clarification.
We look forward to receiving your proposals or submissions.
Current Oncology Editorial Office
14 December 2022
"Thanks a Million!" – One Million Articles Published in MDPI Journals
MDPI has just become the first open access (OA) publisher to reach the milestone of one million articles published. That is one million articles freely available to all, to circulate and build upon! We are proud to share this special moment with the global scientific community.
This landmark has been reached thanks to the immeasurable support of more than 600,000 expert reviewers, 66,000 editorial board members and 6700 hard-working colleagues across MDPI’s global offices.
Within more than 25 years of publishing, our journals received 2.1 million manuscripts and generated 4.6 million peer review reports to get to one million papers published.
Reaching the milestone of one million articles published reinforces our mission to remove any existing barriers and to make scientific research accessible to all. Since its inception, MDPI’s goal has been to create reliable processes to make science open. This is a path towards facilitating the dissemination of novel insights in scientific communities.
Regular feedback from authors and reviewers shows that our service is greatly appreciated and needed. At the same time, the feedback helps us identify areas for further improvement.
As it stands, a significant share of published research findings remain closed access. More than half of the content published with the most well-known legacy publishers stays behind a paywall, and that is not including articles published in hybrid OA journals, or made available months or years after publication.
A new policy announced by the US administration in August 2022 requires that, as of January 2026, all US federally funded research be made freely and immediately available after publication. While the new policy does not mandate articles be published under an open access license, it is aligned with the open access movement in removing all barriers to research. Similarly, some of the most advanced research institutions in the world intend to have all funded research articles published in open access by 2025.
MDPI is proud to be the leading agent of the transition to open access.
"Thanks a Million" to all the contributors!
14 December 2022
Editorial Board Member from Current Oncology Featured in the 2022 Highly Cited Researchers List Published by Clarivate

Recently, ClarivateTM revealed its 2022 list of Highly Cited Researchers™—individuals at universities, research institutes, and commercial organizations.
The scientists who were selected for this year’s list of Highly Cited Researchers have published highly cited papers in the 11-year period from January 2011 to December 2021, with a citation frequency in the top 1% of academic subjects and the same year of publication in the Web of ScienceTM database. Based on Web of Science Citation data, 6938 researchers from across the globe who have demonstrated a disproportionate level of significant and broad influence in their chosen field or fields over the last decade have been awarded Highly Cited Researcher 2022 designations. The list is truly global, spanning 69 countries or regions and spread across a diverse range of research sciences and social sciences.
According to statistics, Dr. Hiroji Iwata (Department of Breast Oncology, Aichi Cancer Center, Aichi, Japan), a member of the Editorial Board of Current Oncology (ISSN: 1718-7729), has been selected for the list of Highly Cited Researchers of Clarivate in 2022. He is being recognized for his high-quality scientific research achievements and outstanding contributions to professional fields. The Current Oncology journal office sincerely congratulates the elected Editorial Board Member and hopes that he continues to have an academically productive relationship with the journal.
12 December 2022
Current Oncology | Call for Special Issue Proposals and Recruiting Guest Editors
Current Oncology (ISSN: 1718-7729) is an interdisciplinary, peer-reviewed, and open access journal published monthly online by MDPI. Articles published in the journal typically contain information that is directly relevant to clinical oncology practices, and have clear potential for applications in the current or future practices of cancer medicine. The journal is indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases. For more details, please see the following link: https://www.mdpi.com/journal/curroncol/about.
The Current Oncology editorial team is pleased to announce this open call for Special Issue proposals, which offers a group of authors the opportunity to work on an interconnected set of papers on an innovative topic. We are soliciting high-quality proposals that will be evaluated in a continuous selection process throughout the year.
If you would like to propose a Special Issue topic for this journal, please contact the Current Oncology Editorial Office ([email protected]) or complete and submit the form at the following link: https://www.mdpi.com/journalproposal/sendproposalspecialissue/curroncol. Our editors will respond to you as soon as possible.
The duties of acting as a Guest Editor are as follows:
- Refining the Special Issue’s title and scope, as well as providing a short introduction (100–200 words) and 5–10 keywords to set up the Special Issue’s website;
- Inviting contributors with the assistance of the in-house editor to achieve a publication target (e.g., 10 papers);
- Supervising the peer review process of the Special Issue, conducting a pre-review check, making final decisions based on at least two review reports that we have collected, etc.
The benefits of acting as a Guest Editor are as follows:
- As the Guest Editor, you will be offered an opportunity to publish one of your papers free of charge in an open access form, in addition to the chance to provide discounts to the papers that you invited for your Special Issue;
- A printed book of the Special Issue can be sent to you if more than 10 papers are published by the end of the Special Issue. See more information at https://www.mdpi.com/books;
- It is an ideal venue for networking and communicating with scholars in the research community, as well as a chance to mark you as influential within your discipline. The relationships you develop will last beyond the publication of your Special Issue, establishing a network for future collaboration.
The Editorial Office will set up the Special Issue’s website, arrange the promotional materials, assist with the invitations for paper contributions, and take care of the administrative tasks associated with peer review (including inviting reviewers, collating reports, contacting authors, and arranging professional production before publication).
Please do not hesitate to contact the Editorial Office ([email protected]) for further details and clarification.
We look forward to receiving your proposals.
Current Oncology Editorial Office
8 December 2022
MDPI Sustainability Foundation: New Look and Nominations for the 2023 Sustainability Awards Now Open
We are pleased to announce that the website of the MDPI Sustainability Foundation has been revamped! For the past couple of months, our UX UI team and front-end developers have been working hard to launch the website in time for the opening of the Sustainability Awards nominations.
The website is not the only thing that has had a remodeling. Indeed, the format of the Emerging Sustainability Leader Award (ESLA) has been updated. ESLA is now a competition open to individual researchers or start-ups founded by researchers under the age of 35. Nominee applications will go through 2 rounds of selection until the final 3 are decided. The finalists will then be invited to give pitch presentations during the Award Ceremony to win either first place (10,000 USD) or runner-up (2 x 5000 USD).
The World Sustainability Award, on the other hand, remains the same: a total prize money of 100,000 USD is up for grabs by senior individual researchers or groups of researchers from the international research community.
Nominations for both the World Sustainability Award and the Emerging Sustainability Leader award are now open! Check out our new website for more information on how to nominate.
28 September 2022
Peer Review Week 2022 – Research Integrity: Creating and Supporting Trust in Research

Peer Review Week began 19 September 2022 under the theme of “Research Integrity: Creating and Supporting Trust in Research”. Through various blog articles, podcast, and webinar, we discussed this crucial subject throughout the week, celebrating the essential role peer review plays in maintaining research quality.
To begin, we held a Webinar on the topic. Professor Peter W. Choate and Dr. Emmanuel Obeng-Gyasi joined Dr. Ioana Craciun, one of MDPI’s scientific officers, for an in-depth discussion.
We invite you to view the event recording:
During the week, the MDPI Blog in a series articles highlighted how good Peer Review safeguards research integrity. The following topics were covered:
- Peer Review Week 2022
- Research Integrity
- What We’ve Learned About Peer Review Reports
- 4 Steps to the Perfect Peer Review Report
- How to Write the Perfect Peer Review Report: An Interview
- Inviting Great Peer Reviewers
In a new edition of Insight Faster, an MDPI podcast, we were delighted to talk to the co-chairs of the Peer Review Week committee, Jayashree Rajagopalan (Senior Manager of Global Community Engagement for CACTUS) and Danielle Padula (Head of Marketing and Community Development at Scholastica) to get their take on this year’s event and its related topics.
You can find the Podcast here.
We hope you enjoy the contents!
23 September 2022
Recruiting Reviewer Board Members for Current Oncology
We are now recruiting Reviewer Board Members (RBMs) for the journal Current Oncology (ISSN: 1718-7729). If you are an active researcher in the field and are passionate about publishing cutting-edge research, do not hesitate to contact the Current Oncology Editorial Office ([email protected]).
Current Oncology is an international, peer-reviewed, and open access journal that represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy to report upon and to review progress in the management of this disease. Current Oncology is indexed by Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases. The 2021 Impact Factor of Current Oncology is 3.109, and the CiteScore is 3.5.
The benefits of joining our Reviewer Board are as follows:
- For each review, you will receive a discount voucher that can be used for reducing the article processing charge (APC) of a future submission to any MDPI journal;
- You may publish one paper per year with a 20% discount after standard peer-review in Current Oncology;
- You will be considered for the journal’s Outstanding Reviewer Award;
- You will receive a personalized reviewer certificate;
- You will have the ability to adjust your review frequency based on your schedule in our system;
- You can verify and showcase your peer-review and editorial contributions for our journal.
If you have any questions, suggestions, or recommendations, do not hesitate to let us know. We look forward to working with you.
Current Oncology Editorial Office
23 September 2022
Recruiting Section Editors-in-Chief for Current Oncology
Current Oncology (ISSN: 1718-7729) is an international, peer-reviewed, open access journal on clinical oncology. It is published monthly online by MDPI.
To develop different research areas and continue to attract high-quality papers, Current Oncology is recruiting Section Editors-in-Chief (https://www.mdpi.com/journal/curroncol/sections) for the following Sections:
- “Gastrointestinal Oncology”;
- “Genitourinary Oncology”;
- “Palliative and Supportive Care”;
- “Dermato-Oncology”.
If you are an active researcher in one of the fields and are passionate about publishing cutting-edge research, please do not hesitate to contact us at [email protected]. More information can be found on our homepage: https://www.mdpi.com/journal/curroncol.
Responsibilities of the Section Editor-in-Chief include the following:
- Deciding whether a manuscript should be accepted based on the reports we collect;
- Reviewing a small number of papers per year and managing the Section in collaboration with other editors;
- Promoting Current Oncology and increasing its visibility at academic conferences.
As a Section Editor-in-Chief, you have the opportunity to publish one paper per year free of charge in our journal. The term for this position is two years and can be renewed.
By combining our rigorous editorial policies with your expertise, we can maintain a high-quality journal. Thank you in advance for your interest. We look forward to collaborating with you soon.
Current Oncology Editorial Office
8 September 2022
Meet Us at the 2022 CAGPO ACMOO 19th Annual Conference, 15–18 September 2022, Toronto, Canada

MDPI will be attending the 2022 CAGPO ACMOO Annual Conference, hosted by the 2022 CAGPO Annual Conference Committee, which will be held from 15 to 18 September 2022 in Toronto, Canada.
The CAGPO mission statement is to unify general practitioners in oncology, promote communication amongst general practitioners in oncology in tertiary care and primary care settings, act and speak as the recognized authority on behalf of and for the benefit of general practitioners in oncology and their interests, and promote the role of general practitioners in oncology within cancer centers and within the primary care setting. The conference is to address the learning needs of general practitioners in oncology (GPOs) and oncology-allied health attendees. During this meeting, we will address recent advancements in the standards of oncology care. Our speakers include GPOs, medical and radiation oncologists, as well as speakers from the disciplines of family medicine and clinical trials.
The following MDPI journals will be represented:
- Current Oncology (leading);
- Cancers;
- Medical Sciences;
- Pharmacy;
- Journal of Clinical Medicine;
- Cells;
- Onco.
If you are attending this conference, please feel free to start an on-site conversation with us. Our delegates look forward to meeting you in person and answering any questions that you may have.
For more information about the conference, please visit the following link: http://cagpo-annual-conference.ca, or contact the Current Oncology Editorial Office at [email protected].
1 July 2022
Current Oncology | Collaboration with the Canadian Leukemia Study Group (CLSG)

In February 2022, Current Oncology (ISSN: 1718-7729) established a new collaboration with the Canadian Leukemia Study Group. As part of this collaboration, all affiliated CLSG members will enjoy a discount on Article Processing Charges (APC) when submitting articles to Current Oncology.
CLSG is a collective of Canadians striving for cutting-edge acute leukemia care. Every Canadian with leukemia deserves access to world-class therapy, including the latest drug advancements, leading-edge research, diagnostic technologies, and trials. That is why CLSG strives to connect Canadians with every resource possible. CLSG’s goal is to improve acute leukemia care in Canada by advancing a world-class standard of care for all Canadians, and by facilitating the ability of those who treat leukemia across the country to deliver optimal quality care equitably.
Current Oncology represents a multidisciplinary medium which invites healthcare workers in the field of cancer therapy to report upon and review progress in the management of this disease. Articles published in the journal typically contain information that is relevant directly to clinical oncology practice and have clear potential for application to the current or future practice of cancer medicine. Current Oncology is covered by leading indexing services, including the Science Citation Index Expanded (Web of Science), Scopus, PubMed, MEDLINE, PMC, Embase, and many other databases.
Current Oncology looks forward to a very fruitful collaboration with CLSG.
30 June 2022
Welcoming Dr. Takuya Koie to the Editorial Board of Current Oncology
We are delighted to welcome Dr. Takuya Koie, who has recently joined the Editorial Board of Current Oncology (ISSN: 1718-7729).
|
Name: Dr. Takuya Koie Affiliation: Department of Urology, Gifu University Graduate School of Medicine, Japan Interests: muscle-invasive bladder cancer; prostate cancer; oligometastasis; robot-assisted surgery; intracorporeal urinary diversion; ileal neobladder; ileal conduit |
We warmly welcome Dr. Takuya Koie to his role as an Editorial Board Member, and we look forward to his contributions to the continued success of the journal.
Further details concerning the Editorial Board can be found at the following link: https://www.mdpi.com/journal/curroncol/editors.
30 June 2022
Welcoming New Section Editors-in-Chief of Current Oncology
We are pleased to announce that Dr. Pierre Yves Marcy has been appointed Editor-in-Chief of Section “Head and Neck Oncology”, Prof. Dr. Tommaso Martino De Pas has been appointed Editor-in-Chief of Section “Bone and Soft Tissue Oncology”, and Dr. Vittorio Gebbia has been appointed Editor-in-Chief of Section “Medical Oncology”. We look forward to their contributions to Current Oncology (ISSN: 1718-7729).
|
Name: Dr. Pierre Yves Marcy Affiliation: Oncology Head and Neck and Interventional Radiologist, PolyClinics ELSAN Group, France Interests: central venous catheter port; PICC line; superior vena cava syndrome; head and neck cancer; thyroid malignancy; fine-needle aspiration cytology; core needle biopsy; thoracic oncology |
|
Name: Prof. Dr. Tommaso Martino De Pas Affiliation: Division of Medical Oncology for Melanoma and Sarcoma, IEO, European Institute of Oncology IRCCS, Milan, Italy Interests: lung cancer; thymic cancer; soft tissue sarcoma |
|
Name: Dr. Vittorio Gebbia Affiliation: La Maddalena Cancer Center, Palermo, Italy Interests: cancer therapy |
Current Oncology Editorial Office
30 June 2022
Prof. Dr. Shahid Ahmed Appointed Associate Editor-in-Chief of Current Oncology
We are honored and pleased to announce that Prof. Dr. Shahid Ahmed has been appointed Associate Editor-in-Chief for the open access journal Current Oncology (ISSN: 1718-7729).
Prof. Dr. Shahid Ahmed is a fellow of the American College of Physicians and the Royal College of Physicians and Surgeons of Canada. Shahid joined the Saskatoon Cancer Center in 2003 as a medical oncologist. His area of interest is breast and gastrointestinal oncology. In addition to patient care, he is committed to medical education and research. He is an active member of various local and national committees involved in patient care, medical education, and research. He has served as a continuing professional development educator for the Royal College of Physicians and Surgeons of Canada. He holds several research grants and is actively engaged in collaborative research and clinical trials. Prof. Dr. Shahid has presented his works at several international meetings, published more than 70 articles in peer-reviewed journals, and author of several book chapters.
We warmly welcome Prof. Dr. Shahid Ahmed as the Associate Editor-in-Chief of Current Oncology, and we look forward to the journal achieving many milestones under his leadership.
28 June 2022
2021 Impact Factors - Released
The 2021 citation metrics have been released in the Journal Citation Reports (JCR), and we’re pleased to announce the following results for MDPI journals:
Journal | Impact Factor | Rank | Category |
Antioxidants | 7.675 | Q1 | Food Science & Technology |
Biochemistry & Molecular Biology | |||
Chemistry, Medicinal | |||
Cells | 7.666 | Q2 | Cell Biology |
Nutrients | 6.706 | Q1 | Nutrition & Dietetics |
Cancers | 6.575 | Q1 | Oncology |
Pharmaceutics | 6.525 | Q1 | Pharmacology & Pharmacy |
International Journal of Molecular Sciences | 6.208 | Q1 | Biochemistry & Molecular Biology |
Q2 | Chemistry, Multidisciplinary | ||
Marine Drugs | 6.085 | Q1 | Chemistry, Medicinal |
Pharmacology & Pharmacy | |||
Biomolecules | 6.064 | Q2 | Biochemistry & Molecular Biology |
Batteries * | 5.938 | Q2 | Electrochemistry |
Energy & Fuels | |||
Materials Science, Multidisciplinary | |||
Viruses | 5.818 | Q2 | Virology |
Biosensors | 5.743 | Q1 | Chemistry, Analytical |
Instruments & Instrumentation | |||
Q2 | Nanoscience & Nanotechnology | ||
Journal of Fungi | 5.724 | Q1 | Mycology |
Q2 | Microbiology | ||
Nanomaterials | 5.719 | Q1 | Physics, Applied |
Q2 | Chemistry, Multidisciplinary | ||
Materials Science, Multidisciplinary | |||
Nanoscience & Nanotechnology | |||
Metabolites | 5.581 | Q2 | Biochemistry & Molecular Biology |
Foods | 5.561 | Q1 | Food Science & Technology |
Drones * | 5.532 | Q2 | Remote Sensing |
Remote Sensing | 5.349 | Q1 | Geosciences, Multidisciplinary |
Imaging Science & Photographic Technology | |||
Q2 | Remote Sensing | ||
Environmental Sciences | |||
Journal of Theoretical and Applied Electronic Commerce Research | 5.318 | Q2 | Business |
Antibiotics | 5.222 | Q1 | Pharmacology & Pharmacy |
Q2 | Infectious Diseases | ||
Pharmaceuticals | 5.215 | Q1 | Pharmacology & Pharmacy |
Q2 | Chemistry, Medicinal | ||
Biology | 5.168 | Q1 | Biology |
Fermentation | 5.123 | Q2 | Biotechnology & Applied Microbiology |
Toxins | 5.075 | Q1 | Toxicology |
Q2 | Food Science & Technology | ||
Bioengineering * | 5.046 | Q2 | Engineering, Biomedical |
Polymers | 4.967 | Q1 | Polymer Science |
Journal of Clinical Medicine | 4.964 | Q2 | Medicine, General & Internal |
Vaccines | 4.961 | Q2 | Immunology |
Medicine, Research & Experimental | |||
Molecules | 4.927 | Q2 | Chemistry, Multidisciplinary |
Biochemistry & Molecular Biology | |||
Microorganisms | 4.926 | Q2 | Microbiology |
Journal of Functional Biomaterials * | 4.901 | Q2 | Engineering, Biomedical |
Materials Science, Biomaterials | |||
Biomedicines | 4.757 | Q2 | Medicine, Research & Experimental |
Pharmacology & Pharmacy | |||
Biochemistry & Molecular Biology | |||
Plants | 4.658 | Q1 | Plant Sciences |
International Journal of Environmental Research and Public Health | 4.614 | Q1 | Public, Environmental & Occupational Health (SSCI) |
Q2 | Public, Environmental & Occupational Health (SCIE) | ||
Environmental Sciences (SCIE) | |||
Membranes | 4.562 | Q1 | Polymer Science |
Q2 | Engineering, Chemical | ||
Materials Science, Multidisciplinary | |||
Chemistry, Physical | |||
Pathogens | 4.531 | Q2 | Microbiology |
Catalysts | 4.501 | Q2 | Chemistry, Physical |
Toxics | 4.472 | Q2 | Toxicology |
Environmental Sciences | |||
Gels | 4.432 | Q1 | Polymer Science |
Journal of Cardiovascular Development and Disease | 4.415 | Q2 | Cardiac & Cardiovascular Systems |
Chemosensors | 4.229 | Q1 | Instruments & Instrumentation |
Q2 | Chemistry, Analytical | ||
Q3 | Electrochemistry | ||
Genes | 4.141 | Q2 | Genetics & Heredity |
Diagnostics | 3.992 | Q2 | Medicine, General & Internal |
Agronomy | 3.949 | Q1 | Agronomy |
Plant Sciences | |||
Land | 3.905 | Q2 | Environmental Studies |
Sustainability | 3.889 | Q2 | Environmental Sciences (SCIE) |
Environmental Studies (SSCI) | |||
Q3 | Green & Sustainable Science & Technology (SCIE) | ||
Q4 | Green & Sustainable Science & Technology (SSCI) | ||
Sensors | 3.847 | Q2 | Instruments & Instrumentation |
Chemistry, Analytical | |||
Engineering, Electrical & Electronic | |||
Materials | 3.748 | Q1 | Metallurgy & Metallurgical Engineering |
Q2 | Physics, Applied | ||
Physics, Condensed Matter | |||
Q3 | Materials Science, Multidisciplinary | ||
Chemistry, Physical | |||
Biomimetics * | 3.743 | Q2 | Engineering, Multidisciplinary |
Q3 | Materials Science, Biomaterials | ||
Tropical Medicine and Infectious Disease * | 3.711 | Q1 | Tropical Medicine |
Q2 | Parasitology | ||
Q3 | Infectious Diseases | ||
Lubricants * | 3.584 | Q2 | Engineering, Mechanical |
Fractal and Fractional | 3.577 | Q1 | Mathematics, Interdisciplinary Applications |
Water | 3.530 | Q2 | Water Resources |
Q3 | Environmental Sciences | ||
Micromachines | 3.523 | Q2 | Instruments & Instrumentation |
Physics, Applied | |||
Chemistry, Analytical | |||
Q3 | Nanoscience & Nanotechnology | ||
Journal of Personalized Medicine | 3.508 | Q2 | Medicine, General & Internal |
Health Care Sciences & Services | |||
Agriculture | 3.408 | Q1 | Agronomy |
Processes | 3.352 | Q2 | Engineering, Chemical |
Separations | 3.344 | Q2 | Chemistry, Analytical |
Magnetochemistry | 3.336 | Q2 | Chemistry, Inorganic & Nuclear |
Q3 | Chemistry, Physical | ||
Materials Science, Multidisciplinary | |||
Brain Sciences | 3.333 | Q3 | Neurosciences |
Buildings | 3.324 | Q2 | Construction & Building Technology |
Engineering, Civil | |||
Forests | 3.282 | Q1 | Forestry |
Energies | 3.252 | Q3 | Energy & Fuels |
Life | 3.251 | Q2 | Biology |
Coatings | 3.236 | Q2 | Materials Science, Coatings & Films |
Physics, Applied | |||
Q3 | Materials Science, Multidisciplinary | ||
Animals | 3.231 | Q1 | Agriculture, Dairy & Animal Science |
Veterinary Sciences | |||
Journal of Intelligence * | 3.176 | Q2 | Psychology, Multidisciplinary |
Fishes | 3.170 | Q1 | Marine & Freshwater Biology |
Q2 | Fisheries | ||
Healthcare | 3.160 | Q2 | Health Policy & Services (SSCI) |
Health Care Sciences & Services (SCIE) | |||
Inorganics * | 3.149 | Q2 | Chemistry, Inorganic & Nuclear |
Insects | 3.139 | Q1 | Entomology |
Atmosphere | 3.110 | Q3 | Meteorology & Atmospheric Sciences |
Environmental Sciences | |||
Current Oncology | 3.109 | Q3 | Oncology |
ISPRS International Journal of Geo-Information | 3.099 | Q2 | Geography, Physical |
Q3 | Computer Science, Information Systems | ||
Remote Sensing | |||
Diversity | 3.029 | Q2 | Biodiversity Conservation |
Ecology | |||
Tomography | 3.000 | Q3 | Radiology, Nuclear Medicine & Medical Imaging |
Current Issues in Molecular Biology | 2.976 | Q3 | Biochemistry & Molecular Biology |
Medicina | 2.948 | Q3 | Medicine, General & Internal |
Symmetry | 2.940 | Q2 | Multidisciplinary Sciences |
Horticulturae | 2.923 | Q1 | Horticulture |
Machines | 2.899 | Q2 | Engineering, Mechanical |
Engineering, Electrical & Electronic | |||
Systems * | 2.895 | Q2 | Social Sciences, Interdisciplinary |
Applied Sciences | 2.838 | Q2 | Engineering, Multidisciplinary |
Physics, Applied | |||
Q3 | Chemistry, Multidisciplinary | ||
Materials Science, Multidisciplinary | |||
Children | 2.835 | Q2 | Pediatrics |
Minerals | 2.818 | Q2 | Mining & Mineral Processing |
Mineralogy | |||
Geochemistry & Geophysics | |||
Universe | 2.813 | Q2 | Astronomy & Astrophysics |
Q3 | Physics, Particles & Fields | ||
Journal of Marine Science and Engineering | 2.744 | Q1 | Engineering, Marine |
Q2 | Oceanography | ||
Engineering, Ocean | |||
Entropy | 2.738 | Q2 | Physics, Multidisciplinary |
Fire * | 2.726 | Q2 | Forestry |
Q3 | Ecology | ||
Metals | 2.695 | Q2 | Metallurgy & Metallurgical Engineering |
Q3 | Materials Science, Multidisciplinary | ||
Electronics | 2.690 | Q3 | Engineering, Electrical & Electronic |
Computer Science, Information Systems | |||
Physics, Applied | |||
Crystals | 2.670 | Q2 | Crystallography |
Q3 | Materials Science, Multidisciplinary | ||
Aerospace | 2.660 | Q1 | Engineering, Aerospace |
Mathematics | 2.592 | Q1 | Mathematics |
Photonics | 2.536 | Q3 | Optics |
Actuators | 2.523 | Q2 | Instruments & Instrumentation |
Q3 | Engineering, Mechanical | ||
Veterinary Sciences | 2.518 | Q2 | Veterinary Sciences |
Behavioral Sciences * | 2.286 | Q3 | Psychology, Multidisciplinary |
Axioms * | 1.824 | Q2 | Mathematics, Applied |
For more information on Impact Factors and what it means to index academic journals, please visit our related blog posts.
* Journals given their first Impact Factor in 2022
Source: 2021 Journal Impact Factors, Journal Citation Reports TM (Clarivate, 2022)
20 June 2022
MDPI’s 2021 Young Investigator Awards in “Medicine & Pharmacology”—Winners Announced
MDPI’s Young Investigator Awards recognize promising junior researchers, acknowledge their contributions, and enhance communication among scientists. We are proud to present the winners for the year 2021 in the “Medicine & Pharmacology” category. The winners were selected by the journals’ editors.
We warmly congratulate the awarded young investigators for their outstanding contributions. MDPI will continue to provide support and recognition to the academic community.
- Jasper Fuk-Woo Chan, Queen Mary Hospital, Hong Kong
- Mateusz Maciejczyk, Medical University of Bialystok, Poland
- Matteo Lambertini, University of Genova, Italy
- Helen Rogers, Newcastle University, UK
- Amir Karami, University of South Carolina, USA
- Andrea Palermo, Campus Bio-Medico University, Italy
Journal of Personalized Medicine:
- Simone Di Franco, University of Palermo, Italy
- Catriona Hippman, University of Calgary, Canada
- Veeru Kasivisvanathan, University College London, UK
- Andrea Cortegiani, University of Palermo, Italy; University Hospital Policlinico Paolo Giaccone, Italy
- Qi Zhou, Purdue University, USA
20 June 2022
MDPI’s 2021 Travel Awards in “Medicine & Pharmacology”—Winners Announced
We are proud to recognize the winners of MDPI’s 2021 Travel Awards in the “Medicine & Pharmacology” category for their outstanding presentations and to present them with the prize.
MDPI journals regularly offer travel awards to encourage talented junior scientists to present their latest research at academic conferences in specific fields, which helps to increase their influence.
The winners mentioned below were carefully selected by the journal editors based on an outline of their research and the work to be presented at an academic conference.
We would like to warmly congratulate the Travel Awards winners for the year 2021 and wish them the greatest success with their future research endeavors. MDPI will continue to enhance communication among scientists.
- Soheil Saeedi, University of Zurich, Switzerland
- Shawn Alexander Hallett, University of Michigan, USA
- Claire Albert, Yale University, USA
- Raquel Filipa da Costa Viveiros, NOVA University of Lisbon, Portugal
- Patrick Jim Küppers, University Hospital Bonn, Germany
20 June 2022
MDPI’s 2021 Outstanding Reviewer Awards in “Medicine & Pharmacology”—Winners Announced
In order to acknowledge our reviewers, who so generously dedicate their time to reviewing papers, and demonstrate diligence, professionalism, and timeliness when reviewing manuscripts, MDPI journals regularly offer outstanding reviewer awards to scholars who participate in the peer-review process.
We are proud to recognize winners for the year 2021 in the “Medicine & Pharmacology” category for their outstanding contributions among extensive competition by presenting them with an Outstanding Reviewer Award.
We would like to take this opportunity to congratulate all of the winners on their achievement. MDPI will continue to provide support and recognition to the academic community.
- Antonio G. Solimando, University of Bari Aldo Moro, Italy
- Chenghui Li, University of Arkansas for Medical Sciences, USA
- Joaquim Carreras, Tokai University, Japan
- Pierfrancesco Franco, University of Turin School of Medicine, Italy
- Laurentiu Pop, University of Texas Southwestern Medical Center, USA
- Margaret Fitch, University of Toronto, Canada
- Caroline Mariano, BC Cancer Agency, Canada; University of British Columbia, Canada
- Naser Alsharairi, Griffith University, Australia
- Peter W. Choate, Mount Royal University, Canada
- Qin Xiang Ng, National University of Singapore, Singapore
- Giulio Francesco, Sapienza University of Rome, Italy
- Sebastian Schnaubelt, Medical University of Vienna, Austria
- Olga Kislitsina, Northwestern University, Northwestern Memorial Hospital, USA
Journal of Personalized Medicine:
- Onofrio Laselva, University of Foggia, Italy
- Ping-Hsun Wu, Kaohsiung Medical University, Taiwan
- Vladimir Vladimirov, Virginia Commonwealth University, USA
- Mauro Giuffrè, University of Trieste, Italy
- Erika Palmieri, National Cancer Institute at Frederick, USA
- Anjul Khadria, California Institute of Technology, Pasadena, USA
20 June 2022
MDPI’s 2021 Best Paper Awards in “Medicine & Pharmacology”—Winners Announced
The purpose of our Best Paper Awards is to promote and recognize the most impactful contributions published within MDPI journals.
The editors of each journal carefully selected reviews and research papers through a rigorous judging process based on criteria such as the scientific merit, overall impact, and the quality of presentation of the papers published in the journal last year.
We are honored to present the winners in the “Medicine & Pharmacology” category, who were selected amongst extensive competition, and congratulate the authors for their outstanding scientific publications.
MDPI will continue to provide support and recognition to the academic community.
by Eunice Ego Mgbeahuruike, Milla Stålnacke, Heikki Vuorela and Yvonne Holm
Antibiotics 2019, 8(2), 55; doi:10.3390/antibiotics8020055
by Bernardo Ribeiro da Cunha, Luís P. Fonseca and Cecília R. C. Calado
Antibiotics 2019, 8(2), 45; doi:10.3390/antibiotics8020045
by Zvi Artzi, Shiran Sudri, Ori Platner and Avital Kozlovsky
Dent. J. 2019, 7(1), 29; doi:10.3390/dj7010029
by Philipp Sahrmann, Cyrill Bettschart, Daniel B. Wiedemeier, Ahmed Al-Majid, Thomas Attin and Patrick R. Schmidlin
Dent. J. 2019, 7(4), 115; doi:10.3390/dj7040115
by Chantal Huisman and Helianthe Kort
Healthcare 2019, 7(1), 31; doi:10.3390/healthcare7010031
by Vijay Kumar Chattu, Soosanna Kumary Chattu, Deepa Burman, David Warren Spence and Seithikurippu R. Pandi-Perumal
Healthcare 2019, 7(1), 37; doi:10.3390/healthcare7010037
by Eija Könönen, Mervi Gursoy and Ulvi Kahraman Gursoy
Clin. Med. 2019, 8(8), 1135; doi:10.3390/jcm8081135
by Yueyuan Zhou, Yusuke Yamamoto, Zhongdang Xiao and Takahiro Ochiya
Clin. Med. 2019, 8(7), 1025; doi:10.3390/jcm8071025
by Tara K. Sigdel, Felipe Acosta Archila, Tudor Constantin, Sarah A. Prins, Juliane Liberto, Izabella Damm, Parhom Towfighi, Samantha Navarro, Eser Kirkizlar, Zachary P. Demko, Allison Ryan, Styrmir Sigurjonsson, Reuben D. Sarwal, Szu-Chuan Hseish, Chitranon Chan-On, Bernhard Zimmermann, Paul R. Billings, Solomon Moshkevich and Minnie M. Sarwal
Clin. Med. 2019, 8(1), 19; doi:10.3390/jcm8010019
by Borros Arneth
Medicina 2020, 56(1), 15; doi: 10.3390/medicina56010015
by Márió Gajdács, Marianna Ábrók, Andrea Lázár, and Katalin Burián
Medicina 2019, 55(7), 356; doi: 10.3390/medicina55070356
by Atheer Awad, Fabrizio Fina, Sarah J. Trenfield, Pavanesh Patel, Alvaro Goyanes, Simon Gaisford and Abdul W. Basit.
Pharmaceutics 2019, 11(4), 148; doi:10.3390/pharmaceutics11040148
by Constantin Mircioiu, Victor Voicu, Valentina Anuta, Andra Tudose, Christian Celia, Donatella Paolino, Massimo Fresta, Roxana Sandulovici and Ion Mircioiu
Pharmaceutics 2019, 11(3), 140; doi:10.3390/pharmaceutics11030140
9 June 2022
2021 CiteScores - Released

The 2021 citation metrics have been officially released in Scopus!
We are pleased to announce that 182 MDPI journals are included, of which:
● 21 journals received their first CiteScore.
● 85% of journals increased their CiteScore from 2020.
● 155 journals (85%) ranked above average, in at least one category.
The following 65 MDPI journals (36%) ranked among the top 25% of journals, in at least one category:
Journal |
CiteScore |
Quartile |
Category |
10.1 |
Q1 |
Genetics |
|
10.0 |
Q1 |
Biomedical Engineering |
|
8.1 |
Q1 |
Pharmacology, Toxicology and Pharmaceutics (miscellaneous) |
|
7.9 |
Q1 |
Electrical and Electronic Engineering |
|
7.9 |
Q1 |
Nutrition and Dietetics |
|
7.4 |
Q1 |
General Earth and Planetary Sciences |
|
7.2 |
Q1 |
Computer Science Applications |
|
6.9 |
Q1 |
Inorganic Chemistry |
|
6.9 |
Q1 |
Computer Networks and Communications |
|
6.7 |
Q1 |
General Biochemistry, Genetics and Molecular Biology |
|
6.6 |
Q1 |
General Chemical Engineering |
|
6.6 |
Q1 |
Health, Toxicology and Mutagenesis |
|
6.6 |
Q1 |
Infectious Diseases |
|
6.5 |
Q1 |
Food Science |
|
6.5 |
Q1 |
Civil and Structural Engineering |
|
6.4 |
Q1 |
Nature and Landscape Conservation |
|
6.4 |
Q1 |
Instrumentation |
|
6.1 |
Q1 |
Management Information Systems |
|
5.9 |
Q1 |
Chemistry (miscellaneous) |
|
5.7 |
Q1 |
Polymers and Plastics |
|
5.6 |
Q1 |
Engineering (miscellaneous) |
|
5.5 |
Q1 |
General Environmental Science |
|
5.5 |
Q1 |
Urban Studies |
|
5.4 |
Q2 |
Computer Networks and Communications |
|
5.3 |
Q1 |
Food Science |
|
5.3 |
Q1 |
Plant Science |
|
5.2 |
Q1 |
Ecology, Evolution, Behavior and Systematics |
|
5.2 |
Q1 |
General Engineering |
|
Journal of Open Innovation: Technology, Market, and Complexity |
5.1 |
Q1 |
Development |
5.0 |
Q1 |
Chemistry (miscellaneous) |
|
5.0 |
Q1 |
Control and Optimization |
|
5.0 |
Q1 |
Geography, Planning and Development |
|
5.0 |
Q1 |
Geography, Planning and Development |
|
4.9 |
Q1 |
Forestry |
|
4.9 |
Q1 |
Control and Optimization |
|
4.9 |
Q1 |
Soil Science |
|
4.8 |
Q1 |
General Earth and Planetary Sciences |
|
4.8 |
Q1 |
Mechanical Engineering |
|
4.8 |
Q1 |
Public Health, Environmental and Occupational Health |
|
4.8 |
Q1 |
Geography, Planning and Development |
|
International Journal of Environmental Research and Public Health |
4.5 |
Q1 |
Public Health, Environmental and Occupational Health |
4.5 |
Q1 |
Physical Therapy, Sports Therapy and Rehabilitation |
|
4.4 |
Q1 |
Mathematical Physics |
|
4.4 |
Q1 |
General Medicine |
|
4.3 |
Q1 |
General Mathematics |
|
4.2 |
Q1 |
Surgery |
|
4.1 |
Q1 |
Health Professions (miscellaneous) |
|
4.1 |
Q1 |
Plant Science |
|
4.0 |
Q1 |
General Engineering |
|
4.0 |
Q1 |
Forestry |
|
4.0 |
Q1 |
Education |
|
3.9 |
Q1 |
General Pharmacology, Toxicology and Pharmaceutics |
|
3.9 |
Q1 |
Applied Mathematics |
|
3.8 |
Q1 |
Development |
|
3.8 |
Q1 |
Architecture |
|
3.8 |
Q1 |
Metals and Alloys |
|
3.5 |
Q1 |
Communication |
|
3.4 |
Q1 |
General Social Sciences |
|
2.9 |
Q1 |
General Mathematics |
|
2.8 |
Q1 |
Analysis |
|
2.7 |
Q1 |
General Veterinary |
|
2.6 |
Q1 |
Algebra and Number Theory |
|
1.8 |
Q1 |
Conservation |
|
1.0 |
Q1 |
Religious Studies |
|
0.9 |
Q1 |
Philosophy |
Source: 2021 CiteScores™ (Elsevier)
24 March 2022
Welcoming New Editorial Board Members of Current Oncology
We are delighted to welcome the following recognized researchers, who recently joined the Editorial Board of Current Oncology (ISSN: 1718-7729):
![]() |
Name: Dr. Lucas Sideris Affiliation: Department of Surgery, Maisonneuve-Rosemont Hospital, University of Montreal, Montreal, QC H3T 1J4, Canada Interests: peritoneal surface malignancy (colorectal, appendix, and peritoneal mesothelioma); breast cancer; colorectal cancer |
![]() |
Name: Prof. Dr. Tommaso Martino De Pas Affiliation: Division of Medical Oncology for Melanoma & Sarcoma, IEO, European Institute of Oncology IRCCS, Milan, Italy Interests: lung cancer; thymic cancer; soft tissue sarcoma |
![]() |
Name: Prof. Dr. Electra D. Paskett Affiliation: Division of Cancer Control and Prevention, Department of Internal Medicine, College of Medicine and Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA Interests: breast cancer screening; cervical cancer screening; colorectal cancer screening; health disparities; cancer prevention; cancer survivorship; rural disparities; implementation science; HPV vaccination; behavioral intervention research |
We wish them every success in developing the journal.
Further details concerning the Editorial Board can be found on the following website: https://www.mdpi.com/journal/curroncol/editors.
24 November 2021
Current Oncology | New Section “Cell Therapy” Established

We are pleased to announce a new Section in Current Oncology (ISSN: 1718-7729), entitled “Cell Therapy”, to provide a specific venue for this research.
The Section will cover basic, translational, and clinical research on all aspects related to cell therapy and transplantation in the treatment of cancer. This includes:
- conventional hematopoietic cell transplantation and associated novel insights, innovations, and new enabling technologies that can improve patient outcomes;
- immune effector cell therapies to treat cancer, such as chimeric-antigen receptor T or NK cell therapy or tumor-infiltrating cell-based approaches;
- identifying, collecting, and manufacturing cell products will also be considered favorably, particularly if related to clinical cancer outcomes.
22 November 2021
722 MDPI Editorial Board Members Receiving "2021 Highly Cited Researchers" Distinction
It is our great honor to congratulate the Editorial Board Members and Editors in MDPI's journals who have been distinguished as 2021 Highly Cited Researchers by Clarivate, according to Web of Science data. We herewith express our gratitude for the immense impact the named researchers continue to make on scientific progress and on our journals' development.
Clarivate's annual list of Highly Cited ResearchersTM identifies the most highly cited scientists for the past decade. Their impactful papers are among the top 1 per cent in the citation distribution of one or more of 22 fields analyzed in the "Essential Science Indicators", distinguishing them as hugely influential among their peers.
Abate, Antonio Abatzoglou, John T. Abbaszadeh, Mostafa Acharya, U. Rajendra Acharya, Viral V. Agarwal, Ravi P. Ahn, Myung-Ju Airoldi, Laura Ali, Imran Allakhverdiev, Suleyman I. Aluko, Rotimi E. Anasori, Babak Andersson, Dan I. Andes, David Anker, Stefan D. Apergis, Nicholas Ariga, Katsuhiko Arqub, Omar Abu Aschner, Michael Assaraf, Yehuda G. Astruc, Didier Atala, Anthony Atanasov, Atanas G. Atangana, Abdon Bahram, Mohammad Bakris, George L. Balandin, Alexander A. Baleanu, Dumitru Balsamo, Gianpaolo Bando, Yoshio Banks, William A. Bansal-Travers, Maansi Barba, Francisco J. Barros, Lillian Basit, Abdul W. Baskonus, Haci Mehmet Bassetti, Matteo Battino, Maurizio Bell, Jordana T. Bellomo, Nicola Benediktsson, Jon Atli Benelli, Giovanni Benjakul, Soottawat Bhatnagar, Amit Biddle, Stuart J. H. Biondi, Antonio Biondi-Zoccai, Giuseppe Bjarnsholt, Thomas Blaabjerg, Frede Blaschke, Thomas Blay, Jean-Yves Blumwald, Eduardo Blunt, John W. Boffetta, Paolo Bogers, Marcel Bonomo, Robert A. Bowman, David M.J.S. Boyer, Cyrille Brestic, Marian Brevik, Eric C. Buhalis, Dimitrios Burdick, Jason A. Byrd, John C. Cabeza, Luisa F. Cai, Xingjuan Cai, Jianchao Calhoun, Vince D. Calin, George Cao, Jinde Cao, Guozhong Carvalho, Andre F. Castellanos-Gomez, Andres Cerqueira, Miguel Ângelo Parente Ribeiro Chang, Jo-Shu Chang, Chih-Hao Chastin, Sebastien Chau, Kwok-wing Chemat, Farid Chen, Xiaobo Chen, YangQuan Chen, Jianmin Chen, Chaoji Chen, Min Chen, Qi Chen, Jun Chen, Xi Chen, Peng Chen, Yulin Chen, Bo Chen, Chen Chen, Zhi-Gang Chen, Wei-Hsin Chen, Gang Chen, Yongsheng Chen, Xiang Chen, Yimin Chen, Runsheng Chen, Lidong Chen, Shaowei Chen, Qian Chen, Yu Chen, Shuangming Chiclana, Francisco Cho, Sun Young Choi, Wonyong Chowdhary, Anuradha Choyke, Peter L. Cichocki, Andrzej Corella, Dolores Corma, Avelino Cortes, Javier Cortes, Jorge Costanza, Robert Crommie, Michael F. Cui, Yi Cui, Haiying Cui, Qinghua Cummings, Kenneth Michael Dai, Shifeng Dai, Sheng Daiber, Andreas Davis, Steven J. Dawson, Ted M. de la Fuente-Nunez, Cesar Decker, Eric Andrew Dekel, Avishai Demaria, Marco Deng, Yong Deng, Xiangzheng DePinho, Ronald A. Desneux, Nicolas Dimopoulos, Meletios-Athanasios Ding, Aijun Dionysiou, Dionysios D. Dokmeci, Mehmet Remzi Dolgui, Alexandre Dong, Fan Dou, Shi Xue Dou, Letian Du, Qian Du, Bo Dube, Shanta Rishi Dufresne, Alain Dummer, Reinhard Dupont, Didier Edwards, David Elaissari, Abdelhamid Elhoseny, Mohamed Ellahi, Rahmat Ellis, Erle C. ElMasry, Gamal Esteller, Manel Estévez, Mario Fabbro, Doriano Facchetti, Antonio Fan, Zhanxi Fang, Chuanglin Fasano, Alessio Fečkan, Michal Felser, Claudia Feng, Liangzhu Fensholt, Rasmus Ferdinandy, Péter Fernandez-Lafuente, Roberto Ferreira, Isabel C. F. R. Filippi, Massimo Fisher, Helen Fortino, Giancarlo Fosso Wamba, Samuel Franceschi, Claudio Fujita, Hamido Fujita, Masayuki Gai, Francesco Gaisford, Simon Galanakis, Charis M. Galluzzi, Lorenzo Galvano, Fabio Gan, Ren-You Gan, Lihua Gandomi, Amir H. Gao, Bin Gao, Feng Gao, Minrui Gao, Huijun Gao, Wei Gao, Huile Garbe, Claus Garcia, Hermenegildo Gasbarrini, Antonio Gasco, Laura Gautret, Philippe Geng, Yong Gerdts, Gunnar Geschwind, Daniel H. Ghadimi, Noradin Ghaffari, Roozbeh Ghamisi, Pedram Giampieri, Francesca Glick, Bernard R. Gnant, Michael Goel, Ajay Gogotsi, Yury Goldewijk, Kees Klein Gong, Jinlong Gong, Yongji Govindan, Kannan Granato, Daniel Grancini, Giulia Green, Douglas R. Grosso, Giuseppe Gu, Ke Guan, Cao Guastella, Adam J. Guerrero, Josep M. Gui, Guan Guizani, Mohsen Guo, Zaiping Gupta, Rangan Gutzmer, Ralf Haase, Dagmar Habibi-Yangjeh, Aziz Hagemann, Stefan Hagger, Martin Hamblin, Michael R. Hammoudeh, Shawkat Han, Heesup Hanes, Justin Harrison, Roy M. Hartung, Hans-Peter Hasanuzzaman, Mirza He, Jr-Hau He, Hongwen He, Jiaqing He, Debiao Henseler, Jörg Herrera, Francisco Herrera-Viedma, Enrique Hetz, Claudio Ho Kim, Jung Holmes, Elaine Hossain, Ekram Hsueh, Po-Ren Hu, Xiaosong Hu, Wenbin Huang, Jianping Huang, Hongwei Huang, Yu Huang, Jianying Huang, Peng Huang, Baibiao Huang, Shaoming Hubacek, Klaus |
Iqbal, Hafiz M. N. |
Saad, Fred |
The full list of 2021 Highly Cited Researchers can be accessed at the following webpage in the Web of ScienceTM https://recognition.webofscience.com/awards/highly-cited/2021/.
--- Highly Cited Researchers (HCR) is a Clarivate product.
16 November 2021
Topical Advisory Panel Established to Support Editorial Board
Academic editors play a crucial role in leading our journals and ensuring that each article undergoes a robust and timely peer-review. With the launch of Topics this year and addition of Topic Editors to our family of academic editors, we decided it would be a good time to restructure our academic boards, thus providing more clarity and support for each role. MDPI is pleased to announce the launch of a new position—Topical Advisory Panel Member, that will replace the previous position of Topics Board Member. The Topical Advisory Panel will be comprised of early career researchers eager to gain experience in editorial work.
The main responsibility of the new members of the Topical Advisory Panel is to regularly provide support to Guest Editors, Topic Editors, and Section Board Members. The responsibilities of the Topical Advisory Panel are available here: https://www.mdpi.com/editors.
Each year, the members’ performances are evaluated, and outstanding members are promoted to the Editorial Board by the Editor-in-Chief.
To qualify as a Topical Advisory Panel Member, applicants must:
- Have expertise and experience in the field related to the journal;
- Have received a Ph.D. in the last 10 years, approximately;
- Have at least 6-8 published papers in the last 5 years as first author or corresponding author;
- Currently hold an independent research position in academia or a government institute.
If you are interested in this role, please contact the editorial office by email.
We look forward to hearing from you soon.
25 October 2021
Open Access Week 2021 | It Matters How We Open Knowledge: Building Structural Equity, 25–31 October
Founded in 1996, MDPI was one of the first fully Open Access publisher. Over 25 years MDPI has grown to become the largest Open Access publisher globally, publishing over 160,000 articles across more than 350 journals in 2020. At the core, MDPI was founded in response to a pressing need of fast publication and inclusion. The scholar was set at the centre of the publication process for the first time. Acting as a service provider, rather than a product provider, MDPI exists to help scientists achive their objective to disseminate research results. At MDPI, we believe scientists deserve a better service from the publishing world.
The International Open Access Week (Open Access Week), founded by the SPARC (the Scholarly Publishing and Academic Resources Coalition) Alliance and student partners in 2008, has been successfully running for 13 years. As an advocate and pioneer of open access publishing, MDPI actively responds to the call of International Open Access Week. This year’s theme of “It Matters How We Open Knowledge: Building Structural Equity” highlights the Recommendation’s call for equitable participation from all authors and readers.
For the last 25 years, MDPI has been committed to disseminating open research. Here is a video showing MDPI’s Commitment to Equity, Inclusion and Diversity for More than 25 Years.
International Open Access Week is an important opportunity to catalyze new conversations, create connections across and between communities that can facilitate this co-design, and advance progress in the building of more equitable foundations for opening knowledge—discussions and actions that need to be continued, year in and year out. MDPI has always aimed to provide professional and efficient publishing services to scholars around the world.
Our mission is to make scientific research accessible to everyone; this year, we interview and hold discussions with open science ambassadors on how to build an equal and inclusive environment for open science. Academic editors help us collaborate with more institutions to advocate for open access ideas.
Besides this, our scientific community is a key driver of our success and MDPI’s remarkable growth. Despite the pandemic, we have prepared online conferences and workshops to gather scholars from different communities.
The Basel Sustainable Publishing online forum provides an equal opportunity for stakeholders and researchers from multi-cultural environments to exchange ideas and eliminate barriers to participation.
Conference date: 25 October 2021, online
Conference website: https://bspf2021.sciforum.net/
Main topics: MDPI discusses the current dilemma of open access science from various perspectives such as governments, libraries, and publishers, and related measures on how to change the status quo of discrimination from a global perspective.
We aim to support equality, inclusion, diversity, and accessibility in scholarly communications. We collaborate with universities and key laboratories and have scholarly communications with researchers, teachers, and students on open access workshops.
- 25 October 2021
Energies journal and Institute of Mechanics, Chinese Academy of Sciences
- 28 October 2021
Machines journal and State Key Laboratory of Traction Power, Southwest Jiaotong University
- 29 October 2021
Processes journal and Beijing Institute of Technology
- 29 October 2021
Coatings journal and Wuhan University of Technology
MDPI is committed to providing open access and high-quality publishing services for scholars and promoting rapid dissemination of academic achievements. We hope to promote the practices and policies of open access publishing and diversify the dissemination of academic achievements.
23 September 2021
2020 MDPI Top Reviewer Award—Winners Announced

Rigorous peer-review is the cornerstone of high-quality academic publishing. Over 369,916 scholars served as reviewers for MDPI journals in 2020. We are extremely appreciative of all those who made a contribution to the editorial process in this capacity. At the beginning of every year, journal editorial offices publish a list of all reviewers’ names to express our gratitude. In addition, this year, the MDPI Top Reviewer Award was announced, to recognize the very best reviewers for their expertise and dedication, and their high-quality, and timely review reports. We are pleased to announce the following winners of the 2020 MDPI Top Reviewer Award:
- Adriana Burlea-Schiopoiu;
- Alban Kuriqi;
- Álvaro González-Vila;
- Alessandro Alaimo;
- Alexey Beskopylny;
- Alexander Yu Churyumov;
- Alberto Fernández-Isabel;
- Andrea Mastinu;
- Antonios N. Papadopoulos;
- Anton Rassõlkin;
- Antonio Humberto Hamad Minervino;
- Arkadiusz Matwijczuk;
- Artur Słomka;
- Baojie He;
- Bartłomiej Potaniec;
- Bojan Đurin;
- Camilo Arturo Rodriguez Diaz;
- Carmelo Maria Musarella;
- Chiachung Chen;
- Chiman Kwan;
- Cristian Busu;
- Danil Pimenov;
- Dan-Cristian Dabija;
- Delfín Ortega-Sánchez;
- Demetrio Antonio Zema;
- Denis Butusov;
- Elena Lucchi;
- Gaurab Dutta;
- Livia Anastasiu;
- M. R. Safaei.
For more information about how to become a reviewer of MDPI journals, please see: www.mdpi.com/reviewers.
22 September 2021
MDPI Joins SDG Publishers Compact
UN's 17 Sustainable Development Goals (SDGs) are the blueprint to achieve a better and more sustainable future for all. In 2020 the SDG Publishers Compact was launched, aimed to inspire publishers and accelerate progress to achieve the 17 goals by 2030. Members of the programme are committed to support the publication of materials that will promote and inspire actions towards SDGs.
MDPI is an eager advocate of SDGs and has already been supporting the programme by creating Special Issues and publishing a series of books on SDGs prior to joining the Compact in 2021. MDPI's Sustainability Foundation initiated the World Sustainability Awards in 2016. We fully support UN's goals to promote sustainable actions that make the world a better place for all and, as part of its commitment, we will focus our actions on SDG10: Reduced Inequalities whilst promoting all 17 SDGs. For more details, please visit the programme’s website: https://www.un.org/sustainabledevelopment/sdg-publishers-compact/.
Joining this initiative was a unanimous decision. MDPI has in its core values the dissemination of science for all, breaking the wall between research access and under-represented members of the scientific community and the general population. To support this initiative further and continue to support under-represented scientists, MDPI will take a series of actions that will be announced once ready.
The first action MDPI takes is to nominate Dr. Liliane Auwerter as the coordinator of the programme. Dr. Auwerter studied Environmental Process Technology (UTFPR, Brazil), obtained her MSc degree in Water and Environmental Engineering (University of Surrey, UK) and in 2020 completed her PhD in self-healing low-friction materials for water transport (Imperial College London, UK), always focusing on diverse scientific projects that would potentially bring sustainability to industrial processes. As a student in Brazil, she engaged in volunteering activities focused on environmental education and took part in the Millennial Development Goals meetings held at the university.
For more information, please contact:
Dr. Liliane Auwerter
Scientific Officer
[email protected]
3 August 2021
Announcement on Japanese Consumption Tax (JCT)
This serves to announce to our valued authors based in Japan that value-added tax, or consumption tax will now be imposed on article processing fees and other service fees for all papers submitted, or resubmitted (assigned new paper IDs), effective from 15 August 2021. The change is in accordance with the Japanese "Act for Partial Revision of the Income Tax Act and Other Acts" (Act No. 9 of 2015), which includes a revision of consumption taxation on cross-border supplies of services such as digital content distribution.
For additional information from the National Tax Agency please see here ("Cross-border supplies of electronic services").
Contact: Setsuko Nishihara, MDPI Tokyo
30 June 2021
2020 Impact Factors - Released
The 2020 citation metrics have been officially released in the Journal Citation Reports (JCR)!
We are pleased to announce that 85 MDPI journals are included, of which:
- 10 journals received their first impact factor
- 96% of journals increased their impact factor from 2019
- 32 journals (38%) ranked among the top 25% of journals, in at least one category
Journal | Impact Factor | Rank | Category |
Cancers | 6.639 | Q1 | • Oncology |
Cells | 6.600 | Q2 | • Cell Biology |
Pharmaceutics | 6.321 | Q1 | • Pharmacology & Pharmacy |
Antioxidants | 6.313 | Q1 | • Food Science & Technology |
• Biochemistry & Molecular Biology | |||
• Chemistry, Medicinal | |||
Biomedicines | 6.081 | Q1 | • Medicine, Research & Experimental |
• Pharmacology & Pharmacy | |||
• Biochemistry & Molecular Biology | |||
International Journal of Molecular Sciences | 5.924 | Q1 | • Biochemistry & Molecular Biology |
Q2 | • Chemistry, Multidisciplinary | ||
Pharmaceuticals | 5.863 | Q1 | • Pharmacology & Pharmacy |
• Chemistry, Medicinal | |||
Journal of Fungi | 5.816 | Q1 | • Mycology |
• Microbiology | |||
Nutrients | 5.719 | Q1 | • Nutrition & Dietetics |
Biosensors | 5.519 | Q1 | • Chemistry, Analytical |
• Instruments & Instrumentation | |||
Q2 | • Nanoscience & Nanotechnology | ||
Marine Drugs | 5.118 | Q1 | • Chemistry, Medicinal |
• Pharmacology & Pharmacy | |||
Biology | 5.079 | Q1 | • Biology |
Nanomaterials | 5.076 | Q1 | • Physics, Applied |
Q2 | • Chemistry, Multidisciplinary | ||
• Materials Science, Multidisciplinary | |||
• Nanoscience & Nanotechnology | |||
Viruses | 5.048 | Q2 | • Virology |
Journal of Personalized Medicine | 4.945 | Q1 | • Medicine, General & Internal |
• Health Care Sciences & Services | |||
Metabolites | 4.932 | Q2 | • Biochemistry & Molecular Biology |
Biomolecules | 4.879 | Q2 | • Biochemistry & Molecular Biology |
Remote Sensing | 4.848 | Q1 | • Geosciences, Multidisciplinary |
Q2 | • Remote Sensing | ||
• Imaging Science & Photographic Technology | |||
• Environmental Sciences | |||
Gels * | 4.702 | Q1 | • Polymer Science |
Antibiotics | 4.639 | Q2 | • Infectious Diseases |
• Pharmacology & Pharmacy | |||
Toxins | 4.546 | Q1 | • Toxicology |
• Food Science & Technology | |||
Vaccines | 4.422 | Q2 | • Immunology |
• Medicine, Research & Experimental | |||
Molecules | 4.412 | Q2 | • Chemistry, Multidisciplinary |
• Biochemistry & Molecular Biology | |||
Foods | 4.350 | Q2 | • Food Science & Technology |
Polymers | 4.329 | Q1 | • Polymer Science |
Journal of Clinical Medicine | 4.242 | Q1 | • Medicine, General & Internal |
Toxics | 4.146 | Q2 | • Toxicology |
• Environmental Sciences | |||
Catalysts | 4.146 | Q2 | • Chemistry, Physical |
Microorganisms | 4.128 | Q2 | • Microbiology |
Membranes | 4.106 | Q1 | • Polymer Science |
Q2 | • Engineering, Chemical | ||
• Materials Science, Multidisciplinary | |||
• Chemistry, Physical | |||
Genes | 4.096 | Q2 | • Genetics & Heredity |
Fermentation * | 3.975 | Q2 | • Biotechnology & Applied Microbiology |
Journal of Cardiovascular Development and Disease * | 3.948 | Q2 | • Cardiac & Cardiovascular Systems |
Plants | 3.935 | Q1 | • Plant Sciences |
Life | 3.817 | Q2 | • Biology |
Diagnostics | 3.706 | Q2 | • Medicine, General & Internal |
Current Oncology | 3.677 | Q3 | • Oncology |
Materials | 3.623 | Q1 | • Metallurgy & Metallurgical Engineering |
Q2 | • Materials Science, Multidisciplinary | ||
• Chemistry, Physical | |||
• Physics, Applied | |||
• Physics, Condensed Matter | |||
Sensors | 3.576 | Q1 | • Instruments & Instrumentation |
Q2 | • Chemistry, Analytical | ||
• Engineering, Electrical & Electronic | |||
Pathogens | 3.492 | Q2 | • Microbiology |
Agronomy | 3.417 | Q1 | • Agronomy |
• Plant Sciences | |||
Chemosensors | 3.398 | Q2 | • Instruments & Instrumentation |
• Chemistry, Analytical | |||
Q3 | • Electrochemistry | ||
Land | 3.398 | Q2 | • Environmental Studies |
Brain Sciences | 3.394 | Q3 | • Neurosciences |
International Journal of Environmental Research and Public Health | 3.390 | Q1 | • Public, Environmental & Occupational Health (SSCI) |
Q2 | • Public, Environmental & Occupational Health (SCIE) | ||
• Environmental Sciences (SCIE) | |||
Tomography | 3.358 | Q2 | • Radiology, Nuclear Medicine & Medical Imaging |
Fractal and Fractional * | 3.313 | Q1 | • Mathematics, Interdisciplinary Applications |
Sustainability | 3.251 | Q2 | • Environmental Sciences (SCIE) |
• Environmental Studies (SSCI) | |||
Q3 | • Green & Sustainable Science & Technology (SCIE) | ||
• Green & Sustainable Science & Technology (SSCI) | |||
Water | 3.103 | Q2 | • Water Resources |
• Environmental Sciences | |||
Journal of Theoretical and Applied Electronic Commerce Research | 3.049 | Q3 | • Business |
Energies | 3.004 | Q3 | • Energy & Fuels |
Agriculture | 2.925 | Q1 | • Agronomy |
ISPRS International Journal of Geo-Information | 2.899 | Q2 | • Geography, Physical |
• Computer Science, Information Systems | |||
Q3 | • Remote Sensing | ||
Micromachines | 2.891 | Q2 | • Instruments & Instrumentation |
• Physics, Applied | |||
Q3 | • Chemistry, Analytical | ||
• Nanoscience & Nanotechnology | |||
Coatings | 2.881 | Q2 | • Materials Science, Coatings & Films |
• Physics, Applied | |||
Q3 | • Materials Science, Multidisciplinary | ||
Children | 2.863 | Q2 | • Pediatrics |
Processes | 2.847 | Q3 | • Engineering, Chemical |
Separations | 2.777 | Q3 | • Chemistry, Analytical |
Insects | 2.769 | Q1 | • Entomology |
Animals | 2.752 | Q1 | • Agriculture, Dairy & Animal Science |
• Veterinary Sciences | |||
Symmetry | 2.713 | Q2 | • Multidisciplinary Sciences |
Atmosphere | 2.686 | Q3 | • Meteorology & Atmospheric Sciences |
• Environmental Sciences | |||
Applied Sciences | 2.679 | Q2 | • Engineering, Multidisciplinary |
• Physics, Applied | |||
Q3 | • Chemistry, Multidisciplinary | ||
• Materials Science, Multidisciplinary | |||
Photonics | 2.676 | Q2 | • Optics |
Buildings * | 2.648 | Q2 | • Construction & Building Technology |
• Engineering, Civil | |||
Healthcare | 2.645 | Q2 | • Health Policy & Services (SSCI) |
Q3 | • Health Care Sciences & Services (SCIE) | ||
Minerals | 2.644 | Q2 | • Mining & Mineral Processing |
• Mineralogy | |||
• Geochemistry & Geophysics | |||
Forests | 2.634 | Q1 | • Forestry |
Crystals | 2.589 | Q2 | • Crystallography |
Q3 | • Materials Science, Multidisciplinary | ||
Entropy | 2.524 | Q2 | • Physics, Multidisciplinary |
Diversity | 2.465 | Q2 | • Biodiversity Conservation |
Q3 | • Ecology | ||
Journal of Marine Science and Engineering | 2.458 | Q2 | • Oceanography |
• Engineering, Marine | |||
• Engineering, Ocean | |||
Medicina | 2.430 | Q2 | • Medicine, General & Internal |
Machines * | 2.428 | Q2 | • Engineering, Mechanical |
Q3 | • Engineering, Electrical & Electronic | ||
Electronics | 2.397 | Q3 | • Engineering, Electrical & Electronic |
• Computer Science, Information Systems | |||
• Physics, Applied | |||
Fishes * | 2.385 | Q2 | • Fisheries |
• Marine & Freshwater Biology | |||
Metals | 2.351 | Q2 | • Metallurgy & Metallurgical Engineering |
Q3 | • Materials Science, Multidisciplinary | ||
Horticulturae * | 2.331 | Q1 | • Horticulture |
Veterinary Sciences * | 2.304 | Q1 | • Veterinary Sciences |
Universe | 2.278 | Q3 | • Physics, Particles & Fields |
• Astronomy & Astrophysics | |||
Mathematics | 2.258 | Q1 | • Mathematics |
Magnetochemistry | 2.193 | Q3 | • Chemistry, Inorganic & Nuclear |
• Chemistry, Physical | |||
• Materials Science, Multidisciplinary | |||
Current Issues in Molecular Biology | 2.081 | Q4 | • Biochemistry & Molecular Biology |
Actuators | 1.994 | Q3 | • Instruments & Instrumentation |
• Engineering, Mechanical | |||
Aerospace * | 1.659 | Q2 | • Engineering, Aerospace |
* Journals given their first Impact Factor in 2021
Source: 2020 Journal Impact Factors, Journal Citation Reports ® (Clarivate, 2021)
28 April 2021
Book Builder—Compile a Customized E-Book from Your Favorite MDPI Open Access Content
MDPI Books recently released Book Builder, a new online tool to conveniently arrange, design and produce an eBook from any content published in MDPI journals. Book Builder offers two functions: on the one hand (1) Selections, available to every registered user of MDPI; on the other hand (2) Special Issue Reprints, which can be used exclusively by Guest Editors of Special Issues.
Selections
In just a matter of a few clicks, all users are now able to assemble books from MDPI articles and receive instantaneous feedback in the form of a fully produced and compiled book (PDF), which can be downloaded or ordered as print copy. Selections can include any paper published with MDPI, picking and combining content from different journals and special issues.
This way, the user may for example choose to compile an ebook focusing around a particular topic, or assemble articles from a group of others.
We invite you to make yourself familiar with the new tool! The Book Builder can be found here: https://www.mdpi.com/books/book_builder.
Special Issue Reprints
The Book Builder allows Guest Editors of MDPI journals to create a reprint from a successfully completed Special Issue or Topical Collection in book format. If you are a Guest Editor for an MDPI journal, you can use the new tool to create an PDF document which includes all articles published in the Special Issue as well as a book cover and table of contents.
For Special Issues containing a minimum of 5 articles, the Guest Editor can request its publication on the MDPI Book platform. Published reprints are assigned an ISBN and DOI.
In addition to the PDF copy of the Reprint Book, as a token of our gratitude, MDPI offers every Guest Editor one (1) complimentary print copy (via print-on-demand). All contributors benefit from a discount on orders of any additional print copies, to share with colleagues or libraries or others.
In line with our organization's values, MDPI Books publishes all content in open access, promoting the exchange of ideas and knowledge in a globalized world. MDPI Books encompasses all the benefits of open access—high availability and visibility, as well as wide and rapid dissemination. MDPI Books are distributed under the terms and conditions of the Creative Commons Attribution License, meaning as an author you retain the copyright for your work. In addition, with MDPI Books you can complement the digital version of your work with a high-quality printed counterpart.
If you are interested in editing a book volume or series, or have a monograph manuscript to be considered for publication, please submit your proposal online and look at our Information for Authors.
Contact: Laura Wagner, MDPI Books Manager (email)
16 April 2021
Recruiting Editorial Board Members for Current Oncology
Current Oncology (ISSN 1718-7729) was transferred from Multimed Inc. to MDPI in late October 2020. We are very excited to continue to develop Current Oncology as an international, scientific, peer-reviewed, open access journal.
Current Oncology is recruiting Editorial Board Members whose research interests are related to clinical oncology practice, encompassing medical, surgical, and psychosocial oncology, as well as clinical research validation that leads to novel systemic and locoregional therapeutics, an evolving role of immunotherapy, and a broader application of precision oncology to enable substantial progress in the management of this disease. Please find more details at https://www.mdpi.com/journal/curroncol/about.
We already have some highly renowned experts on our Editorial Board, and we are looking for more excellent scholars and oncologists in this field to join us. If you are interested in this position or know of any potential candidates you would like to recommend, please contact the Current Oncology Editorial Office ([email protected]).
The main responsibilities of Editorial Board Members are as follows:
- Pre-screening submissions and making decisions on whether a manuscript should be accepted or rejected for processing, as well as suggesting additional reviewers (if necessary);
- Acting as Guest Editor of a Special Issue in your particular field of expertise, or recommending potential topics and Guest Editors;
- Promoting Current Oncology and increasing its visibility at related academic conferences;
- Advising on the journal’s development.
We look forward to hearing from you.
Current Oncology Editorial Office
15 April 2021
MDPI Celebrates Company Milestone With 25th Anniversary Page
"We exist to help scientists achieve their own objectives"

In June of this year, MDPI will celebrate the 25th anniversary of its foundation. To mark this significant milestone, we have created a 25th Anniversary page on our website that evokes the development of our company over the past quarter-century.
MDPI has been a pioneer of Open Access publishing ever since the concept was first created.
In a wide-ranging interview, our CEO Delia Mihaila reflects on the company’s 25th anniversary and its contribution to the world of scientific publishing.
Delia considers how MDPI has evolved since starting life in 1996 as a visionary ‘project’ run out of an apartment in Basel, Switzerland, by Dr. Shu-Kun Lin. A chemist who was passionate about the long-term preservation of rare chemical sample, Dr. Lin was determined to help scholars publish their findings as quickly as possible and make their research results available to as wide a readership as possible worldwide. That determination remains unchanged 25 years later.
Today, MDPI is an international organization with over 4,000 employees based on three continents and in ten countries, and ranks among the world's top four academic publishers.
MDPI's mission is to accelerate access to new scientific research, delivering insight faster for researchers worldwide. Read more here about the company's remarkable success story and what the Open Access publishing model can offer the global scientific community.
10 March 2021
Journal Selector: Helping to Find the Right MDPI Journal for Your Article
At MDPI, we strive to make your online publication process seamless and efficient. To achieve this, our team is continuously developing tools and features to make the user experience useful and convenient.
As the number of academic papers continues to grow, so does the need to analyze and work with them on a large scale. This prompted us to design a new feature aimed at helping researchers find journals that are relevant to their publication by matching their abstract topic. In this regard, we designed a similarity model that automatically identifies the most suitable academic journals for your paper.
We are pleased to introduce Journal Selector, a new feature that measures similarity in academic contexts. By simply entering the title and/or abstract into our Journal Selector, the author will see a list of the most related scientific journals published by MDPI. This method helps authors select the correct journals for their papers, highlighting the time of publication and citability.
The methodology is known as representation learning, where words are represented as vectors in hyperspace. Representation helps us differentiate between different concepts within articles, and in turn, helps us identify similarities between them.
We used an advanced machine learning model to better capture the semantic meanings of words. This helps the algorithm make better predictions by leveraging scientific text representation. In turn, this ensures high precision, helping authors decide which journal they should submit their paper to.
The goal is to support authors to publish their work in the most suitable journal for their research, as fast as possible, accelerating their career progress.
Contact: Andrea Perlato, Head of Data Analytics, MDPI (email)
15 December 2020
MDPI adopts C4DISC principles to improve diversity and inclusion in scholarly communications
MDPI is proud to adopt the principles of the Coalition for Diversity & Inclusion in Scholarly Communications (C4DISC) to support building equity, inclusion, diversity, and accessibility in scholarly communications.
The C4DISC represents organizations and individuals working in scholarly communications and is focused on addressing issues of diversity and inclusion within the publishing industry.
MDPI’s Managing Editors encourage the Editors-in-Chief and Associate Editors to appoint diverse expert Editorial Boards. This is also reflective in our multi-national and inclusive workplace. We are proud to create equal opportunities without regard to gender, ethnicity, geographic location, sexual orientation, age, disability, political beliefs, religion, or socio-economic status. There is no place for discrimination in our workplace and editors of MDPI journals are to uphold these principles in high regard.
Representatives from C4DISC meet monthly, and have started to implement initiatives to shed light and improve on the lack of diversity in scholarly communications. Some of the initiatives include developing a joint statement of principles; conducting market research; providing training resources, best practices, toolkits, and documentation for our collective memberships; and establishing outreach programs, curricula, events, and publications.
The Coalition is committed to:
- eliminating barriers to participation, extending equitable opportunities across all stakeholders, and ensuring that our practices and policies promote equitable treatment and do not allow, condone, or result in discrimination;
- creating and maintaining an environment that respects diverse traditions, heritages, and experiences;
- promoting diversity in all staff, volunteers, and audiences, including full participation in programs, policy formulation, and decision-making;
- raising awareness about career opportunities in our industries to groups who are currently underrepresented in the workforce;
- supporting our members in achieving diversity and inclusion within their organizations.
14 December 2020
Article Layout and Templates Revised for Future Volumes
At MDPI we have slightly revised the layout for articles to be published in the 2021 Volume, starting at the end of December 2020. As of today, the article templates available for download on ‘Instructions for Authors’ pages have been updated.
The most noticeable change can be found on the first page of the article, where a left-hand column has been created to include the following front matter elements: (i) the recommended citation style for the article, (ii) the publishing history, (iii) as well as the Creative Commons Attribution license used (iv) a standard note regarding affiliations. At the same time, the extra spacing on the left means the authors’ affiliations are now more clearly set apart than before. Other front matter key elements such as journal logo, article type, article title, authors, abstract and keywords remain unchanged.
The blank column on the left runs through all pages in an article; as a result, the main text is slightly more condensed, which improve reader friendliness for smaller screens. Small figures/tables are aligned on the left with standard indenture, while large figures/tables are centered and covering the full width of the page. The revised layout was applied in the article pictured below, to serve as an example:
1) Information is displayed in the left information bar.
2) In the main text, there is a blank column on the left.
3) Small tables/figures are aligned on the left, large tables/figures are centered.
11 December 2020
2020 "Highly Cited Researchers" on MDPI Journal's Editorial Boards
We are pleased to acknowledge that many academic editors who have made an impact on MDPI journals as editorial board members, editors-in-chief, or section editors, are recognized as 2020 Highly Cited Researchers by Clarivate.
Highly Cited Researchers highlights the top 1% of researchers, by citations, in one or more of the 22 fields used in Clarivate Analytics Essential Science Indicators. We offer our congratulations to 279 academic editors of MDPI journals who were recognized as the most influential scholars in their fields in 2020.
Adams, Dave Agarwal, Ravi P. Ahn, Choon Ki Ahn, Myung-Ju Albrecht, Randy A. Andersson, Dan I. Anker, Stefan D. Apergis, Nicholas Ariga, Katsuhiko Artaxo, Paulo Balsamo, Gianpaolo Barba, Francisco J. Benediktsson, Jon Atli Benelli, Giovanni Bhatnagar, Amit Bialystok, Ellen Blaabjerg, Frede Blay, Jean-Yves Bogers, Marcel Bolton, Declan J. Boyer, Cyrille Brocca, Luca Bruix, Jordi Buhalis, Dimitrios Burdick, Jason A. Byrd, John C. Cabeza, Luisa F. Cabrerizo-Lorite, Francisco Javier Cai, Jianchao Calhoun, Vince D. Cantu, Robert C. Cerqueira, Miguel Chang, Jo-Shu Chau, Kwok-wing Chemat, Farid Chen, Jianmin Chen, Jun Chen, Min Chen, Shaowei Chen, Wei Chen, Wei-Hsin Chen, Xiaofeng Chen, Yangkang Chen, Zhi-Gang Chiclana, Francisco Corella, Dolores Cortes, Javier Cortes, Jorge Cummings, Kenneth Michael Dai, Shifeng Decker, Eric A. DePinho, Ronald A. Dimopoulos, Meletios-Athanasios Dincer, Ibrahim Du, Yihong Dupont, Didier Edwards, David Ellahi, Rahmat Ellis, Erle C. ElMasry, Gamal Esteller, Manel Estruch, Ramón Fang, Chuanglin Fasano, Alessio Fernandez-Lafuente, Roberto Ferreira, Isabel Fortino, Giancarlo Galluzzi, Lorenzo Galvano, Fabio Gandomi, Amir H. Gandomi, Amir H. Gao, Bin Gao, Feng Gao, Wei Garbe, Claus García, Hermenegildo Geschwind, Daniel H. Giampieri, Francesca Giralt, Sergio A. Glanz, Karen Goldewijk, Kees Klein Gössling, Stefan Govindan, Kannan Granato, Daniel Grosso, Giuseppe Grosso, Giuseppe Guerrero, Josep M. Haase, Dagmar Hagger, Martin S. Hamblin, Michael R. Han, Heesup Jankovic, Joseph Janotti, Anderson |
Jiang, Hai-Long Kalaji, Hazem M. Kalantar-Zadeh, Kourosh Kaner, Richard B. Karimi, Hamid Reza Kataoka, Kazunori Keesstra, Saskia Kepp, Oliver Kerminen, Veli-Matti Keyzers, Robert A. Khademhosseini, Ali Khan, Nafees A. Kim, Ki-Hyun Klemeš, Jiří Jaromír Klenk, Hans-Peter Konopleva, Marina Y. Krammer, Florian Krebs, Frederik C. Kroemer, Guido Kudo, Masatoshi Kurths, Juergen Kurzrock, Razelle Kuznetsov, Nikolay V. Kyrpides, Nikos C. La Vecchia, Carlo Lai, Yuekun Lam, James Lancellotti, Patrizio Lee, Sangmoon Leung, Victor C. M. Li, Jinghong Li, Yurui Lindahl, José M. Merigó Lip, Gregory Y. H. Loh, Xian Jun Long, Hualou Lund, Henrik Luo, Jingshan Luque, Rafael Lyons, Timothy W. Ma, Jun Ma, Wen-Xiu Ma, Yanming Maeda, Keisuke Makarova, Kira Mantovani, Alberto Martín-Belloso, Olga Martinoia, Enrico Marzband, Mousa Masclaux-Daubresse, Celine Masson, Patrick Mateos, María Victoria Mathiesen, Brian Vad Matyjaszewski, Krzysztof McArthur, Grant A. McCauley, Darren Medlock, Jolyon M. Melero, Ignacio Mezzetti, Bruno Miroshnichenko, Andrey E. Moran, Daniel Mueller, Lukas A. Mueller-Roeber, Bernd Naushad, Mu Nemeroff, Charles B. Nieto, Juan J. O'Donnell, Colm Ogino, Shuji Olabi, Abdul-Ghani O'Regan, Donal Orsini, Nicola Oswald, Isabelle P. Ozcan, Aydogan Pahl-Wostl, Claudia Pang, Huan Payne, James E. Peng, Shushi Perc, Matjaz Perez-Alvarez, Jose Angel Piquero, Alex R. Ploss, Alexander Postolache, Mihai Pradhan, Biswajeet Prinsep, Michele R. Qian, Dong Qu, Xiaogang Reiter, Russel J. Riahi, Keywan Richter, Andreas Rignot, Eric Robert, Caroline Ros, Emilio Rosell, Rafael |
Rosen, Marc A. |
The full list of 2020 Highly Cited Researchers can be accessed on https://recognition.webofsciencegroup.com/awards/highly-cited/2020/
--- Highly Cited Researchers (HCR) is a Clarivate product.
2 November 2020
Current Oncology, Canada's Premier Oncology Journal, Published with MDPI from 2021
MDPI acquired Current Oncology (ISSN 1718-7729) in October 2020 from Multimed Publications Inc., who launched the title in 1994, as Canada’s first peer-reviewed journal in oncology.
Current Oncology features papers in all fields of cancer medicine, including radiation oncology, surgical oncology, medical oncology, pediatric oncology, pathology, and cancer rehabilitation and survivorship. It continues to be a trusted source for all members of the oncology community in Canada and abroad.
Coverage in indexing services includes MEDLINE (PubMed/National Library of Medicine), the Science Citation Index Expanded (Web of Science), Journal Citation Reports, Scopus (Elsevier), EMBASE (Elsevier), and more. Current Oncology's 2019 Impact Factor is 2.257, ranked 185/244 in the 'Oncology' category.
Previously published six times annually, normally with one or two additional supplements, MDPI will continue the schedule of bimonthly publications. The current volume of Current Oncology (v. 27) will be concluded at the end of 2020, at which point MDPI will take over publication of the journal, starting with Volume 28, at the beginning of 2021.
The goal is to greatly expand the journal's global reach, alongside MDPI's flagship Cancers journal, in order to become one of the world’s leading oncology journals.
Website: https://www.mdpi.com/journal/curroncol
Contact: Danica Jevtic, Marko Ristic
Current Oncology Editorial Office